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Summary 
 
This research investigated human candidate genes for susceptibility to tuberculosis and the effect 
of various factors on time to sputum conversion in the admixed South African Coloured (SAC) 
population. Population stratification was formally tested and excluded. Population based case-
control studies were the primary analysis method with a variety of genotyping methods.  
 
Candidate polymorphisms in RANTES, CCR5, CCR2 and SDF1, were not associated with 
tuberculosis susceptibility. Initially the RANTES polymorphism -403 was found to be associated 
with tuberculosis susceptibility but after the testing of additional samples the association was lost, 
illustrating the challenges with association studies.  
 
The C-type lectins DC-SIGN, encoded by the gene CD209, and L-SIGN are important 
pathogen-recognition receptors of the human innate immune response. Both lectins have been 
shown to interact with Mycobacterium tuberculosis. CD209 promoter polymorphisms,   -336 and -
871, were both found to be associated with tuberculosis susceptibility. The haplotype containing 
CD209 -871G and -336A was strongly associated with the control group. The CD209 -336A 
allele has been found to be associated with increased DC-SIGN expression, which may be the 
underlying reason for an increased efficiency of host phagocytes.  
 
Susceptibility to tuberculosis in mice has recently been attributed to the Ipr1 gene. Eight 
polymorphisms in the human homologue, SP110, were investigated, including two novel 
polymorphisms. No significant associations were found with any of the polymorphisms 
investigated, including two polymorphisms that were previously found to be associated with 
tuberculosis susceptibility in West African populations.  
 
A cohort of 249 cases from a longitudinal study of first time pulmonary tuberculosis patients was 
available. The cohort was used to investigate if the vitamin D receptor gene (VDR) 
polymorphisms FokI, ApaI and TaqI were associated with tuberculosis susceptibility or time to 
sputum conversion, and to investigate other clinical and demographic factors affecting the rate of 
response to treatment. No association between the VDR genotype and tuberculosis was found in 
the case-control study. The cohort allowed for a reliable conversion time to be determined for 
smear (n=220) and culture (n=222). Analysis was carried out to determine which factors, 
including VDR FokI, ApaI, and TaqI genotypes, contribute to faster mycobacterial resolution in 
sputum. This was done by survival curves and Cox regression models. The results indicate that 
the extent of disease at diagnosis was predictive of both smear and culture conversion times in 
the final models. Smoking status and VDR genotype contributed independently to smear 
conversion time, with ApaI ‘AA’ and TaqI ‘T’ containing genotypes being predictive of a faster 
response to tuberculosis therapy. We can conclude that the time taken for an individual to 
convert to sputum negativity while on DOTS therapy, can be independently predicted by the 
VDR genotype. This may have implications for future immunomodulatory therapies. 
 
Identifying what contributes to susceptibility to tuberculosis will provide us with a better 
understanding of the human immune response to tuberculosis which may lead to the 
development of accurately targeted therapeutics and vaccines. 
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Opsomming 
 
Kandidaatgene vir die vatbaarheid vir tuberkulose en die effek van verskeie faktore op sputum 
oorgangstyd was in hierdie navorsingsstudie ondersoek in die Suid-Afrikaanse Kleurlingbevolking 
(SAC). Dié bevolking was ook getoets vir populasie-stratifikasie, waarvan daar geen bewyse 
gevind is nie. Populasiegebaseerde pasiënt-kontrole studies was die primêre metode van analise 
en verskeie genotipering metodes was gebruik. 
 
Polimorfismes in kandidaatgene soos RANTES, CCR5, CCR2 en SDF1 was nie met die 
vatbaarheid van tuberkulose geassosieer nie. Oorspronklik was daar ‘n assosiasie met die 
RANTES -403 polimorfisme, maar met die genotipering van addisionele individue het die 
assosiasie verdwyn. Resultate verkry vir die polimorfisme illustreer die uitdagings waaraan 
assosiasie studies onderworpe is. 
 
Die C-tipe lektiene DC-SIGN, wat gekodeer word deur CD209, en L-SIGN is belangrike 
patogeen herkenningsreseptore in die aangebore immuunreaksie. Interaksies tussen beide lektiene 
en Mycobacterium tuberculosis is voorheen gerapporteer. Die CD209 promoter polimorfismes, -336 
en -871, was met die vatbaarheid van tuberkulose geassosieer. ‘n Haplotipe bestaande uit die 
CD209 -871G en -336A allele was sterk met die kontrole groep geassosieer. Die CD209 -336A 
alleel was geassosieer met ‘n toename in die DC-SIGN proteïen vlakke, wat moontlik ‘n 
onderliggende rede is vir die toename in die effektiwiteit van die gasheer se fagosiete. 
 
Vatbaarheid vir tuberkulose is onlangs toegeskryf aan die Ipr1 geen in muise. Agt polimorfismes, 
insluitend 2 voorheen onbekendes, was in die mens homoloog SP110 bestudeer. Geen positiewe 
beduidende assosiasie was met enige van die polimorfismes gevind nie ten spyte van die feit dat 
twee van hierdie polimorfismes voorheen met tuberkulose vatbaarheid geassosieer was in 
bevolkings van Wes-Afrika. 
 
 ‘n Versameling van 249 TB pasiënte van ‘n longitudinale studie was beskikbaar.  Dié groep was 
gebruik om polimorfismes FokI, ApaI and TaqI in die vitamien D reseptor geen (VDR) te 
bestudeer ten opsigte van vatbaarheid vir tuberkulose of sputum oorgangstyd sowel as ander 
kliniese en demografiese faktore wat die tempo van respons op behandeling kan affekteer.  In 
hierdie studie was daar geen assosiasie gevind tussen die ontwikkeling van tuberkulose en die 
VDR genotipes nie. Die bepaling van ‘n betroubare oorgangstyd vir beide smeer en kultuur van 
die groep was moontlik. Analises was uitgevoer om te bepaal watter faktore bydrae tot vinniger 
resolusie van Mycobacteria in sputum. Resultate verkry het aangedui dat die aard van die siekte 
tydens diagnose voorspelbaar was van die oorgangstye van beide smeer en kultuur in die finale 
modelle. Die rookstatus van individue sowel as die VDR genotipes het onafhanklik bygedrae tot 
die oorgangstyd van die smeer, met ApaI ‘AA’ en TaqI ‘T’ bevattende genotipes wat ‘n vinniger 
reaksie op tuberkulose behandeling voorspel het. Ter opsomming, die tyd wat dit ‘n individu op 
DOTS terapie neem om na sputum negatief oor te gaan kan onafhanklik deur die VDR genotipe 
voorspel word. Dit kan moontlik implikasies hê vir  ander immunomodulerende terapië in die 
toekoms. 
 
Die identifisering van faktore wat bydra tot die vatbaarheid van turberkulose sal ons in staat stel 
om ‘n beter begrip te hê van die immuunrespons teen tuberkulose wat moontlik kan lei tot die 
ontwikkeling van akkurate behandelings en inentings. 
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1.1 Overview of tuberculosis  
1.1.1 Scale of the problem 
 
One-third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, the 
etiological agent of tuberculosis [153]. However in the absence of immunosuppression, only 10% 
will develop disease [228], resulting in 8.8 million new cases each year and a death toll of between 
2 and 3 million people per year [99, 268]. This disease tops the World Health Organisation 
(WHO) list of deaths caused by a single infectious agent.  
  
With tuberculosis being such a major health problem, the WHO declared tuberculosis as a global 
emergency in 1993. One might imagine that more progress would have been made in eradicating 
this disease, since it has been known for centuries, accurately described since 1852, and a vaccine 
and antibiotics are available. Major progress was made with the development of chemotherapies 
from the mid 1900’s and it was believed that it would be eradicated by the end of the last century. 
But this has not happened (Figure 1.1). It is also surprising that the last major development of 
tuberculosis treatment was over 40 years ago with the licensing of rifampicin for the treatment of 
tuberculosis in 1966 [274].  
 
Figure 1.1: World tuberculosis incidence rates for 2005 from WHO Report 2007 Global 
Tuberculosis Control [398]. 
 
 
With the emergence of extensive drug resistant tuberculosis (XDR-TB) [103] there is increased 
urgency to develop new therapies and a need for a better understanding of this global burden. 
Renewed drives to increase awareness of the ‘re-emergence’ of this burden include the Global 
Plan to Stop TB 2006-2015 programme [269, 323]. In addition, the World Health Assembly 
passed a resolution aimed at accelerating progress towards halving tuberculosis deaths and 
prevalence by 2015 by urging WHO Member States to develop and implement long-term plans 
for tuberculosis prevention and control through the full implementation of the Global Plan to 
Stop TB program. 
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The current vaccine, bacillus Calmette-Guérin (BCG), is prepared from an attenuated live bovine 
tuberculosis bacillus, Mycobacterium bovis, which was developed in the 1920’s. The vaccine can be 
administered at birth and a single inoculation can produce long-lasting protection [36] and works 
well in protecting children against tuberculosis. Caution must be taken when administering the 
vaccination in high incidence human immuno-deficiency virus (HIV) populations as it can cause 
disease in HIV infected individuals when administered. Disseminated BCG can occasionally 
occur in non-HIV infected individuals [339]. The vaccine does not prevent infection and is of 
questionable benefit in many parts of the globe [22]. 
 
HIV is one of the main factors behind the increase in tuberculosis worldwide, particularly in sub-
Saharan Africa. Latent tuberculosis infection (LTBI) individuals have a lifetime risk of from 5 to 
8% of developing tuberculosis, whereas individuals infected with HIV have an annual risk of 8 to 
10% for developing tuberculosis [302]. Over 14 million people are thought to be co-infected 
worldwide (Figure 1.2). In South Africa, 58% of new adult tuberculosis cases were also HIV 
positive according to the 2007 WHO report [398]. Despite being treatable, the combined 
infection has a poor outcome and is hampered by poor diagnosis and delayed reporting to clinics.  
 
Figure 1.2: Estimated HIV prevalence in new adult TB cases 2005 as reported by the WHO 
[398]. 
 
 
Apart from HIV infection, there are a number of other risk factors for developing tuberculosis, 
such as sex, age, stress, immuno-compromising infections, malnutrition, previous exposure to 
mycobacteria, host immune defences [172], substance abuse (for example alcohol or smoking) 
and socio-economic status. A better understanding of the environmental risk factors has 
identified key factors that can be controlled in combating the spread of tuberculosis. Some 
lifestyle changes could reduce risk and transmission of M. tuberculosis, which is important in 
communities where tuberculosis is abundant.  
 
A major stumbling block in the treatment of tuberculosis is that it is largely a disease of the poor. 
The highest burden countries are often the countries least capable of coping with the burden. It 
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should therefore be no surprise that of the 22 high burden countries, 9 of them are on the United 
Nations least developed nations list. These countries are not able to provide a steady supply of 
medications; the health services are often unable to cope with the case load; and regular food 
shortages, skills shortages and civil unrest add to the problems these countries face. Poor 
infrastructure usually means that new cases are either not detected or detected late. Without 
adequate rapid detection of new cases there is increased transmission within the community 
which exacerbates the problem. However this does not mean that tuberculosis will occur only in 
developing nations; it can be found all over the world and all populations are at risk.  
 
1.1.2 Pathology of M. tuberculosis infection in humans 
 
After contact with the pathogen, there is a complex and multistage process of interaction 
between host and pathogen and the true impact and importance of each step is still unclear. For 
example it is unclear why BCG vaccination efficacy decreases with time [91, 330] such that it 
works well for children but not adults.  
 
The mycobacteria generally enter the alveolar space and thereafter the parenchyma, where the 
mycobacteria replicate in the alveolar macrophages or in resident lung macrophages. 
Macrophages are generally able to phagocytose and kill micro-organisms, but some pathogens, 
such as M. tuberculosis, have developed mechanisms to resist intracellular destruction. Dendritic 
cells (DC) and macrophages are the major phagocyte populations that recognise invading bacteria 
through innate pattern recognition receptors (PRR) [360]. It is hypothesised that the choice of 
receptor used to enter the macrophage influences the cellular response of the host [59]. 
Macrophages are the preferred habitat for M. tuberculosis where either a host-defence mechanism 
is stimulated or mycobacterial-induced inhibition of the phagosome-lysosome occurs.  
 
The host-defence mechanism is partly stimulated through toll-like receptors (TLR) on 
macrophages, which then induce the production of inflammatory chemokines and cytokines, 
signalling infection [59, 94]. The early phase immune response of interleukin (IL)-12, from 
natural killer cells drives production of interferon gamma (IFNγ). IL-12 is an important 
component of driving the activation, differentiation and expansion of T- helper 1 (Th1) cells, 
which are a major source of IFNγ during the innate immune response. IFNγ prompts maturation 
of the phagosomes to microbicidal phagolysomes but M. tuberculosis can arrest the phagosomes at 
an early stage of maturation. This is done by preventing the fusion of the phagosomes with 
lysosomes [149]. This mycobacteria-induced inhibition of phagosome-lysosome fusion allows the 
pathogen to avoid both effective antigen presentation and elicitation of the adaptive immune 
response and direct anti-microbial activity of the innate immune response [163]. 
 
IL-12 forms a major link between the innate and adaptive immune response, since it is produced 
by subsets of macrophages and DCs and acts on T cells [360, 363]. IFNγ production results in 
the migration of monocyte-derived macrophages and resident DCs to the focal site of infection 
in the lungs and results in granuloma formation. Granulomas form a wall encompassing the 
bacilli which reside within macrophages. The granulomas function as an immune 
microenvironment to facilitate interactions between T cells, macrophages and cytokines along 
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with other host cells such as B cells, endothelial cells, fibroblasts and probably stromal cells [59, 
354]. 
 
The granuloma becomes a home for M. tuberculosis where some are thought to avoid elimination, 
resulting in latent tuberculosis infection (LTBI). Extensive replication of bacteria is believed to 
result in loss of granuloma structure with extensive necrosis, cavity formation and finally disease. 
The immune response is intricate and varied. Pathways can be disrupted and interrupted at a 
number of steps, resulting in disease (Figure 1.1). The bacterium is able to manipulate many of 
these pathways and the full extent of the host-pathogen interaction is still not clear.  
 
Within the lymph nodes, CD4 and CD8 T cells are primed against mycobacterial antigens. The 
priming of the CD4 T cells is an important step in controlling M. tuberculosis infection, as it is a 
pathway for processing major histocompatibility complex (MHC) II antigens, which M. tuberculosis 
can disrupt [354]. CD4 T cells are important in tuberculosis infection, which is why HIV has such 
a detrimental effect, as it causes the loss of CD4 cells and subsequent immunodeficiency. CD4 
cells produce IFNγ, which activates macrophages to kill the intracellular bacilli [149]. In addition 
IL-12, IL-10 and IL-15 may be produced [354]. IL-12 is important in nitric oxide synthase 2 
(NOS2) production.  
 
Figure 1.3: A simplified representation of the tuberculosis disease process and some of the genes 
that may be involved at different stages [363]. 
 
Stellenbosch University  http://scholar.sun.ac.za
6 
1.1.3 Clinical overview of tuberculosis 
 
The clinical features of tuberculosis will be discussed only briefly as books have been written on 
the subject and there are good reviews available [80, 263, 280].  
 
The main forms of tuberculosis are pulmonary and extra pulmonary [249]. The most frequent in 
South Africa is pulmonary. Pulmonary tuberculosis is generally the most common form of 
tuberculosis with patients presenting with some or various combinations of symptoms, such as a 
persistent cough (>3 weeks), night sweats, loss of appetite, weight loss, shortness of breath, 
fever, chest pains, tiredness and / or sputum containing  blood. The use of chest radiography is 
common in clinical practice to assist with diagnosis. Extra-pulmonary tuberculosis occurs outside 
of the lungs and is more difficult to diagnose [111]. 
 
Tuberculous meningitis (TBM) [75, 347] is a rare form of extrapulmonary tuberculosis, but is the 
most frequent form of central nervous system tuberculosis. Occurring mainly in children, it has a 
poor prognosis, particularly if coma occurs. TBM is difficult to diagnose as the clinical features 
are often non-specific. Diagnosis can be aided by testing central spinal fluid for high protein, low 
glucose and a raised number of lymphocytes. Frequently patients will be treated on the basis of 
clinical suspicion alone, as many of the cases cannot be microbiologically confirmed. When TBM 
is suspected, treatment should be initiated even without microbiological confirmation as there is a 
time lapse to receive results and any delay in treatment can result in permanent brain damage. 
 
Disseminated BCG or BCG-osis disease occurs in children shortly after vaccination. It is rare and 
mainly occurs in immuno-compromised individuals, but it can occur in apparently healthy 
individuals. This is an extreme phenotype of mycobacterial disease and has been associated with 
mutations in the IFNγ / IL-12 /IL-23 pathway [193, 254], where patients are unable to produce 
normal levels of IFNγ. A retrospective study of 25 children from our study area in the Western 
Cape has recently been reviewed by Hesseling et al 2006 [128]. 
 
Diagnosis of LTBI can be done by tuberculin skin test (TST), which was developed in 1910, but 
this test may be hampered in BCG vaccinated individuals and those exposed to atypical 
mycobacteria [400]. The development of immune-based rapid blood tests such as the                
T-SPOT.TB and QuantiFERON-TB Gold will hopefully improve the diagnosis of LTBI [276]. 
However in developing countries there are not enough resources to provide treatment for LTBI 
cases and the focus is necessarily on individuals with active tuberculosis.  
 
Generally, diagnosis of active tuberculosis will be done with a combination of a clinical 
examination, chest radiograph and microbiological results, as only about 60% of cases can be 
microbiologically confirmed. Gram positive staining of the acid fast bacilli (AFB) is done by 
Ziehl Neelsen (ZN) staining. Owing to its simplicity and speed it is the most widely used 
technique for diagnosis. Besides a microscope, no major equipment is required and work can be 
done on a bench not requiring any specific containment facilities. Little technical skill is required 
and the low running costs make it ideal for developing countries. However, sensitivity and 
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specificity is not particularly good, and culture based diagnosis (using Lowenstein-Jensen medium 
(LJ), BACTEC or Mycobacteria Growth Indicator Tube (MGIT)) is preferable. 
 
Culture is also preferable since the isolation of live M. tuberculosis is usually required for drug 
susceptibility testing. The importance of sensitivity testing has gained a new perspective with the 
increasing prevalence of drug resistant (DR-), multi-drug resistant (MDR-) and extensively drug 
resistant tuberculosis (XDR-TB). Unless the patient is suspected of having been in contact with a 
DR-TB case, the only indication that a patient may have DR-TB is that they do not respond to 
standard treatment. Any delay in diagnosis of drug resistance will allow for transmission to other 
individuals, therefore perpetuating the problem. This highlights the importance of initial clinical 
isolates of cases being tested for drug sensitivity.   
 
The current, optimal treatment is considered to be direct observed treatment short-course 
(DOTS), promoted by the WHO since 1990 [84, 98]. When correctly implemented it is 
considered to be the best method of treating tuberculosis and preventing resistance. Where it has 
been implemented correctly, with commitment from the government and health services, the 
treatment success rate has been 78% compared to 45% in areas which did not use the DOTS 
strategy [395]. For new patients, treatment consists of a combination of four medications, namely 
the first line drugs isoniazid, rifampicin, pyrazinamide and ethambutol, taken for at least 6 
months. The initial two months of treatment is known as the intensive phase where all four 
antibiotics are given and this is followed by a four month continuation phase with isoniazid and 
rifampicin only. The intensive phase of treatment is extended if the patient has not responded 
within the first two months or if DR-TB is suspected.  
 
The six months required for treatment often results in problems with compliance, which is vital 
for successful cure and to halt acquired DR-TB. DR-TB can be acquired through poor adherence 
to the DOTS regime by a patient or the TB programme. Disrupted drug supply (due to logistic 
problems or political unrest), poor transport networks or job requirements for example can cause 
interrupted treatment. The side-effects of the treatment may discourage patients from completing 
treatment, or they may stop taking their medication when they feel better and think they are 
cured. However, acquired DR might not be the major problem, as more evidence is appearing 
that drug resistant strains are more capable of being transmitted than previously thought [197, 
373, 374]. If this is true, there is more need for rapid diagnosis of DR-TB to prevent further 
transmission [364], particularly when dealing with vulnerable communities. The spread of XDR-
TB to a community that has high HIV rates would have, and has had, devastating effects [103].  
1.1.4 Mycobacterium tuberculosis 
 
M. tuberculosis is the infectious agent that usually causes tuberculosis. It is generally spread in 
particles that are either coughed or sneezed out by an active case. Half of those exposed to the 
organism become infected [286] and recent studies show that DR-TB strains are as transmissible 
as sensitive strains [10, 33, 374].  
 
Strain identification may be important, as there is also evidence that various strains elicit different 
responses from the host [129, 133, 184, 192, 270]. Worldwide, strain type frequencies differ 
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between countries. It is hypothesised that this could explain why frequencies of the tuberculosis 
forms vary between countries and populations [192] and that the pathogen has adapted to 
specific populations [100, 125]. This may also be reflected in the geographical variation of the 
protective efficacy of the BCG vaccine [9]. 
 
1.1.5 Tuberculosis in South Africa 
 
The revised South African national tuberculosis control programme incorporating the DOTS 
strategy was first established in 1996. DOTS implementation in South Africa has improved over 
the last decade, increasing the detection rate, but progress has been slow over the last few years. 
In 1998 South Africa was listed as one of 16 countries that was struggling to control tuberculosis 
[395] and was ranked ninth globally [397] but in 2007 was ranked seventh globally [398] as a high 
burden country. There are a number of factors that contribute to this, mainly the increasing rates 
of HIV, DR-TB, insufficient investment in personnel and infrastructure and poor quality record 
keeping. With the implementation of DOTS, better statistics are available, as there is improved 
disease surveillance. However, it is clear that the situation is not improving as desired.  
 
The South African Department of Health (DoH) reported a tuberculosis incidence of 1037/100 
000 for the Western Cape in 2005, which is the highest incidence of all South African provinces 
(Table 1.1). However, the HIV rate of the Western Cape was the lowest of all provinces, with a 
reported prevalence of 1.9% compared to a national rate of 10.8% for 2005 (which are believed 
to be minimum estimates). With the absence of HIV until recently [32], the epidemic in this 
population is historically not driven by HIV and it is possible that the population is more 
genetically susceptible than most to tuberculosis (Chapter 2).  
 
Table 1.1: Tuberculosis incidence (all forms) and HIV prevalence per province as reported by the 
South African Department of Health for 2005 (from www.hst.org.za Accessed March 2007).  
Province 
TB incidence 
per 100 000 
HIV prevalence % 
(total population) 
Western Cape  1037.2 1.9 
KwaZulu Natal 885.9 16.5 
Northern Cape  846 5.4 
Northwest  711.5 10.9 
Free State  708.3 12.6 
South Africa  645 10.8 
Eastern Cape  637.9 8.9 
Gauteng  487.8 10.8 
Mpumalanga  333.6 15.2 
Limpopo  237.2 8 
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The annual rate of tuberculosis infection (ARTI) is considered to be one of the most important 
indicators of the trend of a tuberculosis problem. Tuberculin surveys provide information on 
populations ARTI [13]. The estimated ARTI in the Western Cape Ravensmead and Uitsig 
community is 3.9% [161]. Not surprisingly, a randomized survey found that of 2401 adults 
analysed, 76% had a positive TST [71] and a survey of children (<15 years old) found 32% were 
TST positive [72]. 
 
Study site: Ravensmead and Uitsig, Western Cape 
 
The Ravensmead, Uitsig and neighbouring communities are in close proximity to Tygerberg 
Hospital and have been undergoing observational tuberculosis studies since 1992, four years 
prior to the implementation of DOTS in South Africa. These suburbs are predominantly South 
African Coloured (SAC) which represents a present day homogenous population that previously 
received contributions from Khoisan, Malaysian, Bantu and European populations [242, 361]. 
The previous studies were on population health, juvenile tuberculosis, epidemic spread, DR-TB 
monitoring and host susceptibility. Clinical studies have shown that there is a high prevalence of 
childhood tuberculosis and that they frequently present late to the health services in the area [31, 
195, 367]. This research has resulted in contributions to improve the diagnosis of tuberculosis 
and disseminated tuberculosis in children [194, 196].  
 
The strain typing of sputum samples that have been collected from the community since 1993 
provides insight into the tuberculosis epidemic in the area. There is high strain diversity in this 
community [382, 383], and it has been shown that transmission frequently takes place outside of 
the household [56, 299, 371, 372] and that patients can be infected with multiple strains of M. 
tuberculosis at once [384]. Another important finding is that a large proportion of patients that 
require retreatments after cure, are reinfected and are not reactivation cases [368, 370]. 
Individuals who have had a previous episode of disease have a four-fold increased risk of 
developing another tuberculosis episode compared to those who have never had active 
tuberculosis disease [370]. The investigations into strain diversity and variability have lead to 
greater understanding of the dynamics of tuberculosis within this community and can be 
translated to other high tuberculosis prevalence settings.  
 
Some research into genetic susceptibility to tuberculosis using population case-control and TDT 
studies has also been done in this community and revealed that polymorphisms in the genes 
IFNγ [284] and solute carrier family 11A member 1 (SLC11A1, formerly known as NRAMP1, 
natural resistance-associated macrophage protein 1) [132] are associated with susceptibility to 
tuberculosis. The IFNγ +874T allele, which was overrepresented in controls, is preferentially 
bound by transcription factor NFКβ, and is associated with raised IFNγ expression in vitro [284]. 
A case-control using 313 cases and 235 controls found a significant association (p=0.017) 
between the IFNγ +874T allele and protection against tuberculosis, which was then confirmed in 
a TDT using 131 families from the same population (p=0.005) [284].  
 
Polymorphisms in the gene SLC11A1, were also found to be associated with tuberculosis 
susceptibility in a SAC case-control analysis. A 5’(GT)9 allele in the promoter had a significantly 
higher frequency in controls versus cases (p=0.002). Homozygotes for a 3’UTR TGTG deletion 
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(1729+55del4), were over-represented in the cases compared to the controls (p=0.013). After 
stepwise logistic regression, the 5’ and 3’ polymorphisms were found to contribute separate main 
effects. SLC11A1 is the human homologue of the mouse Nramp1 gene which will be discussed in 
Section 1.3. 
 
A number of polymorphisms that were associated with other diseases were hypothesised to be 
candidates in tuberculosis susceptibility, namely butyrophilin-like 2 gene (BTNL2) [218] and 
caspase recruitment domain-containing protein 15 gene (CARD15) [219]. BTNL2 was 
hypothesised to have a possible function as a T cell co-stimulatory molecule [358].  BTNL2 has 
previously been associated with sarcoidosis, a disease of unknown etiology but presents with 
coughing and granulomas, rather similar to tuberculosis [291]. CARD15 is the gene encoding 
nucleotide-binding oligomerisation domain 2 protein (NOD2) which has been recognised as a 
non-redundant recognition mechanism of M. tuberculosis and polymorphisms in CARD15 were 
associated with Crohns disease, also a granulomatous disorder. After large case-control studies, it 
was concluded that the polymorphisms in both BTNL2 and CARD15 were not associated with 
tuberculosis susceptibility in our population.  
 
The frequency of polymorphisms in the genes glutathione S-transferase (GST) and N-
acetyltransferase 2 (NAT2) were determined in various population groups from SA, including the 
SAC. These enzymes metabolise many environmental and chemotherapeutic agents, and 
polymorphisms in these enzymes may contribute to different disease profiles or responses to 
toxic or chemotherapeutic agents. The NAT2 ‘fast’ allele, which has been found to have a 
significant effect on acetylation, was present at a high frequency in this population [6]. It is 
hypothesised that the efficacy of antituberculosis chemotherapy may vary between various ethnic 
groups depending on their NAT2 status. In other words, the acetylation of the isoniazid depends 
on NAT2 status, therefore because of the NAT2 allele frequency, isoniazid efficacy will vary 
between populations. This could have implications for drug development and trials. The NAT2 
status in our population and the effect on tuberculosis therapy is being investigated further and is 
not part of this thesis. 
 
1.2 Host Genetics and Tuberculosis  
1.2.1 Genetic susceptibility to tuberculosis in human populations 
 
Prior to the discovery of the pathological agent M. tuberculosis by Koch in 1882, many believed 
that tuberculosis was actually an inherited disorder. As a result of it being thereafter attributed to 
an infectious agent, there was little focus on the host. The known environmental risk factors such 
as age, immuno-compromising diseases (diabetes or HIV), or substance abuse, do not explain 
why only half of the individuals that are exposed to the organism will become infected, and why 
only 10% will ever develop disease. A complex interplay between environment, pathogen and 
host can account for the development of active disease. The importance of the genetic 
components and heritability of tuberculosis susceptibility is provided by twin [61, 143, 147, 308] 
and adoptee [322] studies. There is a large body of evidence pointing to the major role of genetic 
factors in the human response to a number of infectious pathogens [5, 26, 34, 62, 131, 233], and 
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these genes could impact on treatment and vaccine efficacy [234]. There is also increasing 
evidence that host genetic factors determine differences in host susceptibility to mycobacterial 
infection and might contribute therefore to the pattern of clinical disease [26, 34, 49, 62]. The 
common disease-common variant (CDCV) hypothesis is believed to apply to tuberculosis. The 
CDCV hypothesis suggests that genetic susceptibility to a common disorder will be influenced by 
relatively common polymorphisms [46, 273]. 
1.2.2 Evolution and infection  
 
It has been claimed that during the industrial revolution in Western Europe one-quarter to one-
fifth of all deaths occurred as a result of M. tuberculosis infection. This makes it very likely that M. 
tuberculosis has had an effect on the evolution of the human genome. Not only M. tuberculosis 
infection would have played a role, but also other diseases such as Plasmodium falciparum (malaria), 
the bubonic plague and smallpox. Haldane, one of the pioneers in recognising the role pathogens 
could have on the evolution of the human genome, suggested that micro-organisms have been 
the main agents of natural selection for the past 5000 years [119]. The spread of advantageous 
alleles is fundamental to evolutionary processes and includes the spatial dynamics of co-evolution 
between pathogens and their hosts [241]. Diseases that exert the largest death toll will produce 
the most pronounced evolutionary effect [222]. Time of exposure to the disease will then play an 
important role in the effect and an example of this occurring would be in American Indian 
reservations [353]. There were a large number of deaths attributed to tuberculosis after 
introduction of the disease to the population, but after a generation or two the death rates due to 
tuberculosis decreased drastically. This is presumably due to strong selective pressure against 
tuberculosis-susceptible genotypes. For example, in the Qu’Appelle Indian reservation there was 
a reported tuberculosis incidence rate of 9000 per 100 000 in 1890, which decreased to 800 per 
100 000 by 1926, and further decreased to 273 per 100 000 in 1931 [88, 186]. Within the 
reservation, the death rate due to tuberculosis was double that of surrounding white communities 
in 1931 [88].   
 
1.3 Strategies to identify candidate-genes for susceptibility to tuberculosis 
 
The human genome project has revealed extensive variation between populations and individuals. 
Identifying which variations are associated with susceptibility to a complex disorder requires 
selection of appropriate candidate genes to investigate [256]. The selection can be done through a 
number of different approaches and these have included genome wide studies, mouse models 
and human susceptibility models.  
 
Genome-wide studies are systemic and comprehensive and are capable of identifying genes that 
exert a major effect on population-wide disease susceptibility. Data from genome-wide scans can 
be used to narrow down the number of candidate genes. With genome-wide scans there is usually 
a large number of genes within the identified regions, and determining which could be important 
in tuberculosis infection can be done by hypothesis. This method has been fairly successful in 
determining disease-susceptibility genes for leprosy susceptibility [213, 307, 352]. Bellamy et al 
conducted a genome-wide scan for tuberculosis susceptibility and found two regions, 15q and 
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Xq, that showed suggestive evidence of linkage to tuberculosis [27]. They found that no single 
marker was strongly linked as a susceptibility gene among the African populations [27]. A second 
genome wide scan was conducted in a Brazilian population and found suggestive evidence for 
regions 6p21.32, 17q22 and 20p13 [211]. A more recent genome-wide scan in 96 Moroccan 
families found the 8q12-13q region to be significantly linked to tuberculosis [17]. Currently, 
linkage disequilibrium (LD) mapping of the 8q region is being conducted to identify tuberculosis-
susceptibility genes. In a genome-wide scan for leprosy susceptibility, chromosome region 6q25 
was identified [213], and linkage disequilibrium mapping found that polymorphisms in the 
PARK2/PACRG gene conferred susceptibility to leprosy [212]. 
 
For both of the earlier genome-wide scans done in humans, further fine-mapping has taken 
place. In the 15q11-13 region, fine mapping results suggested that UBE3A or a closely flanking 
gene may be a tuberculosis-susceptibility locus in African families [50]. After a segregation 
analysis was done in a Brazilian cohort, it was determined that only one or two loci may 
determine individual tuberculosis susceptibility [304]. 
 
Genome-wide scans of tuberculosis susceptibility have also been conducted in mouse models and 
resulted in the identification of regions on mouse chromosomes 1 (Nramp1, sst1 (super 
susceptibility to TB 1) and Trl-1), 3 (tbs1 and Trl-2), 7 (Trl3), 19 (Trl-4) and 9 (tbs2) [159, 166, 214, 
215, 375]. Fine mapping of these regions could lead to the identification of particular genes, 
whose human homologues can then be identified for further study. 
 
The mouse Nramp1 region has been successfully transferred to human association studies where 
the human NRAMP1, renamed as SLC11A1, has been found to be associated with susceptibility 
to tuberculosis in a variety of populations [2, 14, 29, 79, 104, 132, 181, 187, 262, 292, 317, 342, 
401]. A recent meta-analysis showed statistically significant associations between the NRAMP1 
variants and tuberculosis susceptibility in Asian and African subjects but not in Europeans [170].  
 
The mouse chromosome 11 has synteny with human chromosome 17q11.1-q12, which contains 
a number of potential candidate genes involved in the immune response. These include regulated 
upon activation, normal T cell expressed and secreted (RANTES), NOS2A which encodes 
inducible nitric oxide synthase (iNOS), genes encoding members of the family of small inducible 
chemokines and genes for signal transducers and activators of transcription [141]. Fine-mapping 
has identified region 17q11.2 as containing potential candidate genes that could account for the 
variable disease and pathology associated with tuberculosis and leprosy. 
 
Fine mapping of the sst1 locus on the mouse chromosome has recently identified Ipr1 in the 
locus as the mouse susceptibility gene to M. tuberculosis [159, 250]. The human homologue is 
SP110, whose function is not clear. It is believed to be involved in regulation of transcription by 
facilitating DNA binding, using the conserved SAND (Sp100, AIRE-1, NucP41/75 and DEAF-
1) domain. The sst1 phenotype differs from Nramp1 and reflects a true murine susceptibility gene 
as it causes lung-specific effects in tuberculosis susceptibility. 
 
A new approach that is coming into its own is genome–wide association (GWA) studies. GWA 
offers the potential of identifying causal genes with modest effects, which would probably be the 
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case in tuberculosis susceptibility. GWA has already been successfully used with Crohn’s disease 
[124] and Inflammatory Bowel disease [82]. However, there are still a number of factors that need 
to be considered when contemplating a GWA study, such as marker set, LD and statistical 
analysis methods that consider multiple testing [130, 380]. In the mean time rigorously designed 
studies are required to determine if this type of approach is feasible.  
 
Hypothesis driven candidate gene selection can be effective in identifying susceptibility to 
tuberculosis genes. It requires an understanding of the pathology of the disease to identify which 
genes could be important in the control of M. tuberculosis infection. As discussed earlier (section 
1.1.2), the response to M. tuberculosis infection is complex. There are a number of pathways 
involved and why there is progression to disease in only 10% of the infected individuals is still 
not clear. Identification of proteins and molecules that are important in the various responses to 
tuberculosis has already been successful done with, for example SLC11A1.  
 
Candidate genes chosen by hypothesis 
 
The gene encoding RANTES is located on chromosome 17 in the chemokine cluster, a region 
which has been shown to contribute to susceptibility to tuberculosis and leprosy in Brazilians 
[141] and has been associated with tuberculosis in a number of instances in the last few years 
[294, 313, 388]. This chemokine plays a significant role in inducing activation and proliferation of 
macrophages and T cells as well as lymphocytes and monocytes, which are essential for 
granuloma formation [294]. 
 
Chemokine receptor 5 (CCR5), Chemokine receptor 2 (CCR2) and Stromal derived factor 
(SDF1) polymorphisms have been found to have an association with HIV infection and disease 
progression, although the effect of the polymorphisms on HIV disease varies between 
populations [114]. As chemokines play a critical role in the immune and inflammatory response 
to infectious diseases, these polymorphisms might be related to susceptibility to tuberculosis [63]. 
The effects and frequencies of these polymorphisms vary in different populations, particularly the 
frequencies of CCR5 polymorphisms [179, 311].  
 
Dendritic Cell Specific Intercellular adhesion molecule (ICAM)-Grabbing Nonintegrin (DC-
SIGN) is known to be a major receptor for M. tuberculosis and other pathogens on human DCs 
[365]. The recognition of pathogens by DCs is crucial in mounting the immune response. DCs 
bind strongly to mycobacteria such as M. tuberculosis and M. bovis BCG through the mannose 
capped cell wall component (ManLAM) of the pathogen, but does not bind to LAM, which lacks 
the mannose cap (AraLAM). ManLAM binding to DC-SIGN induces production of the anti-
inflammatory cytokine IL-10 [157, 338, 366]. Immature DCs bind to M. tuberculosis and M. 
tuberculosis BCG and this inhibits maturation of the DC. These factors both contribute to M. 
tuberculosis virulence. ManLAM is abundant in slow growing virulent mycobacteria, such as M. 
tuberculosis and M. leprae, whereas AraLAM is abundant in fast growing atypical, avirulent 
mycobacteria, such as M. smegmatis. It is suggested that M. tuberculosis targets DC-SIGN both to 
infect DCs and to down-regulate DC mediated immune responses. Investigating polymorphisms 
and haplotypes in our population could show the importance of this gene in tuberculosis 
susceptibility. 
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Vitamin D receptor (VDR) is synthesised in monocytes and activated T and B lymphocytes. Its 
ligand, the active metabolite of Vitamin D, calcitriol, is produced in the kidney and by activated 
monocytes and macrophages, particularly in granulomas. Through its interaction with Vitamin D, 
the retinoid X receptor (RXR) and the Vitamin D response element (VDRE), VDR exerts several 
immunomodulatory effects. These include the activation of monocytes and cell mediated 
immunity, modulation of the Th1-Th2 host immune response, suppression of lymphocyte 
proliferation and restriction of M. tuberculosis survival in macrophages [37, 70]. Various VDR 
polymorphisms and their involvement in tuberculosis susceptibility have been investigated with 
varying results [28, 37, 180, 285, 391]. A study in West Africa on four VDR polymorphisms 
found no association in a case control analysis but an association was found with a particular 
haplotype in the transmission disequilibrium test (TDT) [37]. Evidence of the subtlety of the 
effect of VDR polymorphisms in the immune response was found by Roth et al [285], who 
detected an association with time to sputum conversion in tuberculosis patients after diagnosis.  
1.4 Genetic association studies 
 
There are two study designs that are used in genetic association studies [168] namely, family-
based [165] or population-based studies using unrelated individuals [18]. Currently the most 
widely used family-based method is TDT studies and for population studies the case-control 
methodology.  
 
Family-based TDT studies are robust against population substructure and significant findings 
always imply both association and linkage [165]. The TDT study design was originally developed 
to test for linkage in the presence of association but now, as it is robust to population 
stratification, the most common usage is testing for association in the presence of linkage [165, 
300]. However population-based studies are regaining popularity as there are several methods 
that can compensate for population stratification [74, 261]. In addition case-control studies 
require a smaller sample size compared to family-based studies which requires parents and/or 
siblings also to be sampled.  
 
Case-control analyses were the primary testing methodology applied in this thesis. There are a 
number of important factors that need to be considered for a successful case-control study [18, 
58, 168]. These will mainly impact the power of a study and therefore its validity. Case-control 
studies compare the allele frequency of a polymorphism between two well defined groups; cases 
with the disease and unrelated healthy controls. An increased frequency of the polymorphism in 
cases indicates that the presence of the polymorphism may increase risk of disease. 
Understandably, cases and controls should be from the same ethnic group to control for the 
genetic background of the groups. When the population under investigation is large and there is 
random mating, control genotypes should be in Hardy Weinberg equilibrium (HWE) (Appendix 
A1.6.1). Reasons for a genotype not being in HWE include: random chance, miscalled 
genotyping, and a heterogeneous population [168, 396].  
 
Classification of the phenotype must be done correctly, but clinical heterogeneity is important 
only if a genetic variant influences a disease subset [256]. For example prior to collection, it is 
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vital to define which form of tuberculosis and which controls will be assessed. In tuberculosis, 
controls could be latently infected, i.e. TST positive, or negative and presumably not infected. As 
discussed in section 1.1.6 our population has a high exposure rate, therefore our controls are 
likely to almost all be LTBI [71, 72]. This would be sufficient for our analysis as we are 
investigating progression to tuberculosis disease and not M. tuberculosis infection status. However, 
we are aware that a number of our controls may develop tuberculosis after the sample was 
collected, in particular with younger participants. We recognise this, but it has been shown that 
with a slight misclassification of controls the overall impact will be small and can be compensated 
for by increasing the sample size [58].  
 
Analysis in case-control studies is generally done using 3x2 contingency tables, where the 
genotypes are counted in columns of cases and controls and assessed by a Chi square (χ2) test. 
This method has reasonable power to detect underlying risk.  This is the general genetic model, 
but dominant, recessive and multiplicative models can be assessed in a similar manner [168]. 
Fisher’s exact analysis on alleles and dominant/recessive models can be conducted and can 
estimate the disease risk (odds ratio) conferred by the polymorphism [18, 168]. When there is 
biological support, more complex analysis, using Cochran-Armitage test, can be used for additive 
models [18, 168] and does not rely on an assumption of HWE. 
 
Linkage disequilibrium (LD) refers to the non-random association between two loci. Typically a 
number of polymorphisms spanning a gene will be independently tested, but when there is LD 
this can be redundant. LD is defined as the non-random pattern of association between alleles at 
different loci in a population [225, 240]. If LD is high between two alleles, they are considered to 
be linked and can sometimes be used as a substitute for the state of nearby loci [46]. A 
polymorphism associated with disease susceptibility might be directly associated, but if in 
complete LD with the causative polymorphism, the polymorphisms genotyped is then said to be 
indirectly associated with disease susceptibility [256].  
 
There are two important measures of LD; D’ and r2 [18, 386]. In the context of association 
studies, r2 (the correlation coefficient), is more useful as it reflects the statistical power to detect 
LD [18]. r2 is inversely proportional to the sample size required to detect statistically significant 
LD and also relies on allele frequency [386]. D’ is typically higher than r2, where a D’ of one 
indicates complete LD between the polymorphisms. One of the reasons it is not useful in 
association studies, is that even when an allele is very rare, D’ can be large, which is usually of 
little practical interest. D’ is also sensitive to a few recombination’s between the loci [18]. 
 
When there is complete LD between single nucleotide polymorphisms (SNPs) and one SNP is 
capable of providing information on the other polymorphism, then these SNPs are considered to 
be tagging or tagSNPs [122]. The polymorphism, for which the tagSNP provides complete or 
additional information, is called the tagged SNP. Identifying the tagSNPs spanning a gene can 
increase genotyping efficacy, reducing costs.  
 
Determination of LD over the genome has recognised regions that are in high or low LD. 
Regions of high LD and low haplotype diversity are defined as Haplotype blocks [46]. 
Haplotyping tagging, which involves selection of the minimum subsets of SNPs which represent 
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the haplotypes inferred from the original set [122] within a block, can also increase genotyping 
efficacy. 
 
LD and haplotype diversity has been found to vary between populations. In particular African 
populations have smaller blocks of LD [271] and there is high haplotype diversity within the 
African compared to European populations. Admixed populations have unique LD patterns, 
such as long range LD which can be an advantage in association studies [4, 393]. Using the long 
range haplotypes in admixed populations will provide more power to detect genes that may be 
associated with disease susceptibility [315]. 
 
There are a number of online databases such as HapMap, that provide information on LD and 
tagSNPs. The information from the reference populations has been found to be transferable to 
different populations [116]. However, this should be used cautiously in admixed populations, 
such as the SAC, which have numerous ancestral populations [393]. It is therefore the best 
strategy to use information from all available reference populations is used. 
 
Stratification 
 
Although our cohort is considered a present-day homogeneous community that has received 
genetic contribution from different populations multiple generations in the past [242, 361], 
population stratification between cases and controls can be a confounding factor leading to a 
spurious positive association. However, the use of admixed populations in association mapping 
studies can be very useful in identifying disease-causing genetic variants that differ in frequency 
across parental populations. Nevertheless, when the admixture event is too recent, allelic 
frequencies can differ coincidentally among cases and controls, reflecting a non-uniform genetic 
contribution from the parental populations to each subpopulation (i.e., cases and controls), rather 
than a genuine association between a given genetic variant and the phenotype under study. In this 
case, the study-cohort is said to present population stratification. To formally test and quantify 
the levels of background genetic differences [260], if any, between cases and controls, genomic 
control correction can be done by genotyping a panel of independent SNP markers. Currently 
there is no agreement as to the number of random SNPs that should be genotyped to determine 
the level of stratification within a given population. Genomic control can be used to assess the 
genetic background, and can correct cryptic relatedness between cases and controls [74, 376]. The 
mean χ2 statistic among the random SNPs is compared for allele frequencies between cases and 
controls, which represents the levels of stratification (µ) between the two groups [272].  
 
1.5 Aims of the study  
 
Broadly speaking, this study investigated candidate genes for susceptibility to tuberculosis 
infection and progression to disease in the SAC population of the Western Cape, South Africa. 
Population based case-control studies were the primary analysis method, and this is expected to 
detect genes that exert a low to moderate effect on susceptibility to tuberculosis disease. 
Tuberculosis cases were defined as individuals with past or current active tuberculosis disease and 
Stellenbosch University  http://scholar.sun.ac.za
17 
controls were individuals with no previous or present clinical presentation of disease. Controls 
would more than likely be infected with M. tuberculosis because of the high ARTI in this 
community [71, 72, 161]. 
 
Preliminary population screens determined the genotype frequency and the minimum sample size 
required for sufficient statistical power to detect an association. For genotypes that were at too 
low a frequency, the OR detectable was greatly increased, requiring more samples to be typed to 
detect a smaller OR. Provided the frequency of the genotype was common in the general 
population, the study had enough power to detect a genotype that exerts a smaller effect. Inferred 
haplotype based association studies were done when a number of polymorphisms over a gene 
were genotyped.  
 
A specific aim was to study the frequencies and potential association with tuberculosis of 
candidate polymorphisms in genes RANTES, CCR5, CCR2 and SDF1 using a case-control 
methodology. 
 
A further aim was to investigate the Dendritic cell-specific intercellular adhesion molecule-3 
grabbing nonintegrin (DC-SIGN/ encoded by gene CD209), in collaboration with a group at the 
Pasteur Institute Paris, France. Resequencing of CD209 was done to identify polymorphisms in 
the SAC population to determine whether there were any unique SNPs or haplotypes, and 
determine their frequencies. Subsequent genotyping analysis was done on the Victor (Perkin 
Elmer) using a case-control cohort to determine if there was an association with tuberculosis. 
This cohort was used to assess possible population stratification in our admixed population, 
using genomic control. A length variation in L-SIGN, a close homologue to DC-SIGN, was also 
investigated.  
 
In addition to testing candidate genes that were chosen by hypothesis, a candidate gene selected 
from mouse studies was chosen, namely, the human SP110 gene, which is the homologue of the 
mouse intracellular pathogen resistance 1 (IprI) gene which is within the sst1 locus.  
 
Finally we aimed to investigate the VDR gene, which may be linked to susceptibility or 
progression to disease. This analysis was done with a specific cohort of patients, namely the 
Surrogate Marker (SM) cohort. The SM study was a longitudinal study of first time pulmonary 
tuberculosis patients who were evaluated during and after treatment. They were used in a case-
control analysis to identify the effect of the VDR polymorphisms on phenotype, in particular, 
time to sputum conversion after diagnosis of tuberculosis. This required more intricate statistical 
analysis compared to the case-control study and a specialised statistician was required. 
 
Identifying genes that exert some effect on host susceptibility to tuberculosis will give a greater 
understanding of disease pathogenesis. Clearly the immune response is important in the host 
reaction to M. tuberculosis infection and the genes expressed in the host lungs may influence the 
host’s ability to contain infection and resist disease. The environmental factors play a significant 
role but are not the only determinants in developing disease, where the interplay of these factors 
with the host is vital. The different allele frequencies between cases and controls may provide 
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important information about critical responses of the host to M. tuberculosis. It is hoped that our 
findings will eventually contribute to the development of novel therapeutics and vaccines. 
 
1.6 Summary 
 
The study population, SAC, is an admixed population that has contributions from Africa, Asia 
and Europe, discussed in Chapter 2. Gene polymorphism frequencies will differ in our unique 
admixed population compared to previously investigated populations. The use of an admixed 
population in genetic association studies is believed to be advantageous, but does have a number 
of factors that need be taken into consideration, such as possible population stratification. It is 
important to have some knowledge of the background of the population to determine its 
heterogeneity. By means of extensive literature searches, a table of the HLA class II allele 
frequencies in various South African populations was constructed (Table 2.1). I also contributed 
to the writing of the articles from this chapter. The case-control samples all came from thhe SAC 
community and only Chapter 6 had a unique set of case samples, from them the same population 
group and area. 
 
Candidate genes, CCR5, CCR2, SDF1 and RANTES, which were chosen by hypothesis, were 
investigated. Known candidate polymorphisms that had been associated with other diseases were 
chosen and the results from the SAC population are reported in Chapter 3. I did the genotyping 
for the genes CCR2, CCR5 and SDF1 and the statistical analyses for all the polymorphisms 
tested.  
 
Functional studies had identified DC-SIGN as a major M. tuberculosis receptor on human 
dendritic cells [338] and it was therefore considered a good candidate gene. The genomic region 
of CD209 was sequenced in SAC samples to identify informative markers and avoid 
ascertainment bias. This resulted in the identification of eight polymorphisms that were 
genotyped in a case-control study. The work was extended by looking at a length variation in the 
genes CD209 and L-SIGN, which is a close homologue of CD209. Results are reported and 
discussed in Chapter 4. I prepared all the samples that were subsequently genotyped, did the 
majority of the CD209 polymorphism genotyping and contributed to the writing of the article. 
 
SP110 was identified as a candidate gene for susceptibility to tuberculosis through mouse studies. 
The mouse homologue, Ipr1, was located in the sst1 locus, and mediates innate immunity to 
tuberculosis in mice [250]. As with CD209, the SP110 gene was resequenced to identify 
polymorphisms. This allowed for identification of polymorphisms that were novel and the 
determination of LD. Results are reported in Chapter 5.  
 
Finally a case-control analysis was done to test for an association with tuberculosis and 
polymorphisms in the VDR gene. There are many conflicting studies on the association of VDR 
polymorphisms and tuberculosis, and its contribution to tuberculosis susceptibility is highly 
debated. A unique sample set of cases that were all first time pulmonary tuberculosis patients 
were used in this chapter.  Apart from the case-control study, a more complex study was 
conducted on this well defined cohort of patients. This was done to investigate whether our 
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population would confirm a Peruvian study which found that VDR polymorphisms were 
associated with time to sputum conversion in tuberculosis patients [285]. A cohort of first time 
pulmonary tuberculosis patients from our SAC population, which had sputum tested at various 
time points, allowed for a similar analysis and results are described in Chapter 6. A large number 
of variables, including a reliably estimated time to sputum conversion for both smear and culture, 
were used to assess the contribution of VDR polymorphisms to sputum conversion time. The 
final analysis required new analytical methods and the construction of Cox models which were 
conducted by L. van der Merwe with my guidance and co-operation.  
 
Chapter 7 is the concluding section where general discussion of the results is given, and possible 
future study directions. Problems and difficulties that were encountered are also discussed. As 
there were many novel methods and types of equipment used in assessing the genotypes, the 
methods are presented in Appendix 1. All the different technologies are directed at the same goal; 
the genotyping of polymorphisms. The use of programs available on the internet has greatly 
advanced analysis methods and a variety of free source software was used. Knowledge of the 
variety and type of analytical/ statistical algorithms supporting them ensures correct and 
appropriate use. The information from this unique population was also deposited in publicly 
accessible databases. 
Stellenbosch University  http://scholar.sun.ac.za
20 
 
 
Chapter 2 
 
 
 
South African Coloured Population 
 
 
The major part of this Chapter was published in the following review and article: 
 
Lombard Z, Brune AE, Hoal EG, Babb C, van Helden PD, Epplen JT, Bornman L (2006)  
HLA class II disease associations in southern Africa.  
Tissue Antigens 67:97-110 
 
 
Barreiro LB, Neyrolles O, Babb CL, Tailleux L, Quach H, McElreavey K, Helden PD, Hoal EG, 
Gicquel B, and Quintana-Murci L (2006) 
Promoter Variation in the DC-SIGN Encoding Gene CD209 Is Associated with Tuberculosis.  
PLoS Medicine 3(2):e20. 
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The African continent is home to more than 2000 distinct ethnic groups and languages, 
responsible for a considerable genetic diversity among native African populations [349]. Southern 
Africa has seen waves of immigration from the African continent to the north in pre-recorded 
times, and Caucasoid and Asian during the past three and a half centuries. This population 
diversity within a uniform environment creates a unique opportunity to study population genetics 
and complex diseases of genetic etiology.    
 
The southern African population includes native African groups such as the Zulu, Xhosa, Sotho, 
Tswana, Ndebele, Swazi, Pedi, Lemba, Shona, Khoi-Khoi (Khoi) and San; the white population 
descended from Dutch, British, German and French immigrants; admixture population groups 
such as the South African Coloured (SAC), and groups of Asian descent [223, 242].  
 
Archaeological evidence indicates that southern Africa was first peopled by the ancestors of the 
San people, who exhibit the most ancient of African mitochondrial DNA lineages, the L1 lineage 
[349]. The Khoi migrated into southern Africa about 2000 years ago from the north and co-
existed with the San. Bantu-speaking pastoralists moving south entered the eastern part of 
southern Africa from approximately AD 250 [223]. Pressure from these migration waves and 
subsequent European colonization drove the remaining San into the semi-desert areas of 
southern Africa. It is likely that there was substantial admixture between southern African blacks 
and the Khoi and San, as evidenced by the presence of San-specific Gm markers in the majority 
of black South African groups, particularly the Xhosa population [123, 242]. South Africa’s 
largest population group, the Zulu, belongs to the Nguni linguistic division of the Niger-Congo 
people, as do the Xhosa [255]. The Gokomere people, a Bantu-speaking group of migrant 
farmers, inhabited the Great Zimbabwe site from about 500 A.D., displacing earlier Khoisan 
people. These were the ancestors of the Shona, who constitute approximately 80% of the current 
Zimbabwean population [242]. 
 
The SAC are an ethnic group of mixed ancestry. This distinct group emerged about 300 years ago 
and received genetic input from Malaysia and Indonesia, as well as from the European Caucasoid 
and indigenous Khoi, San and other black Africans [242, 361]. The Indian population in South 
Africa originated from different regions of the Indian subcontinent, including the Hindu group 
originating from South India, Muslims from the Gujerat and Maharashtra and the Tamil 
community, and is considered to be a hybrid population with some genetic contributions from 
Caucasoid, Black and Chinese [242, 267].   
 
The genetic diversity in southern Africa is illustrated by the varying frequencies of both the 
human leukocyte antigen (HLA) -class I [45] and -class II [182] alleles in the different groups. An 
extensive literature search illustrated the diversity of HLA class II alleles within the various 
southern African populations (Table 2.1). When focusing on the SAC population group it can be 
seen that their HLA class II allele frequencies are unique in that they do not correspond with any 
particular population group. For example the DRw5 serological specificity reflects closer to the 
black population groups whereas DR7 and DQ3 reflect more Indian than black input. The 
DRw53 frequency appears to be unique to the SAC population, being midway between that of 
the black and white population group. Comparisons of polymorphism frequencies that are 
available in the HapMap database with the SAC population has revealed similar results, where 
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certain single nucleotide polymorphism (SNP) frequencies are similar to the Caucasian 
population but others are more similar to the Asian or West African populations (unpublished 
data M. Möller). This illustrates that there have been contributions from a number of different 
populations to create the genetic makeup of the SAC population. This also has implications for 
the linkage disequilibrium and haplotypes that will be present in this population, which as 
discussed in Chapter 1 is useful for genetic association studies.  
 
The ‘Coloured’ population originated with the settlement of colonialists in the Cape over three 
centuries ago. Within the Cape there were the local indigenous populations, such as the Khoi and 
San, to which was added the white settlers and their slaves. After the subsequent biological and 
cultural assimilation the term Coloured population arose, as defined by the local community. 
Apart from a small fraction, known as the Cape Malay, which remained largely distinct because of 
their Islamic religion, the majority were Christians. Initially the distinction between different 
groups of people was based on religion, with Christianity being the dominant. Only over time 
was the distinction made through colour and racial background [55]. The name remains a label of 
the past and is not regarded as offensive, but is commonly used by the population group itself. In 
the absence of a viable alternative, the term SAC will be used in this thesis to refer to the 
population studied. It generally refers to people of the Cape who are not Bantu-speaking and do 
not have distinctive ancestry along both the maternal and paternal lines [223]. The term Coloured 
is also an official population group that is counted in Statistics SA censuses, which are reported 
to the Parliament of the Republic of South Africa. In 2006, 8.9% of the South African population 
was of the Coloured population group [1]. 
 
An alternative term that could be used is admixed population. However we feel this is too broad 
a term and the origins of the population might be misinterpreted. Understanding the ethnic 
diversity is important in understanding differences in disease incidence and this has been 
extensively discussed in the literature [19, 112, 277]. However, researchers should be aware of 
cultural sensitivities and the potential misuse of population specific genetic information in racial 
and social characterizations [315].  
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Population stratification  
 
Although this population is considered a relatively homogeneous community that has received 
genetic contribution from different populations multiple generations ago [242, 361], population 
stratification between cases and controls is possible. This can be a confounding factor leading to 
a spurious positive association. Indeed, the use of admixed populations in association mapping 
studies can be very useful to identify disease-causing genetic variants that differ in frequency 
across parental populations. However, when the admixture event is too recent, allelic frequencies 
can differ coincidentally between cases and controls, reflecting a non-uniform genetic 
contribution from the parental populations to each subpopulation (i.e., cases and controls), rather 
than a genuine association between a given genetic variant and the phenotype under study. When 
this occurs, the study-cohort is said to present population stratification. To formally test and 
quantify the levels of background genetic differences [260], if any, between cases and controls, 
the entire cohort was genotyped for a panel of independent SNP markers which are (1) not in 
linkage disequilibrium with the candidate gene locus (CD209 in Chapter 4) and with any other 
known gene, (2) randomly distributed along the genome, and (3) polymorphic among the major 
ethnic groups. 
 
In collaboration with the Pasteur Institute in Paris, France we assessed the level of population 
stratification within the SAC population. Twenty five independent SNPs were genotyped 
(Appendix 1) in the cohort of 711 individuals used in Chapter 4. The mean χ2 statistic among the 
25 SNPs, for the comparison of allele frequencies between cases and controls, which represents 
the levels of stratification (µ) between the two groups [272]. This was 1.25 (p=0.26), implying 
that the two groups were not significantly stratified (Table 2.2).  
 
The SAC population in Ravensmead and Uitsig (Chapter 1) is eminently suitable for genetic 
association studies assessing susceptibility to tuberculosis because of their uniform ethnicity and 
socio-economic status, high incidence of tuberculosis and low prevalence of HIV [32]. Being 
admixed, it represents a community originating from populations with different susceptibilities to 
tuberculosis and offers a unique opportunity to dissect the contributing genetic variants and their 
probable geographic/ethnic origins. 
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Table 2.2:  Frequency distribution in the study cohort of 25 polymorphisms used to test for 
population stratification in the SAC population cohort. 
rs number Location  ObsHET° PredHETΨ HWP MAF  MAF א  p  
          Cases (%)  Controls (%)      
rs2048022  Chr4  0.509 0.497 0.588 43.4 48.3 3.469 0.0625 
rs1380229  Chr8  0.429 0.468 0.034 36.1 38.4 0.815 0.3667 
rs650389  Chr10  0.276 0.287 0.369 15.2 19.5 4.518 0.0335 
rs870384  Chr12  0.511 0.499 0.591 48.3 46.8 0.311 0.5771 
rs695982 Chr12 0.416 0.419 0.888 32.1 27.7 3.376 0.0662 
rs708682 Chr15  0.216 0.212 0.826 11.8 12.3 0.086 0.7693 
rs715774  Chr15 0.244 0.257 0.209 14.3 16.1 0.883 0.3473 
rs1433456  Chr15  0.313 0.317 0.784 19.9 19.7 0.011 0.9169 
rs807131 Chr17 0.478 0.453 0.183 35.5 33.9 0.398 0.5279 
rs11672183  Chr19  0.214 0.209 0.649 12 11.7 0.018 0.8947 
rs2024628  Chr20  0.513 0.494 0.333 42.2 46.5 2.627 0.1051 
rs1028184  Chr2  0.461 0.464 0.9 34.2 39 3.53 0.0603 
rs2056773  Chr3  0.492 0.473 0.32 39.5 37.1 0.808 0.3687 
rs1479067  Chr5  0.398 0.395 0.972 25.9 28.4 1.099 0.2945 
rs327747  Chr7  0.374 0.399 0.111 25.8 29.2 2.084 0.1488 
rs12665321  Chr6  0.239 0.234 0.693 14.2 12.9 0.462 0.4969 
rs1566838  Chr9  0.475 0.497 0.265 46.5 45.8 0.081 0.7762 
rs12785524  Chr11  0.452 0.483 0.106 39 42.4 1.708 0.1912 
rs975423  Chr13  0.429 0.464 0.056 35.1 37.8 1.134 0.2868 
rs914904  Chr13  0.397 0.409 0.462 29.2 28.2 0.179 0.6723 
rs876287  Chr14  0.459 0.484 0.182 41.3 40.9 0.024 0.8765 
rs1582598  Chr16  0.378 0.394 0.321 27.5 26.5 0.164 0.6852 
rs1364198 Chr16  0.361 0.364 0.908 25.2 22.7 1.242 0.2652 
rs739259  Chr22  0.469 0.469 1 36.1 39 1.217 0.27 
rs169479  Chr21  0.217 0.217 1 13.3 11.5 1.064 0.3024 
°Observed Heterozygosity ΨPredicted Heterozygosity 
HWP Hardy Weinberg Equilibrium Probability MAF, Minor allele frequency 
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Chapter 3 
 
 
 
Candidate polymorphisms in genes 
RANTES, CCR5, CCR2 and SDF1. 
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3.1 Introduction 
 
Chemokine receptor 5 (CCR5) is expressed by T cells and macrophages. CCR5 is a receptor for 
macrophage inflammatory protein 1 (MIP-1) and regulated upon activation, normal T cell 
expressed and secreted (RANTES) which play an important role in the inflammatory response 
[137, 226]. CCR5 is a key entry point for human immuno-deficiency virus (HIV) into 
macrophages. It is a major co-receptor for the most commonly transmitted strains of HIV-1 
[156] and this has been widely investigated. Toossi et al found that, in HIV patients, exposure to 
Mycobacterium tuberculosis (M. tuberculosis) in vivo may upregulate the expression of CCR5 on 
mononuclear cells [350]. As uninfected mononuclear cells are recruited to sites of active M. 
tuberculosis infection and exposed to M. tuberculosis, expression of CCR5 may be maintained at high 
levels allowing transmission of HIV-1 to these newly arrived cells [350]. There is evidence that an 
increased number of CCR5-positive monocytes accumulate in the lungs of tuberculosis patients 
[95]. There is increased expression of CCR5 on CD4+ T cells in response to tuberculosis 
infection, when whole blood is incubated with the M. tuberculosis cell wall component LAM [95, 
145]. The mechanism by which CCR5 expression is increased in in vitro infection with low doses 
of M. tuberculosis and in active tuberculosis is still unknown [95]. However, CCR5 knockout mice 
were capable of recruiting immune cells to the lung to form granulomas and successfully induced 
a Th1 response and controlled M. tuberculosis infection [7]. Although several reports show the 
importance of CCR5 in attracting Th1 cells to sites of inflammation [179], the mechanistic basis 
for this effect is not clear. Granuloma formation and the immune response are regulated by host 
and mycobacterial factors, of which one is mycobacterial heat shock protein 70 (myHsp-70), 
which stimulates dendritic cells to release pro-inflammatory mediators. Recently CCR5 has been 
identified as the crucial receptor for myHsp-70 mediated dendritic cell stimulation [93]. 
 
CCR5 has two functional promoters, with the downstream promoter stronger in monocytic and 
lymphocytic cell lines, as well as in CD4+ T cells [226]. The downstream promoter is responsible 
for the majority of transcriptional activity in activated cells and contains several potential 
transcription factor binding sites, including those for TFIID, AP-1, NFκB, CD28RC and STAT 
[57, 226]. Polymorphisms in the CCR5 regulatory region result in changes in the level of CCR5 
gene transcription and mRNA expression. The structure and hypothesised function of CCR5 has 
been reviewed [224, 226]. 
 
The CCR5 A59029G (also known as -2459G [137], rs1799987) single nucleotide polymorphism 
(SNP) is in the promoter of the cis-regulatory region of the CCR5 gene [114]. The CCR5-59029G 
polymorphism results in decreased expression of CCR5 on the cell wall and therefore fewer 
potential entry points for HIV into the cell. The wildtype ‘AA’ genotype has higher promoter 
activity [48, 206] leading to increased expression of CCR5 on the cell wall. The ‘G’ allele has a 
marked effect on delaying HIV disease progression (up to a couple of years) [57, 206]. Although 
this association is not always found [85], this protective effect is independent of any protection 
conferred by CCR2-64I and CCR5∆32 in relation to HIV infection [206]. The mutation 
CCR5∆32 (rs333) is a 32 base pair (bp) deletion in the ORF in exon 4 of the CCR5 gene, 
resulting in the expression of a truncated protein [179, 297]. Homozygosity for the CCR5∆32 is 
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associated with resistance to HIV-1 infection and heterozygosity with decreased HIV-1 disease 
progression to AIDS [179, 297].  
 
Chemokine receptor 2 (CCR2) is a receptor for monocyte chemo-attractant protein-1 (MCP-1) 
which is involved in the inflammatory response. MCP-1, a β chemokine, is upregulated by M. 
tuberculosis infection in macrophages [298, 350]. The CCR2-64I (rs1799864) [155, 206] promoter 
polymorphism is a ‘G’ to ‘A’ bp change leading to a conservative substitution, valine to 
isoleucine, in the first transmembrane domain [206], which has been found to have an effect on 
HIV-1 disease progression [11, 85, 210], but not transmission [210]. The mechanism of action of 
this polymorphism is unknown [167] but it may modulate CCR5 expression by binding to CCR5 
in the cytoplasm [206]. A statistically significant decrease in the frequency of this polymorphism 
was seen between HIV seropositive and HIV seronegative controls in a study on the same ethnic 
group (SAC) [253]. 
 
The Stromal Derived Factor (SDF1) on chromosome 10, also known as pre-B cell growth 
stimulating factor (CXCL12), is a powerful chemo-attractant cytokine and is a CXCR4 ligand 
gene variant [394]. There is increasing evidence for SDF1 being involved in inflammatory 
diseases [173]. A single bp change, ‘G’ to ‘A’, occurs at position 801 in the 3’ untranslated region, 
SDF1 3’A (rs1801157). This polymorphism is represented by the SDF1β transcript but not the 
SDF1α transcript [394]. The SDF1 3’ heterozygote has been shown to have a protective effect on 
HIV infection in high risk individuals [394], where the frequency of SDF1 3’A homozygotes was 
low but had a strong protective effect against HIV progression in a large multi-centre study [394]. 
 
RANTES, also known as CCL5 and SCYA5, recruits several types of inflammatory cells 
including eosinophils, monocytes and T lymphocytes to sites of inflammation. It is a ligand for 
CCR1, CCR3, and CCR5. RANTES also induces monocyte haptotaxis (directed cell migration) 
[389], activation and proliferation of macrophages and T-cells and is found to have a significant 
role in granuloma formation [54, 294]. Mice deficient in RANTES have impaired monocyte and 
T-cell recruitment to sites of inflammation [191]. In particular, in the absence of the HIV 
protective CCR5∆32 polymorphism, the RANTES promoter polymorphisms -403 and -28 
altered HIV transmission and progression [115, 176, 205].  
 
RANTES is located on chromosome 17 in the chemokine cluster, a region which has been 
shown to contribute to susceptibility to tuberculosis and leprosy in Brazilians [141] and has been 
associated with tuberculosis to a greater extent in the last few years. In tuberculosis patients, an 
increased level of RANTES has been found in bronchoalveolar lavage fluid and in lung alveoli 
during active pulmonary tuberculosis [162, 294]. The same study showed that M. tuberculosis 
infection of monocytes and alveolar macrophages stimulated release but not production of 
RANTES [294]. The recruitment of cells is vital for granuloma formation and containment of the 
infection. RANTES recruited infected macrophages more effectively than uninfected 
macrophages, but failed to exert direct antibacterial activity [327]. RANTES efficiently recruited 
M. tuberculosis infected macrophages to CD8+ T cells but failed to exert direct antibacterial 
activity [327], although a previous report showed that RANTES and MIP-1β suppressed 
intracellular growth of M. tuberculosis by two- to three-fold [298]. The chemokine RANTES plays 
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a significant role in inducing activation and proliferation of macrophages and T cells as well as 
lymphocytes and monocytes, which are essential for granuloma formation [294].  
 
The RANTES -403A/G (rs2107538), -109T/C (rs1800825), and -28C/G (rs2280788) are 
promoter polymorphisms and the +1092 polymorphism (rs1065341) is found in the 3’ 
untranslated region of the gene. The -403A variation has been shown to have 8-fold increased 
expression of RANTES [237]. The polymorphism creates a new consensus element for the 
GATA transcription family. This suggests a role in regulation of gene expression. The 
recruitment of cells is vital for granuloma formation and containment of the infection.  
 
Because of the role of chemokines and their receptors in the immune and inflammatory response 
[63], we hypothesized that the RANTES, CCR5, CCR2 and SDF1 polymorphisms might be 
associated with tuberculosis susceptibility. 
 
3.2 Results 
 
3.2.1 Testing for an association with tuberculosis 
 
The genotypes for all polymorphisms investigated in a South African Coloured (SAC) cohort 
showed no departure from Hardy Weinberg equilibrium. The CCR5∆32 polymorphism was at 
too low a frequency (2%) in our population to provide enough power to draw any conclusions 
about an association with tuberculosis (Table 3.1). Only one tuberculosis case in the 331 samples 
tested was a homozygote for the deletion. Because of the low frequency of the deletion in this 
population, further analysis with a very large sample set would be required to determine whether 
there is an association with tuberculosis. With 80% power to detect an odds ratio of 1.86, it is 
unlikely that there is an association with the CCR5-59029 polymorphism and tuberculosis in our 
population (Table 3.1). The CCR5-59029A allele has a frequency of 0.47 in the control group. 
Results were submitted to NCBI (ss35528975). No association was found between the CCR2-64I 
polymorphism (frequency of the ‘G’ allele = 0.12) and tuberculosis (Table 3.1), SNP results were 
submitted to NCBI (ss37042809). There is no statistical difference between cases and controls 
with respect to SDF1 3’A (frequency of the A allele = 0.07) and tuberculosis.  
 
In our study population, only the wild type RANTES -109 ‘TT’ and -28 ‘CC’ were found after 
testing 30 and 63 individuals, respectively. Therefore the frequency of these polymorphisms was 
too low to have statistical power for the number of samples available. The RANTES +1092 
UTR polymorphism, genotyped in over 280 samples was not found to be associated with 
tuberculosis susceptibility in this population. 
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Table 3.1: Case-control analysis of polymorphisms in RANTES, CCR5, CCR2, and SDF1 and 
tuberculosis in the SAC population. A: Genotype frequencies. B: Allele frequencies. 
 A:       Genotype frequencies (%)    
 Allele  Cases  Controls  
Polymorphism 1  2   n 11 12 22   n 11 12 22   
 p value 
(Chi 
square) 
RANTES -403A A G  (n=433) 30 45 25  (n=461) 24.5 49.9 25.6  0.12 
RANTES +1092 C T  (n=163) 45 40 15  (n=119) 45 42 13  0.87 
CCR5-59029 A G  (n=185) 19 51 29  (n=179) 19 57 24  0.48 
CCR5∆32 wt del  (n=158) 94 5 1  (n=173) 97 3 0  0.44 
CCR2-64I G A  (n=146) 82 16 2  (n=160) 78 21 2  0.64 
SDF1 3'A A G   (n=151) <1 13 87   (n=150) 1 13 86   0.98 
 
 
 B:       Allele frequencies (%)     
  Allele   Cases  Controls   
Polymorphism 1 2   n 1 2  n 1 2  
P value 
(Fishers 
Exact) 
RANTES -403A A G  (n=433) 53 47  (n=461) 49 51  0.13 
RANTES +1092 C T  (n=163) 65 35  (n=119) 66 34  0.79 
CCR5-59029 A G  (n=185) 45 55  (n=179) 47 53  0.55 
CCR5∆32 wt del  (n=158) 97 3  (n=173) 98 2  0.31 
CCR2-64I G A  (n=146) 90 10  (n=160) 88 12  0.52 
SDF1 3'A A G  (n=151) 7 93  (n=150) 7 93  0.88 
 
 
After genotyping over 600 samples, a weak association was found with the RANTES -403 AA 
genotype, which was more frequent in cases and was significantly associated with risk of 
developing tuberculosis (p=0.026) (Table 3.2). With this sample set we did have 80% power to 
detect an odds ratio (OR) of 1.62. The RANTES -403 genotype containing a ‘G’ allele was found 
to be protective against developing tuberculosis (p=0.0122) with an OR of 1.622 (95% CI of 
1.113 to 2.365). To ensure that this was a true association, an additional set of 281 samples were 
genotyped, namely 212 controls and 69 cases from the same population. This gave a final total of 
461 controls and 407 cases, which had 80% power to detect an OR of 1.47. However, the 
association was lost as it went from p=0.026 to p=0.134 with the testing of additional samples 
(Table 3.1).  
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Table 3.2: Genotyping of RANTES -403 in the initial 613 samples of the SAC cohort. 
 Controls  Cases P value*,^ 
Genotype n %  n %  
AA 53 21  111 30  
AG 136 55  165 45  
GG 60 24  88 24 0.0262 
 249   364   
Allele       
A 242 49  387 53  
G 256 51  341 47 0.1304 
Total 498   728   
*Genotype associations were analyzed using Chi Square.  
^ Allele associations were analyzed by a Fisher exact Test. 
 
 
Within the 461 tuberculosis cases genotyped, 48 were tuberculous meningitis (TBM) patients. 
Analysis of these cases on their own showed no association between susceptibility to TBM and 
the RANTES -403 polymorphism (Table 3.3). We had 80% power to detect an OR of 2.45 with 
a 95% CI. 
 
Table 3.3: Genotyping of RANTES -403 in TBM patients in the SAC cohort. 
   Controls   TBM   P value* 
Genotype  n %  n %   
AA  113 24.5  18 37.5   
AG  230 49.9  22 45.8   
GG   118 25.6   8 16.7   0.11 
Total  461   48    
* Chi-square analysis was done     
 
 
The polymorphisms CCR5-59029 and CCR2-64I were found to have a linkage disequilibrium 
(LD) of D’=0.825, r2=0.09 in this population. The frequency of the CCR5∆32 (2%) was too low 
to calculate LD. There was strong LD between RANTES -403 and RANTES +1092 with 
D’=0.972 and r2=0.469. 
 
CCR2 and CCR5 genes are separated by 19 kb on chromosome 3, therefore haplotype analysis 
was done between the polymorphisms investigated in these two genes [67]. The effects of CCR2 
and CCR5 polymorphisms have been found to be additive in HIV cohorts [394]. There is 
increasing evidence that the haplotypes formed between CCR2 and CCR5 are important for 
susceptibility to disease. CCR5 haplotype diversity has been found to be highest in Africans, and 
only a subset of these haplotypes were found in non-African populations [114]. As the 
haplotypes were inferred we also looked at manually constructed diplotypes. No significant 
difference in haplotype or diplotype frequencies was found between case and controls (p=0.59) 
(Table 3.4 and 3.5).  
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Table 3.4: Haplotype frequencies inferred by the programs Phase and Haploview for the CCR5 
and CCR2 gene polymorphisms CCR5-59029, CCR5∆32 and CCR2-64I in tuberculosis cases and 
healthy controls from the SAC population. 
CCR5∆32, CCR5-59029, CCR2-64I 
All 
(n=459) 
Tuberculosis 
Cases 
(n=218) 
Controls 
(n=241) 
wt/G/G 0.530 0.539 0.518 
wt/A/G 0.336 0.327 0.345 
wt/A/A 0.103 0.096 0.108 
∆32/A/G 0.022 0.028 0.018 
wt/G/A 0.011 0.010 0.011 
∆32/A/A <0.01 0.000 <0.001 
∆32/G/G <0.01 <0.001 <0.001 
Global p value =0.59 
 
 
Table 3.5: Diplotypes of the CCR5-59029, CCR5∆32 and CCR2-64I gene in tuberculosis cases 
and healthy controls from the SAC population. 
CCR5∆32, CCR5-59029, CCR2-64I 
Tuberculosis 
Cases 
freq 
Controls 
freq 
hetero/AA/GG 0 0 2 0.03 
 wt/AA/GA 2 0.03 3 0.04 
 wt/AA/AA 1 0.01 2 0.03 
homo/AA/GG 1 0.01 0 0 
 wt/AA/GG 8 0.1 10 0.13 
hetero/AG/GG 4 0.05 2 0.03 
 wt/AG/GA 9 0.11 8 0.1 
 wt/AG/GG 28 0.35 35 0.44 
 wt/GG/GA 1 0.01 1 0.01 
 wt/GG/GG 25 0.32 17 0.21 
Global p value =0.6604 
 
No association was found between the RANTES haplotypes or diplotypes and tuberculosis 
susceptibility (Table 3.6 and 3.7). No RANTES -403G/ +1092T haplotype was identified in this 
population. The RANTES -403 AA/+1092 CT haplotype is more frequent in cases than 
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controls, but not significantly. With the use of GAIA [188] no interactions were observed 
between the various polymorphisms. 
 
Table 3.6: Haplotypes inferred by Phase and Haploview for the RANTES gene polymorphisms -
403 and +1092 in tuberculosis cases and controls from the SAC population. 
RANTES -403, +1092 All (n=637) Tuberculosis Cases 
(n=389) 
Controls (n=257) 
A/C 0.180 0.172 0.183 
A/T 0.338 0.330 0.342 
G/C 0.477 0.490 0.468 
Global p value = 0.28 
 
Table 3.7: Diplotypes of the RANTES gene polymorphisms -403 and +1092 in tuberculosis 
cases and healthy controls from the SAC population. 
 RANTES -403, +1092 
Tuberculosis 
Cases Freq 
 
Controls Freq 
AA/ CC 4 0.03 5 0.05 
AA/ CT 17 0.12 4 0.04 
AA/ TT 22 0.15 14 0.13 
AG/ CC 27 0.19 22 0.20 
AG/ CT 40 0.28 39 0.35 
GG/ CC 33 0.23 25 0.23 
GG/ CT 0 0.00 2 0.02 
Chi square p value = 0.2130 
3.3 Discussion 
 
Susceptibility to tuberculosis was investigated by means of a case-control study in a SAC 
population, to determine whether there is an association with polymorphisms in the genes 
RANTES, CCR5, CCR2 and SDF1. All these genes are important in the inflammatory response 
and have been found to be associated with susceptibility and progression of a number of 
diseases, primarily HIV. We found no statistically significant associations between tuberculosis 
susceptibility in the SAC population and the chemokine RANTES -403 promoter polymorphism, 
or with the polymorphisms CCR5-59029, CCR2-64I and SDF1 3’A. The CCR5∆32 and 
RANTES -109, -28, +1092 polymorphisms were all at too low a frequency in this population for 
meaningful analysis. We determined the frequencies of these polymorphisms that are known to 
influence HIV susceptibility and disease progression in this South African population, which has 
a relatively low prevalence of HIV at present [252, 253].  
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As stated above, the polymorphisms CCR5-59029, CCR2-64I and SDF1 3’A were not associated 
with tuberculosis in the SAC population. Both CCR5-59029 AA and CCR2-64I are promoter 
polymorphisms which increase expression of their respective genes. With the CCR5-59029 G 
polymorphism there is decreased expression of CCR5 on the cell wall and therefore fewer entry 
points for HIV into the cell. These mechanisms do not appear to be important in tuberculosis 
disease. The CCR5∆32, RANTES -109, -28 and +1092 polymorphisms were at low frequencies 
in this population.  
 
The CCR5∆32 mutation appears to have an European origin with a heterozygote frequency of 
about 20% in Caucasians [48, 95, 179]. It is rare to almost absent in African and some Asian 
populations [297], and was not found in the San population of Southern Africa [67]. This 
deletion appeared to have been subjected to positive selection pressure in the European 
population and recent speculation on the causative agent has included bubonic plague, smallpox 
and hemorrhagic fever [67, 102].. However Sabeti et al (2005) found no evidence for selection of 
CCR5∆32 and concluded that neutral evolution could be responsible for the frequencies seen in 
today’s populations [293]. Homozygosity for the 32 bp deletion confers resistance against HIV 
infection and heterozygosity is associated with decreased HIV disease progression to AIDS [68, 
179, 209, 297]. 
 
The 2% allele frequency of CCR5∆32 found in the SAC population is probably due to admixture 
with the European population, which is also hypothesised to be the origin of the 2% frequency 
seen in African American populations [48, 156] (Table 3.8).  
 
 
Table 3.8: Allele frequencies of the polymorphisms CCR5-59029, CCR5∆32, SDF1 3’A, CCR2-
64I, RANTES -403 and +1092 in the literature and the SAC controls (in bold). 
  SA 
Caucasian 
US 
Caucasian 
SA 
Black 
African 
American 
US Hispanic SAC 
CCR5 59029 (A) 
rs1799987 0.51 
0.53 [310] 
0.44 [67] 
0.57 [206] 
0.48 
0.46 [310] 
0.56 [67] 
0.43 [206] 
0.51 [311] 
0.68 [206] 
0.48 
CCR5∆32 rs333 
0.09 [392] 
0.09 [67] 
0.10 [48] 
0.06 [156] 
0 [127, 392] 
0.02 [48, 67, 156] 
 
0.02 [156] 
0.03 [67] 
0.03 [127] 
0.02 
SDF1 3’A 
rs1801157 0.21 [392] 
0.19 [310], 
0.21[394] 
0.01[392] 
0.077 [310], 
0.06 [394] 
0.16 [394] , 
0.19 [310] 
0.07 
CCR2 64I 
rs1799864 
0.07 [392] 
0.10 [253] 
0.09 [310] 
0.13 [392] 
0.17 [253] 
0.16 [310] 0.13 [310] 
0.12 
0.17 [253] 
RANTES -403A 
rs2107538 - 0.19 - 0.48 0.24 0.51 
RANTES 
+1092T 
rs1065341 
- 0.06 - 0.32 0.05 0.34 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  41 
 
An association between susceptibility to tuberculosis and the RANTES -403 polymorphism was 
initially found in our South African cohort, with the AA genotype being more frequent in cases 
than controls, but this did not hold up to validation. It was initially characterised by the AA 
genotype being more frequent in tuberculosis cases than controls. However when additional 
samples were genotyped, the significant difference between cases and controls was lost. This is an 
indication of the importance of replicating association studies, as they might not be true 
associations. The initial p value in this study was not strong (p=0.03) and after multiple testing 
correction using Bonferroni, the association would have been lost. No association was found 
with TBM and the RANTES -403 polymorphisms either. 
 
Haplotypes were inferred for CCR5-59029, CCR5∆32 and CCR2-64I polymorphisms but no 
significant associations were found with any specific haplotype. However a larger percentage of 
cases had the RANTES -403 AA/ +1092 CT diplotype compared to controls (Table 3.7) but this 
was not significant.  
 
Previous studies have shown that the RANTES -403A allele is in strong LD with the         
RANTES -28G polymorphism and the haplotype A/G is associated with increased production 
of RANTES [176, 237]. Therefore it has been predicted that the RANTES -403A allele would be 
associated with increased production of the chemokine [237]. It is observed that the AA 
genotype is a risk factor, and the G allele-containing genotypes are protective.  
 
A study by Stegelmann et al [327] has shown that RANTES is important in the adaptive immune 
response for M. tuberculosis infection and that previous exposure is important for macrophages to 
trigger RANTES expression in CD8+ T cells. BCG vaccination is widespread in the population 
studied here and there is a tremendous infection pressure in this community [372] so the 
probability that controls have been exposed to M. tuberculosis is extremely high. In a randomised 
survey within our study community, of 2401 adults analysed 76% had a positive TST result [71, 
393]. In this community the adaptive immune response is more than likely activated, so CD8+ T 
cells will express RANTES.  
 
Although there has been a fair amount of speculation on the similarities of pathogen entry into 
the cells in HIV and tuberculosis, it would appear from these results that the method of 
pathogenesis is sufficiently different that SNPs in RANTES, CCR2, CCR5 and SDF1, that have 
an effect on HIV infection and/or progression to disease, do not affect the development of 
tuberculosis disease.  
■ 
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Chapter 4 
 
 
Re-sequencing of  the DC-SIGN (CD209) 
gene and genotyping of  polymorphisms, 
including a length variation and a L-SIGN 
length variation. 
 
These results were published: 
 
Barreiro LB, Neyrolles O, Babb CL, Tailleux L, Quach H, McElreavey K, Helden PD, Hoal EG, 
Gicquel B, Quintana-Murci L (2006) Promoter Variation in the DC-SIGN Encoding Gene 
CD209 Is Associated with Tuberculosis. 
PLoS Medicine 3:e20 
 
Barreiro LB, Neyrolles O, Babb CL, van Helden PD, Gicquel B, Hoal EG, Quintana-Murci L 
(2007) Length Variation of DC-SIGN and L-SIGN Neck-Region has no Impact on Tuberculosis 
Susceptibility. 
Human Immunology 68:106-12
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4.1 Introduction 
 
Phagocytic cells express a range of cellular receptors, known as pattern recognition receptors 
(PRR), involved in sensing micro-organisms [142]. One of the ways macrophages and dendritic 
cells (DC) perform their function in the innate immune system is through PRR. DCs bear a range 
of PRR, such as C-type lectins and Toll-like receptors, involved both in recognition of conserved 
microbial molecules and in the induction of adaptive immunity [142, 208, 341]. In particular, C-
type lectins detect pathogens by their characteristic carbohydrate structures and internalise them 
for further antigen processing and presentation [207]. PRR bind to conserved microbial ligands, 
promoting phagocytosis and antigen presentation, and trigger intracellular signalling and cytokine 
secretion [264]. The quality of this initial pathogen recognition can have important consequences 
for both the outcome of infection and the pathogenesis of infectious disease. Two particular PRR 
of the C-type lectin receptor family, dendritic cell-specific intercellular adhesion molecule 
(ICAM)-3 grabbing nonintegrin (DC-SIGN, encoded by CD209) and dendritic cell-specific  
ICAM-3 grabbing nonintegrin related (L-SIGN, also known as DC-SIGNR) have recently been 
the focus of considerable  attention [65, 107, 108, 257, 319]. These two lectins, are encoded by 
two genes located on chromosome 19p13.2-3 within a ~26 kb segment [25, 318]. 
 
DC-SIGN is specifically, though not exclusively, expressed on DCs and functions both as a cell 
adhesion receptor and as a PRR [321]. As an adhesion receptor, it plays an important role in 
many DC functions, such as DC-T cell interaction and DC migration [106, 107]. Besides its 
cellular recognition role, DC-SIGN serves as pathogen uptake receptor and mediates interactions 
with a plethora of pathogens other than M. tuberculosis [108]. Indeed, it has been shown that    
DC-SIGN allows DCs to capture other bacteria such as Helicobacter pylori and certain Klebsiella 
pneumonia strains, but also viruses such as HIV-1, Ebola, cytomegalovirus, hepatitis C virus 
(HCV), dengue, and severe acute respiratory syndrome coronavirus (SARS-coV), and parasites 
like Leishmania pifanoi and Schistosoma mansoni [8, 12, 30, 60, 105, 118, 185, 203, 340, 366]. In 
addition, recent data suggest that DC-SIGN may mediate intracellular signalling events leading to 
cytokine secretion and, on this basis, it has been proposed that the lectin could be used by 
pathogens, including M. tuberculosis, as part of an immune evasion strategy to their own advantage 
[109, 336]. 
 
Interactions between the tubercle bacillus and host phagocytes are crucial for immunity to 
mycobacteria and for tuberculosis pathogenesis [149]. DC-SIGN has been shown to be an 
important M. tuberculosis receptor on the surface of human monocyte derived DCs [109, 338], 
and, more recently, it has been shown that L-SIGN can also interact with the tubercle bacillus 
[154]. Both DC-SIGN and L-SIGN binding to M. tuberculosis is mediated by the mycobacterial 
cell-wall component mannosylated lipoarabinomannan (ManLAM) [365, 366] but does not bind 
to AraLAM, which is effectively LAM without the mannose cap [189]. This is intriguing because 
AraLAM is abundant in fast-growing atypical, avirulent mycobacteria, such as M. smegmatis and M. 
fortuitum whereas ManLAM is abundant in slow-growing virulent mycobacteria such as M. 
tuberculosis and M. leprae [109, 338, 366]. Pathogens that interact with DC-SIGN appear to have 
the features of being able to cause chronic infections that can last a lifetime. There is evidence 
that they manipulate the Th1 versus the Th2 cell balance which is central to their persistence 
[366].   
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DC-SIGN and L-SIGN exhibit high nucleotide (73%) and amino-acid (77%) identity, and 
identical exon-intron organization [318]. An additional characteristic of both lectins is the 
presence of a neck region, made up of primarily 7 highly conserved 23 amino-acid repeats, that 
separates the carbohydrate recognition domain (CRD) involved in pathogen binding from the 
transmembrane region. With regard to expression profiles, DC-SIGN is expressed mainly on 
endocytic cells, such as DCs and macrophages, whereas L-SIGN is expressed on endothelial cells 
in liver and lymph nodes, and in cells lining placental capillaries [24, 320, 321]. DC-SIGN and     
L-SIGN share the ability to bind high–mannose oligosaccharides through their CRD. 
 
The extent to which the length of the neck region of both DC-SIGN and L-SIGN might have an 
impact on the host susceptibility to tuberculosis is unclear at present. This tandem-repeat region, 
which shows a varying degree of length polymorphism [25, 227], is involved in assembling both 
lectins into a tetrameric protein conformation on the cell surface, and the length of this region 
can critically influence the pathogen-binding properties of the CRD of these proteins [87, 117, 
316]. At the population level, the length of the DC-SIGN neck region is highly conserved (mainly 
7 repeats), whereas the L-SIGN neck region exhibits an extraordinarily high level of 
heterozygosity [20]. Furthermore, several studies suggest that the number of DC-SIGN and/or   
L-SIGN repeat units can contribute to the risk of HIV-1 [175, 177] and SARS infections [51], as 
well as to HCV replication efficacy [231]. 
 
Considering the ability of both DC-SIGN and L-SIGN to bind M. tuberculosis, the fact that neck-
region length-variation may determine the ligand-binding capacities of these lectins and the 
observation that variation in these regions is associated with a number of infectious diseases, we 
hypothesized that variations in the DC-SIGN and L-SIGN neck regions might affect individual 
susceptibility to tuberculosis. To test this hypothesis, we explored the CD209 promoter region 
and the relationship between the DC-SIGN and L-SIGN tandem repeat variation in the neck 
region and susceptibility to tuberculosis. 
 
4.2 Results 
 
4.2.1 DC-SIGN gene variation and susceptibility to tuberculosis 
 
The CD209 gene was sequenced in over 20 random South African Coloured (SAC) samples. L. 
Barreiro (Pasteur Institute) conducted the analysis of these results in collaboration with ourselves 
and determined which single nucleotide polymorphisms (SNP) were possibly tagSNPs. In total, 
eight haplotype-tagging SNPs were genotyped in all samples. Two variants located in the CD209 
promoter region (-871 A/G and -336 A/G) exhibited a frequency distribution significantly 
distorted between tuberculosis patients and controls, as indicated by a Chi-square (χ2) test (Table 
4.1).  
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Table 4.1: DC-SIGN genotype distributions in patients with tuberculosis and in healthy 
controls. 
   Genotypes frequencies (%)      
   Cases (N=351)  
Controls 
(N=360)  Cases vs. Controls† 
htSNP* 1 2 11 12 22   11 12 22   p OR 
-939 G A 52.1 39 8.8  45.3 46.9 7.8  0.07 0.76 (0.57-1.02) 
-871 A G 83.2 15.7 1.1  72.8 26.1 1.1  8.2x10-4 1.85 (1.29-2.66) 
-336 A G 29.3 50.4 20.2  38.1 43.3 18.6  0.01 1.48 (1.08-2.02) 
-139 A G 8.3 37.6 54.1  7.2 43.1 49.7  0.24 0.84 (0.62-1.13) 
2392 G A 96.6 3.4 0  95 4.7 0.3  0.29 0.67 (0.32-1.42) 
3220 T C 74.6 23.4 2  75.8 22.8 1.4  0.71 1.07 (0.76-1.50) 
3838 A C 80.1 17.9 2  84.7 14.4 0.8  0.1 1.38 (0.94-2.04) 
4235 G C 51.6 41 7.4   57.2 37.8 5   0.13 1.26 (0.94-1.69) 
* All htSNPs (haplotype tagging SNPs) were in Hardy Weinberg (HW) equilibrium 
† The Homozygotes for the most frequent allele were compared with the sum of the homozygotes 
and heterozygotes for the rare allele 
 
 For the -871 variant, genotypes GG and GA were less frequently observed in cases (16.8%) 
compared to the control group (27.2%) (p = 8.2 x 10-4). For the -336 variant, genotypes GG and 
GA were more frequent in cases (70.6%) than in controls (61.9%) (p = 0.01). These observations 
suggest that the alleles -871A (odds ratio (OR): 1.85; 95% confidence interval (CI): 1.29–2.66) 
and -336G (OR: 1.48; 95% CI: 1.08–2.02) increase the risk of developing tuberculosis in our 
cohort.  
 
At the haplotype level (Table 4.2), a χ2 test showed that the global distribution of haplotype 
frequencies was significantly different between cases and controls (p=1.2x10-3). One haplotype 
(H3) was found to be the haplotype responsible for most of the distorted frequency distribution 
(Table 4.2). This haplotype, which contains both -871G and -336A, was found to be strongly 
associated with the control group (p=1.6x10-3; OR: 1.7; 95% CI: 1.22– 2.38). The associations 
with this haplotype, and with the -871 SNP, remained highly significant (p = 1.3 x 10-2 and 6.6 x 
10-3 respectively), even after the conservative Bonferroni correction for multiple testing. Figure 
4.1 shows the linkage disequilibrium (LD) plot of the eight SNPs genotyped in the CD209 
promoter region. Block 1 contains the -871 and -336 SNPs. Permutation tests were done in 
Haploview, which also found block 1 -871G/-336A haplotype to be associated with tuberculosis 
(p=0.0022).  
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Table 4.2: DC-SIGN Haplotype distribution in patients with tuberculosis and in healthy controls. 
 Haplotype frequencies (%)  Cases vs. Controls§ 
Haplotype‡ Cases Controls   p OR 
H1-AAAGGTCG 10 6.2  0.01 1.70 (1.15-2.52) 
H2-AAAGGTAG 7.6 9.3  0.25 0.80 (0.55-1.16) 
H3-AGAGGTAG 8.9 14.2  1.6x10-3 1.70 (1.22-2.38) 
H4-GAAAGTAG 26 27.9  0.41 0.91 (0.72-1.15) 
H5-GAGGGTAG 17.3 15  0.25 1.17 (0.88-1.55) 
H6-GAGGGTAC 12.2 8.5  0.02 1.49 (1.05-2.11) 
H7-GAGGATAC 1.7 2.2  0.44 0.77 (0.36-1.63) 
H8-GAGGGCAC 12.8 11.2   0.35 1.16 (0.84-1.60) 
‡ Haplotypes with frequency greater than 1%. The alleles are ordered from SNP-939 until SNP4235  
§ The frequency of each haplotype in cases and controls was compared with the sum of all the others 
 
 
Figure 4.1: Linkage Disequilibrium plot for the eight polymorphisms genotyped in DC-SIGN 
gene of the cases and controls. 
 
 
 
To correct for potential stratification, we divided the χ2 values obtained for our candidate gene 
CD209 by the level of stratification detected in this population sample set (1.25) (Chapter 2) 
[272]. Even after such a conservative correction, the associations observed with -336 and -871 as 
well as with H3 remained significant (CD209-336 p = 2.8 x 10-2; CD209 -871 p = 2.7x 10-3; H3   
p = 4.8 x 10-3). These observations therefore support the idea that the -871G and -336A variants 
are indeed genuinely associated with a protective role against tuberculosis. 
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4.2.2 Repeat units in neck regions of DC-SIGN and L-SIGN 
 
The allelic and genotype frequencies of the DC-SIGN and L-SIGN neck-region tandem repeats 
in the 351 tuberculosis patients and 360 healthy controls are summarized in Table 4.3 and 4.4, 
respectively. When examining the allelic frequencies of repeat units for DC-SIGN and L-SIGN 
neck regions, no statistical differences were observed between tuberculosis cases and healthy 
controls (Table 4.3). 
 
Table 4.3: DC-SIGN and L-SIGN neck-region allelic frequencies among patients with 
tuberculosis and healthy controls. 
 DC-SIGN  L-SIGN 
Alleles 
Cases    
(n =702) 
Controls 
(n=720) p OR (95% CI)   
Cases    
(n=702) 
Controls 
(n=720) p OR (95% CI) 
4          0.14  0 0.49 nc  0.43 0.69 0.5 0.61 (0.15-2.58) 
5          0.28  0 0.24 nc  9.40 11.81 0.14 0.78 (0.55-1.09) 
6          1.28  0.97 0.58 1.32 (0.49-3.57)  28.49 24.17 0.06 1.25 (0.99-1.59) 
7        98.15  98.89 0.25 0.60 (0.25-1.45)  58.40 59.72 0.61 0.95 (0.77-1.17) 
8          0.14  0.14 1 1.02 (0.06-16.43  0.43 0.97 0.22 0.44 (0.11-1.70) 
9             -    0 - nc   2.85 2.64 0.81 1.08 (0.57-2.05) 
n= Number of chromosomes analyzed       
nc= not computable      
 
 
Table 4.4: DC-SIGN and L-SIGN neck-region genotype frequencies among patients with 
tuberculosis and healthy controls. 
 DC-SIGN  L-SIGN 
Genotype 
Patients 
(n=351) 
Controls 
(n=360) p OR (95% CI)   
Patients 
(n =351) 
Controls 
(n=360) p OR (95% CI) 
4/4 0 0 - nc  0 0.28 1.00 nc 
5/4 0 0 - nc  0.28 0 1.00 nc 
5/5 0 0 - nc  0.57 2.5 0.06 0.22 (0.04-1.04) 
6/4 0 0 - nc  0.28 0.56 1.00 0.51 (0.05-5.67) 
6/5 0 0 - nc  5.13 5.28 0.93 0.97 (0.50-1.88) 
6/6 0 0 - nc  7.12 5.83 0.48 1.24 (0.68-2.26) 
7/4 0.28 0 1.00 nc  0.28 0.28 1.00 1.03 (0.06-16.46) 
7/5 0.57 0 0.24 nc  12.25 13.33 0.67 0.91 (0.58-1.41) 
7/6 2.56 1.94 0.58 1.33 (0.49-3.60)  36.18 29.72 0.07 1.34 (0.98-1.83) 
7/7 96.30 97.78 0.24 0.59 (0.24-1.44)  31.34 35.28 0.27 0.84 (0.61-1.14) 
8/6 0 0 - nc  0 0.28 1.00 nc 
8/7 0.28 0.28 1.00 1.03 (0.06-16.46)  0.85 1.67 0.51 0.51 (0.13-2.05) 
9/6 0 0 - nc  1.14 0.83 0.72 1.37 (0.30-6.17) 
9/7 0 0 - nc  4.56 3.89 0.66 1.18 (0.57-2.46) 
9/9 0 0 - nc   0 0.28 1.00 nc 
n=  number of individuals nc= not computable    
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In the case of DC-SIGN, the 7-repeat allele was by far the most frequently observed, with a 
frequency of more than 98%. As for L-SIGN, the 7-repeat and the 6-repeat alleles account for 
more than 83% of the overall diversity. We next examined whether the frequency distributions of 
DC-SIGN or L-SIGN neck-region genotypes were significantly different between cases and 
controls. Again, no significant differences were detected between diseased individuals and healthy 
controls for either DC-SIGN or L-SIGN. With regard to DC-SIGN, low genotypic variation was 
observed in accordance with the allelic data. The 7/7 genotype accounted for nearly all genetic 
variation (more than 96%), and genotypes 7/4, 7/5, 7/6, and 7/8 were observed at very low 
frequencies (Table 4.4). For L-SIGN, the genotypes 7/7 and 7/6 were present at similar 
frequencies (30 –36%), followed by 7/5 (~12%), 6/6 (~6%), 6/5 (~5%), and 9/7 (~4%).  
 
4.2.3 Frequency distribution of DC-SIGN -871 and -336 polymorphisms 
 
In order to gain insights into the frequency distribution, these two SNPs, were genotyped in 254 
human chromosomes from sub-Saharan Africa, Europe, and East Asia as well as in eight 
chimpanzee chromosomes. Samples from African, Asian and European populations were 
provided by L. Quintana-Murci, Pasteur, France. We observed that the -871G and -336A forms, 
which we propose offer protection against tuberculosis, corresponded to the derived allele in 
humans; we also observed that these forms are present at higher frequencies in Eurasians as 
compared to Africans (Table 4.5).  
 
Indeed, the -871G is absent in African populations, whereas it reaches high frequencies (20%–
40%) in European and Asian populations. Given the absence of the haplotypic combination of -
871G and -336A among sub-Saharan Africans, its presence among SAC suggests that it was 
introduced through the historically well known admixture with Europeans and Asians (Chapter 
2) [361]. This observation highlights the power of using admixed populations to better 
understand historical issues associated with the geographic/ethnic origin of disease-affecting 
alleles, provided that their prevalence varies in the ancestors of the admixed population (i.e., 
different frequency of H3 in Africans versus non-Africans; Table 4.5) (Chapter 2). The SAC 
population represents a present-day homogeneous population which originated from the variable 
admixture of different populations, such as African Khoisan and Bantu-speakers, Malaysians, 
Indians, and Europeans (Chapter 2) [242, 361]. Consequently, the SAC population presents a 
large degree of genetic diversity, resulting in a high number of alleles or genotype combinations 
that can be used in association studies. For example, the L-SIGN genotypes 6/5, 7/5, and 9/7 
are observed at relatively high frequencies among the South Africans (providing evidence for the 
genetic input received from European and Asian populations), whereas they are rare or even 
absent in other sub-Saharan African populations [20]. The presence of these genotypes in the SA 
population offers a unique opportunity for testing their association with disease in a single 
population, a hypothesis that would be difficult to test in other African populations because these 
genotypes are found at a very low frequency, or are even absent.  
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Table 4.5: Frequency distribution of the eight CD209 polymorphisms genotyped in the multi-
ethnic panel of 127 individuals (n=254 chromosomes) as well as in the 711 individuals of the 
SAC cohort (n=1422 chromosomes) 
 
 Population frequencies (%) 
Polymorphism Variant* 
African 
(N=84) 
Asian 
(N=86) 
European 
(N=86) 
SAC 
(N=1422) 
A 45.1 29.1 54.7 29.8 -939 
G 54.9 70.9 45.3 70.2 
A 100 79.1 61.6 88.4 -871 
G 0 20.9 38.4 11.6 
G 37.8 5.8 20.9 42.8 -336 
A 62.2 94.2 79.1 57.2 
G 87.8 33.7 75.6 72.1 -139 
A 12.2 66.3 24.4 27.9 
G 100 98.8 91.9 97.8 2392 
A 0 1.2 8.1 2.2 
C 14.6 0 0 13.2 3220 
T 85.4 100 100 86.8 
A 70.7 100 90.7 90.5 3838 
C 29.3 0 9.3 9.5 
G 76.8 96.5 86 74.1 4235 
C 23.2 3.5 14 25.9 
*The allele in bold corresponds to the derived allele when compared with 
the sequence of the chimpanzee 
 
4.3 Discussion 
 
In the context of tuberculosis, it has been suggested that present-day susceptibility to tuberculosis 
is determined by previous history of exposure [243]. There is fairly convincing evidence that 
tuberculosis has been endemic in Europe for several hundred years, whereas in Africa it has 
probably been rare before contact was initiated with Europeans [66, 325, 326]. It is expected 
therefore that M. tuberculosis has exerted stronger selective pressures on European than African 
populations [325]. Our results lend support to this hypothesis and suggest that the protective 
alleles -871G and -336A increased in frequency in non-African populations as a result of genetic 
adaptation to a longer period of tuberculosis exposure. The potential impact of tuberculosis on 
the frequency of resistant alleles in European populations has recently been addressed using 
epidemiological data and statistical modelling [174]. They sought to evaluate the expected 
changes in resistant allele frequencies, during the 300 year period corresponding to the peak 
epidemics of tuberculosis in Europe. They concluded that if a given resistant allele was at a low 
frequency in the beginning of an epidemic, selection by M. tuberculosis alone would increase the 
frequency of this allele, but not significantly. In this context, since DC-SIGN is known to interact 
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with a vast range of pathogens, it is indeed likely that the increased frequencies observed today 
for both -871G and -336A in non-African populations (specially for -871G which is absent in 
sub-Saharan Africans) may have been driven, not only by the selective pressures imposed by M. 
tuberculosis, but also by other infectious agents. Indeed, two independent studies have reported a 
genetic association between the -336A variant and protection against parental HIV infection 
[200] and severity of dengue pathogenesis [295]. Although HIV infection, for example, is too 
recent to have left any signature of selection on CD209, these observations emphasize the 
possible action of other pathogens in shaping the patterns of variability of this gene.  
 
From a functional point of view, the -336A allele has been shown to affect an Sp1-like binding 
site and to modulate transcriptional activity in vitro by increasing the levels of expression of     
DC-SIGN [295]. In the context of tuberculosis, increased DC-SIGN expression levels by DCs 
may result in better capture and processing of mycobacterial antigens, leading to a stronger and 
wider T-cell response. In addition, it has recently been shown that DC-SIGN expression is 
markedly induced in alveolar macrophages in active tuberculosis patients and that M. tuberculosis is 
preferentially phagocytosed by DC-SIGN-expressing macrophages in these individuals [337, 338]. 
Thus, the higher prevalence observed among healthy individuals of the -336A variant, which is 
associated with increased DC-SIGN expression, may underlie an increased efficiency of host 
phagocytes, such as DCs and macrophages, to control the infection. In addition to the -336A 
variant, our genetic data showed a strong association of the -871G allele with healthy controls, 
suggesting also a functional consequence of this variant that, either alone or in combination with 
-336A, remains to be defined. 
 
The results also indicate that the number of repeats of the DC-SIGN and L-SIGN neck regions 
does not seem to influence the host susceptibility to develop tuberculosis. In the case of         
DC-SIGN, our results are in agreement with a case-control study in a cohort of north-western 
Colombian origin [113]. In this report, the authors analyzed DC-SIGN neck-region variation in a 
cohort of 110 tuberculosis patients and 299 matched controls, and observed no statistical 
differences between the two study groups. Thus, both studies support the notion that length 
variation of the DC-SIGN neck region does not influence the host susceptibility to develop 
tuberculosis.  
 
In the context of other infectious diseases, the only positive association published so far between 
DC-SIGN neck-region variation and susceptibility to infectious disease is restricted to HIV-1 
infection [177]. In this study, they observed an excess of heterozygous individuals for DC-SIGN 
tandem-repeats (repeat deletion 7/6) in a group of repeatedly exposed seronegative individuals, 
compared HIV-1 seronegative and HIV-1 seropositive individuals. These observations were 
interpreted to imply that heterozygosity in the DC-SIGN neck region can be associated with 
reduced susceptibility to HIV-1 infection [177]. At the level of the general population, it is of 
interest that the DC-SIGN neck region exhibits a very low level of the polymorphism [20, 24]. 
The entire Human Genome Diversity Panel (CEPH panel), which is composed of more than 
1,000 control individuals from 52 different ethnic groups, was recently screened for repeat 
variation in the neck regions of both DC-SIGN and L-SIGN [20]. For DC-SIGN, it was observed 
that the 7-repeat allele accounts for nearly all genetic variation (~99%), and that the other alleles, 
which range from 2–10 repeats, are present at very low frequencies. In addition, the levels of 
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sequence variation in the entire DC-SIGN coding-region, particularly of those that affect amino-
acid identity, were found to be extremely low [20]. The low levels of genetic variation observed in 
the DC-SIGN coding region are also reflected in the context of disease association studies. 
Indeed, the different associations published so far between DC-SIGN genetic variation and 
susceptibility to infectious disease always involve polymorphisms in the DC-SIGN promoter 
region, and not polymorphisms in the coding region [200, 295]. We have now also shown this 
with the -336 and -871 promoter region SNPs [21]. The genetic variation in DC-SIGN has been 
associated with protection against parental HIV-1 infection [200] and with the severity of dengue 
pathogenesis [295] and involves polymorphisms (i.e. -336A/G) restricted to the DC-SIGN 
promoter region. Taken together, all these studies support the view that it is the variation in the 
amount of DC-SIGN protein being produced that can influence infectious disease susceptibility, 
and not differences in the DC-SIGN protein itself or variation in its neck region.  
 
This study presents the first investigation of the role of L-SIGN neck-region variation in 
susceptibility to tuberculosis. A number of studies have already explored possible correlations 
between L-SIGN neck-region variation and susceptibility to other infectious diseases [51, 171, 
175, 231]. For example, the L-SIGN tandem-repeat 7/5 genotype has been associated with an 
increased protection against HIV-1 infection in high risk individuals [175]. However, this 
association remains controversial because a previous study failed to detect such an association 
[171]. In the context of HCV infection, a study comparing the frequency distribution of L-SIGN 
neck-region polymorphisms in a group of infected patients versus non-infected individuals failed 
to demonstrate any statistical difference between the two groups [231]. However, the same 
authors did observe an association between neck-region polymorphisms and individual HCV 
viral loads, and suggested that length variation in the L-SIGN neck region affects HCV 
replication efficacy. Finally, a study focusing on susceptibility to SARS infection has shown that 
individuals who are homozygous for L-SIGN neck region repeats are better protected against 
SARS infection [51]. Our results however, clearly indicate that the L-SIGN neck-region 
allele/genotype frequencies are not statistically different between tuberculosis patients and 
healthy controls in our cohort. However because of the low frequency of this polymorphism in 
our population, we cannot conclusively exclude this length variation in the L-SIGN neck region 
as a factor influencing tuberculosis susceptibility. A larger cohort would be required to confirm 
this. 
 
In summary, the results show that the length of the neck regions of both DC-SIGN and L-SIGN 
are not associated with an increased or decreased host susceptibility to develop tuberculosis, at 
least in our cohort [21]. These data are in contrast with other disease association studies where 
the tandem-repeat polymorphisms of DC-SIGN and/or L-SIGN seem to contribute to different 
susceptibilities to HIV-1 and SARS infections, and to the HCV replication efficacy [51, 175, 177, 
231]..  
 
In conclusion, the significant association found for the CD209 promoter variants together with 
their phylogenetic status and frequency distribution strongly suggests that the -871G and -336A 
alleles may reduce the risk of developing tuberculosis [21]. More generally, our results, together 
with those reporting association of CD209 promoter variants with both HIV susceptibility and 
dengue pathogenesis [200, 295] suggest that variation in this lectin may be of crucial importance 
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in the outcome of a number of infections due to DC-SIGN interacting with pathogens. The low 
level of sequence variation indicates the conservation of an important gene product and the 
immune system is presumably more tolerant of fluctuation in transcription levels of DC-SIGN. 
Detailed in vitro and in vivo studies assessing the functional consequences of CD209 variants on 
the quality of the host immune response against pathogens, including M. tuberculosis, are now 
required to eventually develop knowledge based and effective pathway targeted treatments. 
■ 
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Chapter 5 
 
 
Re-sequencing of  the SP110 gene and 
genotyping of  polymorphisms. 
 
 
 
The major part of these results was published: 
 
Babb C, Keet EH, van Helden PD, Hoal EG (2007) 
SP110 polymorphisms are not associated with pulmonary tuberculosis in a South African 
population. 
Human Genetics 121:521-2 
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5.1 Introduction 
 
As discussed in Chapter 1, the use of murine models has led to the identification of genes such as 
solute carrier family 11A member 1 (SLC11A1, formerly known as NRAMP1, natural resistance-
associated macrophage protein 1), where association with human tuberculosis has been 
confirmed in a number of studies [132]. C3HeB/FeJ inbred mice are extremely susceptible to 
virulent Mycobacterium tuberculosis (M. tuberculosis) and develop marked lung pathology, which leads 
to their rapid death after infection [148, 158, 250]. The “super susceptibility to TB1” (sst1) locus 
in C3HeB/FeJ inbred mice has a specific effect on the progression of tuberculosis and was 
related to less efficient control of M. tuberculosis multiplication, primarily in the lungs, after 
infection [250]. It was recently reported that the intracellular pathogen resistance 1 (Ipr1) gene, 
within the sst1 locus, conferred a measure of innate immunity to M. tuberculosis infection in mice 
[250]. Unlike SLC11A1, which affects resistance to bacillus Calmette-Guérin (BCG) infection in 
mice, Ipr1 plays a major role in outcome of M. tuberculosis infection. Ipr1 is therefore a good 
candidate gene to test human susceptibility to tuberculosis.  
 
The human homologue of Ipr1 is SP110, a nuclear body protein, which is believed to be involved 
in regulation of transcription by facilitating DNA-binding, as it contains a conserved SAND 
domain (Sp100, AIRE-1, NucP41/75, and DEAF-1) [38, 333]. The expression of both Ipr1 and 
SP110 is regulated by interferons [146], indicating a role in immunity. The SP110 gene is found 
on chromosome 2q, consists of 18 exons and has three transcripts (a, b and c). Transcript SP110b 
is the closest homologue to the predicted Ipr1 protein [35]. The SP110b protein physically 
interacts with viral proteins such as Epstein-Barr virus SM protein and hepatitis C virus (HCV) 
core protein [236, 385]. In addition, it has recently been found that there is an association 
between mutations in the SP110 gene and hepatic veno-occlusive disease with immunodeficiency, 
an autosomal recessive disorder, characterised by combined B and T cell immunodeficiency, 
which presents with multiple infections [283].   
 
A transmission disequilibrium test (TDT) association study in families from the Gambia, Guinea 
Bissau and the Republic of Guinea, identified three SP110 gene polymorphisms that possibly 
influenced genetic susceptibility to tuberculosis [351]. The single nucleotide polymorphisms 
(SNPs) associated with tuberculosis susceptibility were rs2114592, rs3948464 and a novel SNP, 
SP110int10 (rs41547617). Association testing by TDT showed that the haplotype rs2114592 and 
rs3948464 (C/C) conferred susceptibility when all three populations were analyzed separately or 
together (all populations combined, 384 families, p=0.000005) [351]. Polymorphisms in this gene 
were tested in our South African Coloured (SAC) population (Chapter 2) in order to perform 
replication of the above study in a different population, which is always important in validating 
the association of a gene with a disease [15].  
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  55 
 
5.2 Results 
 
5.2.1 Sequencing of the SP110 gene 
 
We sequenced the following regions of the SP110 gene in more than 11 random case-control 
samples; exons 4 to 8, 11, 14, 15, alternative 15, 17 and 18 including surrounding intronic regions. 
These regions contained either known polymorphisms or domains such as a SAND, zinc finger 
or bromo domain, or caused a splice variant. The results are summarised in Table 5.1 and the 
linkage disequilibrium (LD) plot is shown in Figure 5.1. Of the 46 SNPs investigated, 15 were 
novel and identified by re-sequencing of at least 11 individuals (22 chromosomes) bi-directionally 
(Appendix A1.4). All novel polymorphism were submitted to NCBI dbSNP and received rs 
numbers (Table 5.1). Of the known polymorphisms reported in previous studies and in public 
databases, 10 were not polymorphic in our population (Table 5.1). Exon 15 had no 
polymorphisms within the sequenced region. As can be seen in Figure 5.1 there are no definable 
blocks when using the parameter’s confidence intervals, and no tagSNPs were identified. 
Heterozygosity was calculated with HaploView.  
 
Although the D’ was high (reported value in block), the LOD score was low (light shading of the 
block) (Figure 5.1). This is possibly because of the low polymorphism frequency and since few 
samples were sequenced. However, when LD for the eight SNPs investigated in over 750 
samples was analysed, there was still low LD (Figure 5.2).  
 
 
Table 5.1: Polymorphisms found through bidirectional sequencing of the SP110 gene in the SAC 
population. 
  
  
 
      Genotype Frequency   
Location 
in SP110 
gene 
dbSNP rs 
number 
Base 
position 
Major/ 
Minor 
allele Novel 
Number of 
Samples 
sequenced MAF  
Homo-
zygote 
major 
allele 
Hetero-
zygote 
Homo-
zygote 
Hetero-
zygosity 
Exon 4 rs3177554 7529 C/T  15 0 1 0 0 0 
 rs11556887 7578 C/T  23 0.217 0.696 0.174 0.13 0.34 
  rs41552315# 7714 C/T yes 23 0.13 0.826 0.087 0.087 0.227 
Intron 4 rs6749386 7894 C/T  23 0 1 0 0 0 
 rs41554115# 7993 T/C yes 23 0.13 0.826 0.087 0.087 0.227 
  rs41309096# 8101 C/T yes 20 0.2 0.7 0.2 0.1 0.32 
Exon 5 rs28930679 8142 C/T  20 0.025 0.95 0.05 0 0.049 
 rs9061 8144 G/A  18 0.278 0.611 0.222 0.167 0.401 
 rs1063154 8153 T/G  20 0 1 0 0 0 
  rs1047254 8160 A/G   22 0 1 0 0 0 
Intron 5 rs3769839 8629 A/G  5 0 1 0 0 0 
 rs4973299 8637 T/C  11 0 1 0 0 0 
 rs3769837 8679 A/G yes 11 0.318 0.364 0.636 0 0.434 
  rs3820974 8965 A/C   11 0.136 0.727 0.273 0 0.236 
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Table 5.1: Continued          
      Genotype Frequency  
Location 
in SP110 
gene 
dbSNP rs 
number 
Base 
position 
Major/ 
Minor 
allele Novel 
Number 
of Samples 
sequenced MAF  
Homo-
zygote 
major 
allele 
Hetero-
zygote 
Homo-
zygote 
Hetero-
zygosity 
Exon 6 rs3769838 9063 A/G   11 0 1 0 0 0 
Intron 6 rs3769837 9222 A/C  11 0.364 0.273 0.727 0 0.463 
 *rs2114592 10048 C/T  778 0.283 0.53 0.375 0.095 0.406 
 rs41552220# 10246 T/C yes 12 0.333 0.333 0.667 0 0.444 
  rs41548221# 10350 C/T yes 11 0.182 0.636 0.364 0 0.298 
Exon 7 rs1129425 10579 A/G  12 0 1 0 0 0 
  rs12467 10608 G/A   12 0 1 0 0 0 
Intron 7 rs6719893 12013 A/G  20 0 1 0 0 0 
 rs41553213# 12221 A/T yes 20 0.325 0.4 0.55 0.05 0.439 
  rs41543312# 12291 G/A yes 20 0.1 0.8 0.2 0 0.18 
Exon 8 rs1365776 12545 A/G   777 0.166 0.705 0.257 0.037 0.277 
Intron10 rs41545715#  Indel yes 798 0.085 0.83 0.17 0 0.156 
  *rs41547617# 34384 A/G   30 0 1 0 0 0 
Exon 11 *rs3948464 34539 C/T   763 0.267 0.547 0.374 0.08 0.391 
Intron 11 rs41563112# 34660 A/C yes 25 0.08 0.84 0.16 0 0.147 
 rs41552512# 34667 G/C yes 21 0.095 0.81 0.19 0 0.172 
  rs2114591 34685 C/T   23 0.196 0.652 0.304 0.043 0.315 
Exon 14 rs1804027 42978 T/C   742 0.302 0.495 0.407 0.098 0.422 
Intron 14 rs41559116# 43130 T/C yes 13 0.038 0.923 0.077 0 0.074 
 rs41543719# 43315 C/G yes 13 0.038 0.923 0.077 0 0.074 
 rs1427285 43398 C/T  13 0.269 0.462 0.538 0 0.393 
  rs10933327 43474 T/C   13 0.269 0.538 0.385 0.077 0.393 
Exon 15 
Alternative rs35495464 47638 T/C   792 0.021 0.958 0.042 0 0.041 
Intron 17 rs12995739 47899 A/C   12 0.083 0.833 0.167 0 0.153 
Exon 17  rs13018234 48388 C/T  11 0.045 0.909 0.091 0 0.087 
  rs3948463 48394 G/A   797 0.018 0.964 0.036 0 0.036 
Intron 17 rs34034766 48486 A/G  11 0.091 0.818 0.182 0 0.165 
 rs34897866 48500 T/C  11 0.091 0.818 0.182 0 0.165 
  rs45567238 48722 A/T yes 11 0.045 0.909 0.091 0 0.087 
Intron 18 rs41541917# 48923 C/T yes 792 0.064 0.878 0.117 0.005 0.119 
 rs12988385 48943 A/G  11 0.091 0.818 0.182 0 0.165 
  rs11690519 48957 G/A   11 0 1 0 0 0 
# indicates new NCBI dbSNP rs numbers after submission by Babb et al [15]  
 
* SNP found to be associated with tuberculosis susceptibility by Tosh et al [351]   
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Figure 5.2: A: Linkage Disequilibrium plot for the eight polymorphisms investigated in 
gene SP110 B: Block 1 (in A) haplotypes and their frequency, defined by confidence 
intervals in Haploview. 
 
 
A 
B 
Figure 5.1: LD plot for the SP110 regions in all samples sequenced. The shading of a block 
indicates the LOD score (darker blocks represent a higher LOD score). 
 
Stellenbosch University  http://scholar.sun.ac.za
  58 
 
5.2.2 Genotyping of eight polymorphisms and case-control analysis 
 
The SNPs that were chosen to be genotyped were SNPs that had previously been investigated 
and SNPs that spanned the gene. Eight SNPs were genotyped by SNaPshot ® Multiplex System 
(Appendix A1.5.1) in 381 tuberculosis cases and 417 healthy controls. The mean ages for the two 
groups were 37.1 and 33.1 years, respectively. The SNPs analysed included two novel intronic 
polymorphisms; one was an insertion/deletion (indel) of 4 base pairs (submitted to NCBI 
dbSNP, rs41545715) and the other was in Intron 18 (rs41541917) and had a heterozygosity value 
that indicated it would provide enough power with our sample size to detect a meaningful 
significant difference between cases and controls. In addition we genotyped two polymorphisms 
(rs2114592 and rs3948464) that were previously found to be associated with susceptibility to 
tuberculosis [351]. The third novel polymorphism, SP110int10 (rs41547617), that Tosh et al 
found to be associated with susceptibility to tuberculosis [351], was not found to be polymorphic 
in the SAC population after 30 samples were sequenced. The information on this polymorphism 
was submitted to the NCBI dbSNP and the SNP received the rs number rs41547617. As this 
SNP was found to be in LD with rs3948464 [351] it would not have provided additional 
information. The technique used to genotype the samples, SNaPshot, also restricts SNP selection 
because primers are designed to be adjacent to the polymorphism (Appendix A1.5.1). 
Interestingly, SNP rs1804027 in Exon 14 falls within the SAND domain and if it had been 
associated would have provided clues to a possible function. However, no significant associations 
were found between the SP110 polymorphisms and susceptibility to tuberculosis (Table 5.2). 
 
All polymorphisms were in Hardy-Weinberg equilibrium. This study had 95% confidence, 80% 
power to detect an OR of 1.6 for both the previously implicated SNPs. 
 
Table 5.2: SP110 genotype distributions in tuberculosis cases and healthy controls in the SAC 
population. 
  
   Genotype frequencies     
 Allele Cases   Controls  Cases vs Controls^ 
Poly. 1 2 11 12 22   11 12 22   p OR (95% CI) 
rs2114592* C T 0.526 0.379 0.095  0.533 0.372 0.095  0.886 0.971 (0.733-1.288) 
rs1365776 A G 0.710 0.253 0.037  0.701 0.262 0.037  0.813 1.046 (0.768-1.425) 
rs41545715 GAAG - 0.816 0.184 0.000  0.842 0.158 0.000  0.348 0.835 (0.577-1.209) 
rs3948464* C T 0.551 0.373 0.077  0.543 0.374 0.083  0.828 1.033 (0.776-1.374) 
rs1135791 T C 0.500 0.407 0.093  0.490 0.407 0.103  0.825 1.041 (0.780-1.389) 
rs3948463 G A 0.950 0.050 0.000  0.976 0.024 0.000  0.060 0.472 (0.217-1.028) 
rs41541917 C T 0.869 0.123 0.008  0.886 0.112 0.002  0.516 0.855 (0.559-1.308) 
rs35495464 T C 0.947 0.053 0.000   0.969 0.031 0.000   0.583 0.156 (0.217-1.028) 
^The homozygotes for the most frequent allele were compared with the sum of the heterozygote and homozygote for the rare 
allele. Comparing the homozygotes for the rare allele with the sum of the heterozygotes and homozygotes for the most 
frequent allele gave similar results. 
* Polymorphism found to be associated with tuberculosis susceptibility by Tosh et al in West Africa [351] 
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5.2.3 Sequencing of the SP110 gene in two disseminated BCG patients 
 
In addition to the sequencing of case-control samples, the SP110 gene (regions as outlined in 
section 5.2.1) was sequenced in two patients that suffered from disseminated BCG. Disseminated 
BCG is an extreme phenotype where shortly after BCG vaccination the child develops disease. It 
may be a rare event but the genetic, immunological and clinical study of the signalling defects can 
lead to invaluable insights in human control of intracellular pathogens. In addition, the 
identification of these unique defects should enable us to identify individuals at risk of an 
adverse, sometimes fatal, reaction to BCG vaccination.  
 
The patients investigated are described in a recent publication [128]. Patient DNA sample ID 
4338 is Patient ID 22 in the publication and Patient DNA sample ID 4339 is Patient ID 19 
(Table 5.3). Neither was HIV positive, but Patient ID 4339 had a primary immunodeficiency (T-
cell deficiency). Both were from the SAC population, had a BCG scar present, were unrelated 
and were adherent in terms of their therapy. Good adherence is defined as more than 80% of 
doses taken.  
 
No novel SP110 gene polymorphisms or mutations were identified in the disseminated BCG 
patients and there were no unique differences between them and the SAC samples sequenced 
(Table 5.4). Both the disseminated BCG samples are heterozygotes for a polymorphism in Exon 
5, rs28930679, of which the minor allele frequency is 0.025 in the general population. The major 
alleles of three SP110 polymorphisms (rs2114592, rs3948464 and rs41547617) were associated 
with tuberculosis susceptibility in the West African populations. Of these, only one, rs2114592, 
was heterozygous in one of the BCG disseminated patients. The other two, rs41547616 and 
rs3948464 were both homozygous for the major allele in the BCG disseminated patients.  
 
Table 5.3: Disseminated BCG patient information. 
 4338  4339 
Patient ID, reference [128]  22  19 
Gender M  F 
Age (in months) at diagnosis (culture 
positive M. tuberculosis complex infection) 
2  16 
Mantoux TST finding (mm) 6  11 
Revised paediatric disease classification Regional and dual disease 
due to M. tuberculosis. 
 Distant 
disease. 
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Table 5.4: Comparison of the overall minor allele frequency (MAF) in SP110 of the SAC case-
control samples and the sequencing results for the disseminated BCG patients (4338 and 4339). * 
Polymorphisms found to be associated with tuberculosis susceptibility by Tosh et al (2006) [351] . 
 BCG-osis patient Location in 
SP110 gene Polymorphism 
Major/ Minor 
Allele 4338 4339 
MAF (SAC 
case-control) 
Number of 
samples 
Exon4 rs3177554 C/T cc cc 0 15 
 rs11556887 C/T cc cc 0.217 23 
  rs41552315 C/T cc cc 0.13 23 
Intron 4 rs6749386 C/T cc cc 0 23 
 rs41554115 T/C tt tt 0.13 23 
  rs41309096 C/T ct tt 0.2 20 
Exon 5 rs28930679 C/T ct ct 0.025 20 
 rs9061 G/A aa aa 0.278 18 
 rs1063154 T/G tt tt 0 20 
  rs1047254 A/G aa aa 0 22 
Intron 5 rs4973299 T/C tt tt 0 11 
 SP110Int5 A/G aa ga 0.318 11 
  rs3820974 A/C cc ca 0.136 11 
Exon6 rs3769838 A/G aa aa 0 11 
Intron6 rs3769837 A/C aa ca 0.364 11 
 *rs2114592 C/T cc ct 0.283 778 
 rs41552220 T/C tt ct 0.333 12 
  rs41548221 C/T cc cc 0.182 11 
Exon 7 rs1129425 A/G aa aa 0 12 
  rs12467 G/A gg gg 0 12 
Intron 7 rs6719893 A/G aa aa 0 20 
 rs41553213 A/T aa at 0.325 20 
 rs41543312 G/A gg gg 0.1 20 
Exon8 rs1365776 A/G aa aa 0.166 777 
Intron10 rs41545715 Indel wt wt 0.085 798 
 *rs41547617 A/G aa aa 0 30 
Exon11 *rs3948464 C/T cc cc 0.267 763 
Intron 11 rs41563112 A/C aa aa 0.08 25 
 rs41552512 G/C gg gg 0.095 21 
 rs2114591 C/T tt ct 0.196 23 
Exon 14 rs1804027 T/C tt ct 0.302 742 
Intron 14 rs41559116 T/C tt tt 0.038 13 
 rs41543719 C/G gg cg 0.038 13 
 rs1427285 C/T ct ct 0.269 13 
 rs10933327 T/C tt ct 0.269 13 
Exon 15 Alt. rs35495464 T/C tt tt 0.021 792 
Intron 17 rs12995739 A/C aa aa 0.083 12 
Exon 17  rs13018234 C/T cc cc 0.045 11 
  rs3948463 G/A gg gg 0.018 797 
Intron 17 rs34034766 A/G aa aa 0.091 11 
 rs34897866 T/C tt tt 0.091 11 
 SP110Int17C A/T aa aa 0.045 11 
Intron 18 rs41541917 C/T cc cc 0.064 792 
 rs12988385 A/G aa aa 0.091 11 
  rs11690519 G/A gg gg 0 11 
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5.3 Discussion  
 
The SP110 gene was investigated by sequencing exons and their surrounding intronic regions and 
determining the frequency of the polymorphisms found in tuberculosis cases and controls, as 
well as two patients with disseminated BCG. We intended to use haplotype tagging through 
Haploview to determine which SNPs would be most informative to genotype. However, for the 
number of samples sequenced, the frequency of the polymorphisms was too low to provide high 
enough confidence intervals to determine reliable haplotype tags. Allele frequencies were 
determined and used as a guide for the selection of the polymorphisms investigated.  
 
In the SAC population, no significant association with tuberculosis susceptibility was found for 
any of the eight polymorphisms investigated (Table 5.2) [15]. Analysis of the haplotypes by 
Haploview also revealed no association with any of the inferred haplotypes. LD over the whole 
gene (Figure 5.1) appears to be low but this might be because of the low frequency of the 
polymorphisms and sequencing of too few samples. However, when the LD for the eight SNPs 
investigated in over 750 samples was analysed there was still low LD (Figure 5.2). A low LOD 
score was a result of the low frequency of the polymorphism.  
 
Replication of the association with tuberculosis susceptibility reported by Tosh et al was not 
found in the SAC case-control study. Each of the three polymorphisms found to be associated 
with susceptibility to tuberculosis were genotyped by Tosh et al in a TDT study involving 298 to 
373 families from three different West African nations, namely Guinea-Bissau, Republic of 
Guinea and the Gambia.  While this investigation was underway, two large studies in a Ghanaian 
population [348] (over 990 cases, and 1000 controls) and a Russian cohort [335] (1912 cases and 
2104 controls) found no association with SP110 polymorphisms, also by means of a case-control 
analysis. Since a number of independent populations [15, 335, 348] and SP110 variations 
spanning most of the gene, have now been investigated (Table 5.5), with only the  West African 
TDT study indicating an association with tuberculosis [351], it is likely that this gene does not 
contribute significantly, if at all, to genetic susceptibility to tuberculosis in all human populations.  
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In the West African TDT cohort, the major allele of the SNPs rs2114592, rs41547617 
(SP110int10) and rs3948464 conferred susceptibility to tuberculosis. The two BCG-osis patients 
were nearly always homozygous for these major alleles, but this was to be expected given the 
allele frequencies of the three SNPs in the SAC population. This, unfortunately, does not provide 
useful information for BCG-osis susceptibility prediction. If the minor alleles had been associated 
with tuberculosis susceptibility and the BCG-osis patients were homozygous for the minor allele 
(i.e. the frequency of the allele was higher than expected) then this would have provided useful 
information for further investigation. The BCG-osis patients display an extreme phenotype and 
identifying a genetic association will lead to a better understanding of tuberculosis pathology. 
Further studies to identify polymorphisms in the IL-12/IL-23/IFNγ axis previously associated 
with BCG-osis patients [193, 254] should be done in these two patients.  
 
Further investigation of the SP110 gene and promoter polymorphisms could be done by 
association studies. It would also be interesting to investigate whether there is an association 
between these SNPs and time to sputum conversion in first time pulmonary tuberculosis 
patients, as was done with the VDR gene (Chapter 6). Finally, it is possible that SP110 may 
confer protection against infection, which was not tested in this study (Chapter 7), as the majority 
of the SAC population is latently infected with M. tuberculosis.  
 
The SP110 gene was a promising candidate because of studies done in a mouse model, but was 
subsequently not confirmed in human case-control studies. This situation is unlike that with the 
SLC11A1 gene [29], which was also identified through mouse studies of control of susceptibility 
to BCG inoculation [159, 375]. As mentioned earlier SP110 was a more promising candidate, 
since in mice, its homologue Ipr1 conferred innate immunity to M. tuberculosis infection. That this 
was not found in humans raises the question of whether mouse models are useful in identifying 
human genes involved in resistance to M. tuberculosis. Although M. tuberculosis is not a natural 
pathogen of mice, the mouse model has proved very helpful in understanding the immune 
response in tuberculosis [247]. Proteins of the signalling pathway upstream and downstream of 
the SP110b protein should not be excluded as candidates for susceptibility to tuberculosis, as 
different stages in the pathway may be affected and in turn may affect susceptibility to 
tuberculosis (Figure 5.3). The influence of the SP110 gene might be minor and not detectable in 
an outbred human population, although it was detected in the inbred mouse strains. Alternatively 
there might be different pathways between the two species that confer resistance or susceptibility 
to tuberculosis. 
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Figure 5.3: Predicted Functional Partners with the SP110b protein according to the 
STRING website (http://string.embl.de//).  
Note these are only text mining results, none are experimental. 
http://string.embl.de/newstring_userdata/net_image_XxsXn8jrshUA.png accessed 
June 2007. 
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Chapter 6 
 
 
 
Vitamin D Receptor gene polymorphisms 
and sputum conversion time in first time 
pulmonary tuberculosis patients. 
 
The major part of these results was published in: 
 
Babb C, van der Merwe L, Beyers N, Pheiffer C, Walzl G, Duncan K, van Helden P, Hoal EG 
(2007)  
Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis 
patients.  
Tuberculosis 87, 295-302
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6.1 Introduction 
 
The role of Vitamin D and its receptor (VDR) in innate immunity, and specifically tuberculosis, is 
a subject of intense debate [37, 92, 169, 301, 391]. The treatment of tuberculosis in the earlier 
part of the 20th century frequently consisted of consuming cod liver oil, or heliotherapy (sun 
bathing), an important step in the synthesis of Vitamin D in the skin. Vitamin D is subsequently 
metabolised in the liver to its active steroid hormone 1,25 dihydroxyvitaminD3 (1,25(OH)2D3) or 
calcitriol [83, 86, 169]. In vivo studies have shown that calcitriol suppresses growth of M. 
tuberculosis [73, 278] and is produced within granulomas by activated monocytes and macrophages 
[303]. The growth-suppressive effect may be facilitated by Toll-Like Receptors in vivo [178]. The 
nuclear hormone receptor for calcitriol is encoded by the VDR gene, which belongs to the family 
of trans-acting transcriptional regulator factors. The receptor regulates a variety of metabolic 
pathways such as those involved in the immune response, but the principle downstream targets 
are involved in mineral metabolism. The receptor is widely expressed in all cells of the immune 
system such as monocytes, macrophages, and dendritic cells (all antigen presenting cells), natural 
killer cells, T cells and B cells [204, 230, 282]. In addition, when appropriately stimulated by 
interferon gamma, calcitriol can be locally produced in monocytes [282, 331]. The importance of 
Vitamin D and VDR has been investigated in a variety of conditions such as diabetes [244, 251], 
cancer [44, 402], bone mass density [221, 344], Vitamin D dependent rickets type I [136, 152] and 
mycobacterial infection [37, 92, 110, 169, 301, 391].  
 
Case-control studies to assess the importance of VDR polymorphisms in tuberculosis have 
produced varying results in different populations [180, 391]. Roth et al (2004) reported an 
association of VDR TaqI and FokI single nucleotide polymorphisms (SNP) with the time to 
sputum conversion in 78 pulmonary and extra-pulmonary tuberculosis patients [285], although 
no association with susceptibility to tuberculosis was found in a case-control analysis. They found 
that sputum culture conversion was significantly faster if cases had the FokI ‘FF’, or the TaqI ‘Tt’ 
genotype. This was the first report of tuberculosis treatment response being investigated in 
relation to a genetic component. Validation of this preliminary report of tuberculosis treatment 
response being investigated in relation to a genetic component is vital and should preferably be 
done in a different population.  
 
We analysed three VDR polymorphisms, FokI, ApaI and TaqI, and a number of other clinical and 
demographic factors in a large, well characterised group of first time pulmonary tuberculosis 
cases from what is known as the Surrogate Marker (SM) study that was conducted over a 30 
month period in the population discussed in Chapter 2, the South African Coloured (SAC). The 
SM cohort is independent of all the previous case-control studies discussed in this thesis and is a 
unique cohort of patients. A large number of patients were followed up with regular clinic visits 
[39, 378] and blood samples were available for DNA analysis of the cohort.  
 
VDR Polymorphisms 
 
The VDR gene spans 79kb, has 11 exons and is found on chromosome 12q13.11. Four VDR 
gene polymorphisms have been extensively studied in a variety of diseases. Three polymorphisms 
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were analysed in this cohort because two of the four are in strong linkage disequilibrium (LD) in 
a number of studies and in a variety of populations; in other words the SNP is tagged. 
 
The FokI (rs10735810) polymorphism is a functional polymorphism [379] and forms a new start 
site / initiation codon (ATG to ACG) at the junction of intron 1 and exon 2. Although its role 
still remains unclear, it has been shown that the FokI ‘ff’ polymorphism has increased expression 
[232, 357]. FokI is not known to be in LD with any other known VDR polymorphism [232, 356].  
 
ApaI (rs7975232) a G (ApaI ‘a’) to T (ApaI ‘A’) change in intron VIII, 3’ region was analysed 
because it appears to form an important haplotype [232], in particular with FokI. Bornman et al 
[37], showed significantly more transmission of the haplotype combination ‘FA’ to tuberculosis 
affected offspring (χ2 =11.621, P=0.0007, 1 degree of freedom). 
 
TaqI (rs731236) is a silent polymorphism with a base T (TaqI T) to base C (TaqI t) change, 
located in exon IX, in the 3’ region. Roth et al [285] found an association with the TaqI Tt 
genotype and response to treatment of tuberculosis. There is strong linkage between ApaI and 
TaqI, yet they are not predictive of each other. They are separated by 80 base pairs and are in LD 
with a polyA variable number of tandem repeats (VNTR) in exon 9 which results in either a long 
or short allele, where the former is more transcriptionally active [126, 387].  
 
BsmI (rs1544410) is a T/C SNP in intron VIII at the 3’ end and has frequently been analysed. 
This polymorphism is in strong LD with TaqI (the ‘T’ and ‘b’ genotypes) and was not analysed in 
this study [285, 344, 391].  
 
These VDR gene polymorphisms have been suggested by Roth et al as having potentially for 
being involved in the response of tuberculosis patients to treatment, which requires validation in 
a different population. In this study, we have extended the number of variables and examined 
their effect on response during tuberculosis chemotherapy in a large, well-characterised cohort of 
our SAC population. 
 
6.2 Methods  
 
6.2.1 Surrogate Marker Patient enrolment and surveillance 
 
The tuberculosis cases used in this chapter were distinct from those in the rest of the thesis. All 
tuberculosis cases were enrolled in a longitudinal study to evaluate pulmonary tuberculosis cases 
during and after treatment; known as the SM study [39, 378]. All information and data was 
accessed from version 4 of the SM database. Informed consent was obtained from all subjects. 
Supplementary documentation for the SM database is in Appendix 2. Cases were all first-time 
pulmonary tuberculosis patients, not non-tuberculous mycobacteria (NTM) infected, HIV 
negative, 18-65 years old, not pregnant, had no chronic diseases, not multi-drug resistant 
tuberculosis (MDR-TB) and received direct observed treatment short-course (DOTS). All cases 
were diagnosed by having a positive sputum sample on auramine staining, a second positive 
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sputum sample or a posterior anterior and lateral chest radiograph typical of pulmonary 
tuberculosis. Blood was collected at diagnosis and total peripheral white blood cell (WBC) 
counts, absolute neutrophil, monocyte, and lymphocyte numbers were measured.  
 
Cases were followed up with regular clinic visits from diagnosis (day 0), including day 1 and day 
2, then weekly visits until month 2 (day 55) followed by monthly visits until month 6 (day 182) 
and subsequent visits in month 9 (day 273) and month 12 (day 364). Patients were followed for a 
total of 30 months, to detect possible second episodes of disease. However, for our purposes, 
information for the first episode of tuberculosis disease only was used.  
 
For research purposes, sputum was collected at all time points for smear microscopy using Ziehl-
Neelsen (ZN) staining and for M. tuberculosis culture using the BACTEC method (Beckton-
Dickinson, USA). Restriction fragment length polymorphism (RFLP) of the M. tuberculosis strain 
and isoniazid and rifampicin susceptibility testing was performed. Serum was not available for the 
majority of samples, therefore the Vitamin D levels were not measured. 
 
At enrolment to the study, a questionnaire was used to collect data on education level 
(completion of high school, yes/no), smoking of tobacco or cigarettes (yes/no), cannabis use 
(yes/no), alcohol consumption (yes/no) and limited data on income, measured as either above or 
below ZAR1000 / ± £80/ ±$150 per month. The following data was collected for all cases: age, 
gender, number of self reported tuberculosis symptoms (Cough, Coughing Blood, Night sweats, 
Chest pain, Back Pain, Deep breathing, Chest Tight, Fever, Weight Loss) at first clinical 
examination, weight, height, body mass index, and Mantoux skin test size at diagnosis and month 
2. The chest radiographs were interpreted based on a previous method [309], by a single clinician 
who used a standardized reading form to evaluate the number of cavities visible on the chest 
radiograph, and the extent of pulmonary involvement (<right upper lobe (RUL), =RUL, >RUL 
and > 1 lung) as an indication of disease severity (Figure 6.1). Data on the number of cavities 
present was also available but was not as informative as the extent measured by RUL, as it does 
not take the actual size of the cavity into consideration.  
 
 
Figure 6.1: Diagram of the lungs showing the lobes. The right upper lobe (RUL) was used 
as a reference for the extent of pulmonary  
involvement for the cases used in the  
Surrogate Marker study. 
1. Right upper lobe (RUL)    
2. Right middle lobe  
3. Right lower lobe              
4. Left upper lobe  
5. Left lower lobe                  
6. Oblique fissure 
7. Horizontal fissure 
 
 
1 
2 
3 
4 
5 
6 
7 
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6.2.2 Case-control samples 
 
The 249 tuberculosis cases were those enrolled in the longitudinal SM study as first time 
pulmonary tuberculosis patients. The 352 healthy controls were taken from the “EileenTB” 
database as discussed in Appendix 1 (Figure 6.2). Controls were older than 17 years. The average 
age of males in the cases was 37 years, and the female cases 33 years. In controls the average age 
of the males was 30 years and in female controls 31 years. Males formed 58% of the cases and 
15% of the controls.  
 
 
 
6.2.3 Cohort with known sputum conversion times 
 
A cohort from the longitudinal SM study (249 cases, section 6.2.1) was selected for conversion 
time analysis. Inclusion required the case to have a conversion time for smear and/or culture. 
Defaulters (patients who did not take the prescribed medication for at least 2 consecutive 
months) and cases that transferred outside of the study area were excluded if there was no 
conversion time available before this event. A conversion time in days (from positive to negative 
M. tuberculosis in sputum) was estimated from the day of diagnosis (day 0) and a date midway 
between the last positive result and the first of two successive negative results [285]. This resulted 
in a total of 220 cases with smear conversion times and 222 cases with culture conversion times 
(Figure 6.2). When more than 91 days had elapsed between the last positive and the first of two 
successive negative results, samples were censored for analysis purposes and the last positive day 
was used as the day of conversion. 
 
The conversion time was estimated from information provided from the SM database. The smear 
and culture sputum results were available in the ‘resSputum’ table in the SM database. This table 
listed the results according to the ‘WhenID’ (Table 6.1). The ‘WhenID’ was based on the number 
of days of an expected clinical visit from the diagnosis. The clinical visit days were predetermined 
Figure 6.2: Samples that were genotyped for the VDR polymorphisms FokI, ApaI and TaqI. 
Surrogate Marker Samples
DNA Extraction and 
genotyping 
N=249
Case control
Case: n=249
Cohort:
Conversion time reliably 
estimated
(mid point between the last 
positive and the first of two 
consecutive negatives)
Smear: 
n=220
Culture: 
n=222
Controls: 
n=352
+
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and part of the SM study design. However, use of the WhenIDs for the construction of survival 
curves and Cox regression analysis the resulted in clustering of results on the particular ‘WhenID’ 
days. To have more accurate and reliable results and the actual visit date to the clinic was 
therefore used. 
 
Table 6.1: The look up table: ‘TestInterval Table’ in the SM database which lists the WhenID and 
has a description of all the clinical visits when samples were collected.  
WhenID When 
(days) 
Interval Description 
1 0 Diagnosis 
20 1 Day 1 
21 3 Day 3 
2 7 Week 1 
3 14 Week 2 
4 21 Week 3 
5 28 Week 4 
6 35 Week 5 
7 42 Week 6 
8 49 Week 7 
9 56 Week 8 (month 2) 
23 59 Week 8 + 3 days 
11 91 Month 3 (week 13) 
12 126 Month 4 (week 18) 
13 154 Month 5 
14 182 Month 6 (week 26)* 
24 245 Month 8 
15 273 Month 9 
16 364 Month 12 
17 546 Month 18 
18 728 Month 24 
19 910 Month 30 
22 0 Other 
*Following standard DOTS, medication was stopped at Month 6. 
 
The ‘WhenID’ of the last positive sample for a patient was identified in the ‘resSputum’ table, 
which also has the field ‘VisitDate’. The visit date lists the calendar date of a clinic visit. The visit 
date of the diagnosis (‘WhenID’ 1), the last positive and the first date of two consecutive negative 
samples were extracted. This was done for both smear and culture outcomes. The actual number 
of days from diagnosis was calculated with the use of Microsoft Excel. This resulted in the 
conversion time not falling exactly on a particular ‘WhenID’ day, giving a more accurate 
conversion day. The true date was on average one or two days from the expected ‘WhenID’ visit 
day.  
 
The SM database was also carefully checked for samples that were possibly NTM samples (which 
was frequently mentioned in the comments column and not correctly coded with 999/888 in the 
result field). This was corrected in the next version of the SM database.  
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Once the conversion day was established, patients could be divided into slow and fast responders 
for both smear and culture conversion time. Fast responders were defined as cases that converted 
to negativity before day 55 (month 2) and slow responders on or after day 55. Month 2 was 
chosen as the cutoff as this corresponds to the International Union Against Tuberculosis and 
Lung Disease recommendations for the time at which sputum conversion is determined in order 
to establish treatment effectiveness.  
 
6.3 Statistical analysis 
 
A number of statistical analyses were done with the data from the study using SM samples. This 
was because this was not only an association study but an investigation of variables affecting the 
conversion time from a positive M. tuberculosis sputum sample to negative in both culture and 
smear. There were a large number of factors available that could be risk predictors or possible 
confounders for time-to-sputum conversion. Each analysis will be discussed in the relevant order: 
Fast versus slow, survival curve, univariate and then multivariate analysis.  
 
Case-control 
 
Genotype, allele and diplotype frequencies of the polymorphisms were calculated. As unrelated 
cases and controls were analysed, haplotypes could only be inferred using R (done by L. van der 
Merwe) and Haploview (done by C. Babb) (Appendix A1.6.3). However, the diplotype is a true 
representation of the genotype and was constructed by combining the observed genotypes in the 
order in which they occur in the gene: FokI, ApaI and TaqI and their association with tuberculosis 
was analysed by logistic regression. Hardy-Weinberg equilibrium and LD were determined.  A 
total of 249 cases and 352 controls were analysed to investigate associations with susceptibility to 
tuberculosis using Fisher’s exact test.  
 
Cohort 
 
Analyses were done in R: A language and environment for statistical computing, Base R [266], as 
well as packages survival [345], genetics [381], and haplo.stats [312] by Dr. L. van der Merwe, a 
bio-statistician, specialised in genetic statistics, who conducted the analysis of the univariate and 
multivariate analysis and assisted with the interpretation of results. The genotypes of the fast and 
slow responders to treatment were compared by a χ2 test using GraphPad Prism (version 5). In 
the construction of the Kaplan-Meier survival curves, the cases are subgrouped according to their 
genotype (or whichever factor is investigated). The survival curve demonstrates the decreasing 
proportion of positive sputum samples in the cohort, where Day 0 is the day of diagnosis and 
initiation of treatment. Analysis is done by (Mantel-Cox) log rank, where differences in the curves 
are assessed. Kaplan-Meier survival curves were constructed in Prism, where a significant p value 
(<0.05) indicates significant differences between the curves. The use of Kaplan-Meier survival 
curves possibly indicated to Roth et al that there was an association with the VDR polymorphism 
and time to sputum conversion in their tuberculosis patients. However, Kaplan-Meier survival 
curves are not conclusive and further statistical analyses were required, including univariate 
analyses to identify which factors could be possible confounders. Variables with significant p-
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values could then be used in the multivariate analysis, which provides a more statistically accurate 
outcome of any association, by taking the confounders into consideration. 
 
An individual, age and gender adjusted, Cox regression analysis (univariate) was done for the 
variables separately for both smear and culture conversion times using R. 
 
A multivariate analysis was done using R by means of the selection of an optimal Cox model for 
each of the methods (smear and culture) for measuring conversion times. A set of candidate 
variables were identified from which the optimal selection was made. They included those that 
have previously been found to be important for conversion in tuberculosis by Roth et al [285] i.e. 
high school completion, TaqI and FokI. Isoniazid mono-resistance was investigated instead, as no 
rifampicin mono-resistance was seen in this cohort (MDR-TB, a previously noted predictor, was 
one of the exclusion criteria for our cases). We also added variables that were significantly 
associated (p<0.050) with conversion time in smear or culture according to the age and gender 
adjusted individual Cox analyses (univariate). A basic set of variables consisting of age, gender 
and the genotypes were included in the optimal model irrespective of their effect. The variables 
included in the final models were selected with a backwards procedure. With the backwards 
procedure, one starts with a Cox model containing all the candidate factors.  Factors are 
discarded one at a time, until the model with the lowest possible Akaike information criterion 
(AIC) is reached. The AIC is a measurement that describes how well the model fits the data: the 
lower the AIC value the better the fit of the model. The procedure discards factors until the 
lowest possible AIC is reached. The factors remaining indicate the best combination of factors 
that describes the observed conversion rates.  
 
Some individuals (12%) had the value for a single variable missing and a few individuals had two 
or a maximum of three data points missing, which were mainly blood measurement variables. 
Following advice from the statistician, missing values were replaced with the mean (numerical 
values) or median (categorical variables) of all the values for the individual’s diplotype, as it was 
assumed that the missing values were missing at random for that diplotype.  
 
6.4 Results 
6.4.1 Case-control  
 
For the VDR polymorphisms a lower case (‘f’, ‘a’ or ‘t’) was used to indicate the presence of an 
endonuclease site (Appendix A1.5.2). In the controls, there was strong LD between ApaI and 
TaqI (D’ = 0.999). FokI was not linked with either TaqI or ApaI, (D’=0.048 and D’=0.005, 
respectively). All polymorphisms were in Hardy Weinberg equilibrium. 
 
No association was found between genotype or alleles for the individual VDR polymorphisms 
and the presence or absence of pulmonary tuberculosis (Table 6.2). A non-significant association 
was seen between the inferred FokI-ApaI-TaqI haplotype and tuberculosis (global p value=0.078), 
with the FokI-ApaI-TaqI ‘FaT’ haplotype overrepresented in controls (p=0.063) and the ‘FAT’ 
haplotype more frequent in cases (p=0.062) (Table 6.3). Of the 27 possible diplotypes only 18 
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were observed. There were no significant differences between the diplotype frequencies in cases 
and controls after adjusting for age and gender using logistic regression (p=0.24) (Table 6.4). 
 
Table 6.2: Case-control analysis of VDR genotype and pulmonary tuberculosis in the SAC 
population. 
    Genotype frequencies     
 Allele  Control (n=352)   Cases (n=249)  Cases vs Controls ^ 
  1 2   11 12 22   11 12 22   p OR (95% CI) 
FokI f F  6 37 58  5 42 53  0.279 1.21 (0.8711-1.674) 
ApaI a A  18 49 33  16 43 41  0.058 0.72 (0.5143-1.009) 
TaqI t T   6 40 54   8 38 55   0.934 0.97 (0.7034-1.350) 
^The homozygotes for the most frequent allele were compared with the sum of the heterozygote and 
homozygote for the rare allele.  
 
Table 6.3: Two and three locus inferred haplotypes for the VDR gene polymorphisms FokI, ApaI 
and TaqI in pulmonary tuberculosis cases and controls in the SAC population. 
 
Haplotype:  
% of Controls 
(n=352) 
% of Cases 
(n=249) P value 
Global 
p value 
FokI, ApaI, TaqI     
faT 10 11 0.913  
fAt 6 9 0.117  
fAT 8 6 0.826  
FaT 32 27 0.063  
FAt 20 17 0.386  
FAT 24 30 0.062 0.078 
ApaI, TaqI    
aT 43 38 0.099  
At 26 27 0.896  
AT 31 36 0.111 0.206 
FokI, ApaI    
fa 10 11 0.866  
fA 14 15 0.327  
Fa 32 27 0.069  
FA 45 44 0.285 0.279 
FokI, TaqI    
ft 6 10 0.107  
fT 18 17 0.95  
Ft 20 17 0.388  
FT 56 57 0.947 0.247 
Note: Haplotypes for the polymorphisms were inferred and tested for 
association with pulmonary tuberculosis using the R package: haplo.stats. 
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Table 6.4: Observed diplotypes of VDR gene polymorphisms FokI, ApaI and TaqI, in pulmonary 
tuberculosis cases and healthy controls from the SAC population. 
 
 Diplotype Controls n (%) Cases   n (%) Total    n (%) 
ffaaTT 3 (1) 2 (1) 5 (1) 
ffAaTt 5 (1) 5 (1) 10 (2) 
ffAaTT 5 (1) 0 (0) 5 (1) 
ffAAtt 2 (1) 3 (1) 5 (1) 
ffAATt 4 (1) 2 (1) 6 (1) 
ffAATT 1 (<1) 1 (<1) 2(<1) 
FfaaTT 25 (7) 17 (7) 42 (7) 
FfAaTt 23 (7) 25 (10) 48 (8) 
FfAaTT 39 (11) 27 (11) 66 (11) 
FfAAtt 8 (2) 7 (3) 15 (2) 
FfAATt 21 (6) 17 (7) 38 (6) 
FfAATT 13 (4) 11 (4) 24 (4) 
FFaaTT 35 (10) 21 (8) 56 (9) 
FFAaTt 50 (14) 20 (8) 70 (12) 
FFAaTT 51 (14) 31 (12) 82 (14) 
FFAAtt 12 (3) 9 (4) 21 (3) 
FFAATt 37 (11) 25 (10) 62 (10) 
FFAATT 18 (5) 26 (10) 44 (7) 
 Total n 352 249 601 
Note: Logistic regression analysis of cases and controls, adjusting for 
age and gender, gave a p value =0.24. 
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6.4.2 Cohort and Sputum Conversion times 
 
A variety of basic demographic information was available for the SM cohort. Some is 
summarized in Table 6.5. 
 
Table 6.5: Basic demographic information from the Surrogate Marker patient cohort. 
    Count Frequency 
Age (years) 18-20 8 4 
 21-30 84 37 
 31-40 64 28 
 41-50 45 20 
 >51 25 11 
Gender Males 132 58 
  Females 94 42 
Yes  23 10 Drug sensitivity 
to isoniazid No 199 88 
 Unknown 4 2 
Education None 5 2 
 <Std 3 53 23 
 Std 4-7 105 46 
 Std 8-10 50 22 
 Diploma 3 1 
 Unknown 10 4 
Income Self None 16 7 
In SA Rands  <R250 pm 22 10 
per month (pm) R251-500 pm 10 4 
 R501-1000 pm 18 8 
 R 1001-1500 pm 10 4 
 R1501-2000 pm 12 5 
 >2001 pm 6 3 
  Unknown 132 58 
Drink Alcohol Yes 174 77 
 No 36 16 
 Unknown 16 7 
Smoke Yes 202 89 
 No 12 5 
 Unknown 12 5 
Died (none of tuberculosis) 5 2 
Age (Years) Average Age 35.3   
 Average Age Males 37  
  Average Age Females 33.0   
BMI Average male 18.1  
 Average female 18.63  
Height (m) Average male 1.7   
  Average female 1.6   
 
Time to sputum conversion was used as a measure of time to recovery. The median conversion 
times for both smear and culture are in Table 6.6. 
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Table 6.6: Median and average sputum conversion days for smear and culture results in the SAC 
cohort of first time tuberculosis patients. 
 Smear  Culture 
 Median 
days 
Average 
days    
Median 
days 
Average 
days   
Overall  41 44.1    71.5 67.5   
Males 41 40.2    44 59.7   
Females 41 47.0    72 73.0   
FokI FF 41 41.2    61 63.4   
FokI Ff 42 48.6    71.5 72.3   
FokI ff 41 36.4    71 67.5   
ApaI AA 42 45.9    71 68.7   
ApaI Aa 41 40.0    48.5 64.2   
ApaI aa 41 50.8    72.5 74.2   
TaqI TT 41 44.3    71.5 70.1   
TaqI Tt 41 40.8    61 63.1   
TaqI tt 43 61.1    69.5 70.6   
 
6.4.2.1 Fast/slow sputum conversion time analysis of the VDR genotype 
 
When the cases were divided into either fast (n=160) or slow (n=60) responders according to 
smear conversion before/after day 55, i.e. month 2 (Table 6.7), there was a strong trend to slower 
conversion in the ‘F’-containing genotypes of FokI (p=0.055). Dividing cases into fast (n=96) 
and slow (n=126) responders with respect to culture conversion before or after and including day 
55 showed a significant association with the ApaI genotypes (p=0.029). Fewer fast responders 
(10%) had an ApaI ‘aa’ genotype than slow responders (23%). None of the diplotypes were 
significantly associated with a fast or slow response. 
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Table 6.7: VDR genotypes of fast versus slow responders for tuberculosis treatment (at day 55) 
for the SAC cohort. 
  Smear (n=220)  Culture (n=222) 
Polymorphism, 
genotype  
Fast responders§ 
n (%) 
Slow responders† 
n (%)  
Fast responders§ 
n (%) 
Slow responders† 
n (%) 
FokI       
ff  10 (6) 1 (2)  5 (5) 6 (5) 
Ff  61 (38) 33 (55)  38 (40) 58 (46) 
FF  89 (56) 26 (43)  53 (55) 62 (49) 
 p value‡    p=0.055     p=0.649 
ApaI       
aa  28 (18) 11 (18)  10 (10) 29 (23) 
Aa  67 (42) 24 (40)  47 (49) 46 (37) 
AA  65 (41) 25 (42)  39 (41) 51 (40) 
 p value‡     p= 0.959    p= 0.029 
TaqI       
tt  9 (6) 6 (10)  7 (7) 8 (6) 
Tt  63 (39) 21 (35)  40 (42) 45 (36) 
TT  88 (55) 33 (55)  49 (51) 73 (58) 
 p value‡     p= 0.490     p= 0.573 
§ Pulmonary tuberculosis cases that responded to treatment before day 55 after treatment initiation  
† Pulmonary tuberculosis cases that responded to treatment on or after day 55 after treatment initiation 
‡ A Chi-square analysis was done. 
 
In the Peruvian study, Roth et al used the much earlier time point of month 1. It is unclear why 
they chose this particular time point but, by using it, associations with the VDR polymorphism 
FokI (p=0.02) and TaqI (p=0.012) were found. Analysing our results at the time point of 30 days 
did not show an association between VDR genotype and time to conversion (Table 6.8). The 
difference between the studies might be due to the culture method, namely MODS versus 
BACTEC. 
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Table 6.8: VDR genotype and fast response to tuberculosis treatment at 30 days (1 month) in the 
Peruvian and SAC populations. 
    Sputum conversion* at month 1 (30 days after treatment initiation) 
Population: Peruvian SAC   Peruvian SAC 
  Culture Culture  Smear Smear 
  MODS BACTEC  Auramine stained  Ziehl Neelsen  
  n=78 n=222  n=78 n=220 
FokI FF 0.78 (7/9) a 0.14 (16/115)  1 (9/9) b 0.43 (50/115) 
 Ff 0.41 (9/22) 0.10 (10/96)  0.64 (14/22) 0.36 (34/94) 
  ff 0.30 (14/47) 0.09 (1/11)  0.62 (29/47) 0.36 (4/11) 
TaqI TT 0.34 (24/71) c 0.11 (13/122)  0.66 (47/71) 0.43 (52/121) 
 Tt 0.86 (6/7) 0.13 (11/85)  0.71 (5/7) 0.39 (33/84) 
  tt 0 0 0.20 (3/15)  0 0 0.20 (3/15) 
ApaI AA - - 0.12 (11/90)  - - 0.33 (30/90) 
 Aa - - 0.13 (12/93)  - - 0.46 (42/91) 
  aa - - 0.10 (4/39)   - - 0.41 (16/39) 
*Sputum conversion is expressed as percentage of patients with a negative sputum result per genotype, where 
the numbers that are negative are divided by the total number with the given genotype. 
a Significant difference between FF and either Ff or ff (p=0.023) 
b Significant difference between FF and either Ff or ff (p=0.025) 
c Significant difference between Tt and TT (p=0.012) 
 
In addition, we investigated cases that had a fast or slow conversion time at day 30 (n=150) or 
day 55 (n=149) according to both culture and smear conversion time (Table 6.9). In other words, 
both their smear and culture results were negative at day 30 or day 55 for a fast conversion time. 
There was no significant association in these cases between their genotypes or haplotypes and 
time to sputum conversion. 
  
Table 6.9: Pulmonary tuberculosis cases having a concordant culture and smear conversion time 
at month 1 (day 30) or month 2 (day 55). 
 Smear and culture conversion day  
VDR Polymorphism <30 ≥30 p-value  <55 ≥55 p-value 
FokI FF 12 61   50 24  
 Ff 9 60   36 33  
  ff 1 7 0.836   5 1 0.088 
                  
ApaI AA 8 57   37 24  
 Aa 10 48   44 23  
  aa 4 23 0.742   10 11 0.333 
                  
TaqI TT 10 67   47 32  
 Tt 10 50   38 21  
  tt 2 11 0.831   6 5 0.757 
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6.4.2.2 Kaplan-Meier survival curves and Log rank analysis 
 
Construction of Kaplan-Meier survival curves allows for visualization of the conversion time and 
differences in the curves are assessed by log rank (Mantel-Cox) analysis. All variables had a 
Kaplan-Meier curve constructed and were assessed by log rank (Table 6.10). No significant 
differences were detected with the Kaplan-Meier survival curves for conversion time with the 
different genotypes (Figure 6.3). 
 
Table 6.10: Kaplan-Meier (Mantel-Cox) log rank test results for VDR polymorphisms genotyped 
in a SAC population assessing smear and culture conversion times to negative smear. 
 p values* 
Variables Smear Culture 
Gender 0.148 0.008 
Smokers: yes versus no 0.018 0.202 
Isoniazid sensitive only, smokers versus non smokers 0.003 0.598 
FokI 0.193 0.333 
ApaI 0.501 0.652 
TaqI 0.194 0.516 
FokI; Combined (ff versus Ff and FF) 0.169 0.142 
TaqI; Combined (tt versus Tt and TT) 0.831 0.342 
FokI; Smokers only 0.284 0.273 
ApaI; Smokers only 0.491 0.811 
TaqI; Smokers only 0.030 0.306 
FokI; Isoniazid sensitive cases only 0.255 0.308 
ApaI; Isoniazid sensitive cases only 0.427 0.545 
TaqI; Isoniazid sensitive cases only  0.213 0.492 
FokI; Isoniazid sensitive and smokers 0.278 0.216 
ApaI; Isoniazid sensitive and smokers 0.413 0.720 
TaqI; Isoniazid sensitive and smokers 0.045 0.325 
Number of cavities (1,2,3,4,>4) 0.036 0.279 
Extent of TB at Diagnosis (<RUL,RUL, >RUL, >1 lung) 0.003 0.005 
Absolute neutrophil number (40-60, 60.1-70, 70.1-80, 80.1-92) 0.046 0.043 
Absolute lymphocyte number (4-9, 9.1-12.0, 12.1-15, 15.1-18, 18.1-
21, 21.1-24, >24.1) 0.164 0.037 
High school completion 0.014 0.120 
* All p values are uncorrected for multiple comparisons. 
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Figure 6.3: Kaplan-Meier survival curves for the time to sputum conversion (as measured by 
smear and culture) of individuals with the VDR genotypes. 
 
 
In the log rank analyses there were significant associations with faster smear conversion time and 
no smoking, low number of cavities at diagnosis, low extent of tuberculosis at diagnosis, low 
absolute neutrophil numbers and completion of high school (Table 6.10). Non-smokers (n=12) 
converted sooner than smokers. This association was significant with smear conversion time and 
not with culture conversion time, but there was a similar trend in both (Figure 6.4). In smokers 
(n=202), an association between smear conversion time and VDR genotype was observed (p= 
0.031), where individuals with a TaqI ‘tt’ genotype took longer to become sputum negative 
(Figure 6.5).  
 
Smear Culture 
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Faster culture conversion time was associated with females, low extent of tuberculosis at 
diagnosis, high absolute lymphocyte numbers and low absolute neutrophil numbers (Table 6.10). 
 
 
 
 
 
 
 
  
 
 
 
 
Kaplan-Meier survival curves were constructed for all variables available. Of particular interest in 
this department was the mycobacterial strains and the conversion time in patients. It has been 
hypothesized that different M. tuberculosis strains may give different responses to infection and 
treatment by the host. The SM cohort gave us the opportunity to investigate whether different 
strains have an effect on time to sputum conversion. The M. tuberculosis strain families and the 
median conversion times found in this cohort are summarized in Table 6.11. Kaplan-Meier 
survival curves were constructed for survival of all the RFLP families and also the genotypic or 
Figure 6.5: Kaplan-Meier survival curves for smear conversion time to negativity, of only 
smoking tuberculosis patients, sub-grouped according to TaqI genotype (p=0.0314). 
 
Figure 6.4: Kaplan-Meier survival curves of A: smear (p=0.0162) and B: culture 
(p=0.1066) conversion times for smokers and non-smokers.  
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virulence groups [324] (Figure 6.6) of the families. No significant associations were observed. The 
most frequent M. tuberculosis families in this cohort were Family 11 and Beijing and these made up 
more than 50% of the cohort (Table 6.11). 
 
 
Table 6.11: M. tuberculosis RFLP families in the SM cohort and the median conversion time for 
each family. 
RFLP 
Family Count   Frequency 
Median Culture 
conversion day 
Median Smear 
Conversion day 
Virulence 
Group 
0 6 2.7 67.5 21.5 0 
2 8 3.6 60 42 2 
4 4 1.8 65.5 72.5 2 
6 6 2.7 42.8 21 2 
7 7 3.1 58.5 23 2 
8 1 0.4 41.5 21 3 
9 5 2.2 56 41 2 
11 47 20.9 72 42 2 
12 1 0.4 42.5 139 0 
13 3 1.3 42 21 2 
14 6 2.7 31.5 23 2 
16 4 1.8 66.5 31 3 
17 1 0.4 73.5 10 3 
18 4 1.8 57.8 27.5 3 
19 1 0.4 59 73 2 
21 2 0.9 47.2 23 3 
23 2 0.9 21 41 3 
24 2 0.9 42 42.5 2 
25 1 0.4 20.5 2 1 
27 2 0.9 57.3 57.5 1 
28 6 2.7 41.3 20.5 2 
29 69 30.7 72 41 1 
30 1 0.4 116 212 0 
31 1 0.4 72 72 1 
110 5 2.2 43.5 22.5 2 
120 8 3.6 56.8 42 2 
130 2 0.9 72 57 2 
140 18 8.0 43 38 2 
150 2 0.9 42.3 16 2 
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6.4.2.3 Individual Cox regression analysis 
 
In the age and gender adjusted individual Cox analyses of smear conversion time (Table 6.12), 
only the following factors were found to have a significant (p <0.050) effect on faster conversion: 
not smoking, high school completion, low extent of tuberculosis at diagnosis, low total WBC and 
absolute neutrophil numbers, and high absolute lymphocyte numbers. The number of cavities 
present at diagnosis was weakly associated with smear conversion time (p=0.054). In the 
individual, age and gender adjusted, Cox analyses of culture conversion time (Table 6.12), only 
the following factors significantly affected faster conversion: low extent of tuberculosis at 
diagnosis, short height, high absolute lymphocyte numbers and low absolute neutrophil numbers. 
Figure 6.6: Kaplan-Meier survival curves for the sputum conversion time of the M. 
tuberculosis genotypic groups represented in the SM cohort. 
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Table 6.12: Results of the age and gender adjusted individual Cox regression analysis of the SAC 
cohort for smear and culture conversion times. 
 Smear  Culture 
 estimated coefficient  p value  estimated coefficient p value 
FokI 0.116 0.330  0.220 0.074 
ApaI 0.053 0.570  0.057 0.560 
TaqI 0.062 0.550  -0.050 0.650 
Smoker Yes -0.064 0.0430  -0.274 0.390 
Isoniazed sensitive No -0.159 0.490  0.078 0.740 
High school completion Yes 0.427 0.0140  0.270 0.120 
Self reported symptoms -0.037 0.540  -0.043 0.470 
Extent at diagnosis -0.226 0.0005  -0.208 0.0017 
Income level 0.077 0.180  0.013 0.820 
White blood cell numbers -0.051 0.0077  -0.024 0.260 
Absolute Monocyte numbers -0.013 0.700  -0.010 0.790 
Absolute Lymphocyte numbers 0.027 0.0160  0.035 0.0063 
Absolute Neutrophil numbers -0.021 0.026  -0.029 0.0047 
Mantoux size at diagnosis 0.001 0.940  -0.015 0.230 
Height (m) 0.073 0.930  -1.963 0.0400 
Number of cavities >4 -0.293 0.054  -0.147 0.350 
High Income (>R1000 per month) 0.044 0.830  -0.262 0.210 
BMI 0.039 0.084  0.021 0.340 
 
6.4.2.4 Optimal Cox model 
 
Smear conversion time: Variables that were independently predictive of faster smear conversion 
time in the final, optimal Cox model (Table 6.13), were the genotypes ApaI ‘AA’ versus ‘aa’ and 
TaqI ‘Tt’ and ‘TT’ versus ‘tt’. Low extent of tuberculosis at diagnosis, not smoking and low total 
WBC count at diagnosis were also predictive.  
 
Culture conversion time: Variables that were significantly associated and independent predictors 
in the optimal Cox model for faster culture conversion time were low extent of tuberculosis at 
diagnosis, short height and low absolute neutrophil numbers. The magnitude of the effect of the 
variables can be seen by referring to the estimated coefficient in Table 6.13. 
 
The final optimal Cox models constructed for time to smear and culture conversion, were both 
highly significant (p=0.0004) (Table 6.13). These models obviate the need to adjust for multiple 
testing. 
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Table 6.13: Optimal Cox regression analysis model of factors influencing time to sputum 
conversion in tuberculosis patients from the SAC population. 
 
  Smear (n=220)  Culture (n=222) 
Variables:  p value Est. coef.  p value Est. coef. 
Age  0.910 -0.001  0.560 -0.004 
Gender  0.940 0.011  0.440 -0.145 
Smoking Yes/No  0.047 -0.675  - - 
High school completion Yes/No   0.150 0.272  0.078 0.318 
Extent of TB at diagnosis from 
chest radiograph (<RUL, =RUL, 
>RUL, > 1lung)  0.010 -0.186  0.024 -0.164 
Total White blood cell count at 
diagnosis  0.039 -0.043  - - 
Absolute Neutrophil numbers at 
diagnosis  - -  0.023 -0.026 
Height (cm)  - -  0.003 -0.029 
FokI Ff versus ff  0.094 -0.576  0.470 0.262 
FokI FF versus ff  0.480 -0.235  0.180 0.476 
ApaI Aa versus aa  0.130 0.338  0.960 -0.011 
ApaI AA versus aa  0.040 0.480  0.920 0.024 
TaqI Tt versus tt  0.047 0.600  0.740 0.105 
TaqI TT versus tt  0.026 0.679  0.960 -0.014 
Final model Global p value  0.0004   0.0004  
RUL Right Upper Lobe 
A significant p value (in bold) indicates that a variable in the model contributes independently to 
conversion time. 
Est. coef. = Estimated coefficient for modelled conversion time in days. 
6.5 Discussion 
 
Host genetic susceptibility to the development of tuberculosis after infection has been the subject 
of many case-control studies comparing genotypes between the groups. More subtle effects of 
genotype are those impacting on the severity of disease, or the ability of the treated tuberculosis 
cases to recover i.e. undergo sputum conversion to negative culture or smear stain. We 
investigated both of the above aspects with respect to the VDR gene in a large study of a South 
African population, as VDR polymorphisms have been implicated both in susceptibility to 
pulmonary tuberculosis disease [28, 37, 169, 301], and recently, in the time to mycobacterial 
resolution of tuberculosis in a Peruvian population [285].  
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No significant association was found in our case-control analysis between pulmonary tuberculosis 
and the VDR polymorphisms. Diplotypes and haplotypes were also analysed because they are 
believed to be more informative than individual polymorphisms [37], but we found only weak 
associations between the VDR haplotype and tuberculosis susceptibility. In our study the FokI-
ApaI-TaqI ‘FAT’ haplotype tended to be associated with tuberculosis and may be a risk factor, 
whereas the ‘FaT’ haplotype is possibly protective. A recent case-control analysis of a South 
African Venda population found that the haplotype ‘FbAT’, but not the genotypes, significantly 
protected from tuberculosis [183]. In a TDT study of West African families, Bornman et al [37] 
found an association between tuberculosis and the FokI-ApaI ‘FA’ haplotype where the ApaI ‘A’ 
allele showed increased transmission to affected offspring. However no association between the 
ApaI genotype and tuberculosis susceptibility was found in a Gambian case-control study [28]. In 
our case-control study 41% of cases had the ApaI ‘AA’ genotype compared with 33% of 
controls, but this difference was statistically non-significant, as was the association of the FokI-
ApaI ‘Fa’ haplotype with controls (p=0.070). There was no association between the VDR 
diplotype and tuberculosis susceptibility. A larger sample set might provide more information 
although the present case-control study provided 80% power to detect an OR of 1.7 or higher.  
 
The polymorphisms investigated here may be in LD with another polymorphism which 
determines susceptibility, possibly the polyA repeat region which affects transcription [139, 387]. 
Patterns of LD vary between populations, often accounting for the inconsistency in results from 
different investigations [69, 140, 169]. The population frequencies for the VDR genotypes differ 
between populations. Particularly in the Peruvian population there appears to be a major change 
in population frequency of the FokI VDR polymorphism. The most frequent allele in the 
Peruvian population for SNP FokI (f) is the least frequent in all other populations (Table 6.14). 
 
Table 6.14: Frequency of VDR genotypes in various populations (adapted from Wilbur et al 
2007) [390]. 
 Genotype 
 FokI  TaqI 
Population FF Ff ff  TT Tt tt 
US, Mostly white [314] 0.36 0.49 0.15  0.36 0.46 0.18 
African (Gambian) [28]     0.48 0.43 0.09 
Gujarati [391] 0.61 0.34 0.05  0.41 0.50 0.09 
Indian [301]     0.42 0.43 0.15 
Indian [288]     0.43 0.45 0.12 
Korean females [151] 0.39 0.44 0.17     
Chinese [332]     0.95 0.05 0.00 
Han Chinese [52]     0.90 0.10 0.00 
Taiwenese Females [53, 135] 0.42 0.34 0.24  0.90 0.10 0.00 
Japanese [239]     0.66 0.31 0.03 
Peruvian [285] 0.08 0.35 0.57  0.87 0.12 0.00 
Ache, S. America [390] 0.67 0.33 0.00  0.44 0.51 0.05 
Ava, S. America [390] 0.78 0.16 0.06  0.69 0.31 0.00 
South African Coloured [16] 0.56 0.40 0.28  0.55 0.39 0.07 
South African Venda [183] 0.77 0.21 0.02  0.57 0.42 0.01 
West African (The Gambia, Guinea and Guinea-Bissau) [37] 0.62 0.34 0.05  0.52 0.39 0.08 
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Comparison between the fast and slow responders to therapy indicated that individuals with an 
ApaI ‘A’-containing genotype had a faster response to treatment (culture conversion time 
p=0.029), and tended to convert before day 55 (month 2) when on standard DOTS treatment. 
FokI ‘F’-containing genotypes tended to show delayed conversion, but the frequency of FokI ‘ff’ 
was too low in our population to show a significant effect (smear conversion time p=0.055). 
Roth et al [285] (n=78) found a significant difference at an earlier time point of 30 days (month 
1), where the homozygous FokI genotype of the less frequent allele was associated with faster 
conversion time by culture or smear. Their study also found an association between TaqI 
genotype and culture conversion time at 30 days although no TaqI ‘tt’ genotypes were present in 
the Peruvian cases. In the SAC, the frequency of the TaqI ‘tt’ genotype is 7%. Investigating 
individuals that had a negative sputum result for both their culture and smear conversion times at 
days 30 or day 55 revealed no associations with the genotypes (Table 6.9). We found no 
association with TaqI and the response to treatment at day 30 or day 55, but TaqI was an 
independently significant predictor of smear conversion time in our final, optimal Cox model 
where TaqI ‘tt’ genotype was associated with delayed smear conversion time. Such associations 
could be used to identify people who would benefit from more intensive treatment or follow up. 
 
The use of Kaplan-Meier survival curves allows for the visualization of the conversion time. The 
log rank analysis assesses differences between conversion times of the different subgroups but 
cannot take confounding factors into consideration. Roth et al found an association with FokI 
and both culture and smear conversion time, where the FokI ‘FF’ genotype (the least frequent 
genotype in the Peruvian population) converted fastest (Figure 6.7). We did not find an 
association in our Kaplan-Meier survival curves and the genotype FokI time to smear conversion 
(Figure 6.7). 
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There were numerous M. tuberculosis strains represented in this cohort, however the frequency of 
the rarer families was low and therefore did not provide enough information to make an 
assessment of their impact on time to sputum conversion. Families 29 and 11 were the most 
frequent in this cohort. This corresponds with previous studies done in the same population 
[275]. More samples of the rarer strains would be required to determine if they affect time to 
sputum conversion. Assessing the families according to their genotypic groups [324] did not 
reveal an association with time to sputum conversion.  
 
In the cohort study of pulmonary tuberculosis cases, the only variable to contribute 
independently to the final optimal model of both smear and culture conversion time during 
treatment, was the extent of tuberculosis at diagnosis as determined by chest radiograph. It could 
Figure 6.7: Kaplan-Meier survival curves assessing the VDR FokI genotypes in A: Culture 
(MODS) and B: Smear (auramine staining) in a Peruvian cohort (n=78) compared to the 
conversion time in the SAC population C: Culture (BACTEC) and D: Smear (Ziehl Neelsen). 
The solid line is FokI ‘FF’ genotype, the dashed line is FokI ‘Ff’ genotype, and the dotted line is 
the FokI ‘ff’ genotype. The FokI genotype was associated with conversion time in the Peruvian 
cohort [285] as measured by culture, and by smear, where ‘FF’ resulted in faster conversion 
(p=0.0179). 
A: Culture (MODS), in a Peruvian 
population, p=0.0179 
 
B: Smear (Auramine staining), in a Peruvian 
population p=0.0037 
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be expected that the extent of tuberculosis at diagnosis would be associated with the length of 
time to sputum conversion, with severely affected cases taking longer, as has been shown to 
occur with MDR-TB disease [134]. However, this is the first report, to the best of our 
knowledge, of a correlation between the severity of tuberculosis disease and the rate of treatment 
response.  
 
In the final, optimal model of variables contributing to smear conversion time, VDR genotypes 
contributed independently to the model. Both the TaqI and ApaI genotypes were independently 
significant, as were smoking status and total WBC count at diagnosis. In the culture conversion 
optimal model, additional independently significant variables were absolute neutrophil numbers 
at diagnosis and height. Although not independently predictive of faster conversion, high school 
completion contributed to both optimal models, and lower educational level is a known risk 
factor for tuberculosis [306, 343]. The final models were both highly significant (p=0.0004). 
  
The final model of the Cox regression analysis therefore indicates that the following variables are 
independent predictors of a faster conversion time in smear and/or culture: not smoking, low 
extent of tuberculosis at diagnosis, low total WBC count and low absolute neutrophil number at 
diagnosis, shorter height, an ApaI ‘AA’ genotype, and a TaqI ‘T’ containing VDR genotype. In 
the optimal model for smear conversion (Table 6.13), it can be seen from the estimated 
coefficient that VDR genotype and smoking had a greater clinical effect than the other variables. 
All effects were fairly modest. 
  
The function of the TaqI polymorphism is not clear. Previously, the TaqI ‘tt’ genotype was found 
to protect against tuberculosis in a Gambian population [28] and the combination of the TaqI 
‘TT/Tt’ genotype and 25-hydroxycholecalciferol deficiency was associated with tuberculosis in 
Gujarati Asians [391]. Contrary to these indications that TaqI ‘t’ may be advantageous, the TaqI 
‘tt’ genotype is associated with decreased levels of VDR mRNA and protein levels in peripheral 
blood mononuclear cells [244]. Roy et al [289] found the TaqI ‘tt’ genotype to be associated with 
susceptibility to leprosy per se, and TaqI ‘tt’ predisposed Tamil-speaking females to tuberculosis 
[301]. Our results correspond with the latter views of the function of TaqI in that cases with a ‘tt’ 
genotype take longer to respond to tuberculosis chemotherapy, and therefore may have a poorer 
immune response. Even though a patient is undergoing chemotherapy for tuberculosis, an 
efficiently functioning immune system is still necessary for optimum response and early sputum 
conversion. 
  
The negative correlation between total WBC count at diagnosis or absolute neutrophil number at 
diagnosis and time to conversion in the final models for smear or culture respectively, may reflect 
the involvement of both of these cell types in the acute response to inflammation. Our results 
extend to the human model, the evidence recently presented by Keller et al [150], that an early 
influx of granulocytes contributes to susceptibility to M. tuberculosis in mice. 
 
An association between smoking and tuberculosis infection status (a positive tuberculin skin test) 
has been reported in our population [71] and in India smokers have a higher rate of progression 
from infection to clinical tuberculosis [101]. We have shown here that smoking is also a 
significant factor in delaying sputum conversion time while on DOTS, as measured by smear. 
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This was seen in all three analyses done; log rank, univariate, and multivariate, optimal model. 
However, the number of non-smokers in this cohort was low and a further study would be 
needed to confirm this.  
 
The association between height and culture conversion time could be an artifact due to the fact 
that there were a small number of people of small stature and high mass in whom culture 
conversion time was unusually fast. As can be seen from the estimated coefficient in Table 6.13, 
the actual effect of height was negligible.  
 
The statistical model that is the most informative is the optimal cox regression (multivariate) 
model, as it takes all factors into consideration. The two analyses done before this model provide 
clues and assists in the interpretation of the optimal model. The association between smoking 
was consistently associated with time to sputum conversion. The same applies to extent of 
disease according to chest radiograph at diagnosis, which was associated with conversion time in 
both smear and culture. The absolute neutrophil number was also a significant factor in all three 
analyses. WBC count was not significant in the Kaplan-Meier survival curves but this might be 
because the subgroups were incorrect and the association was missed. Grouping could also 
explain why height was not found associated in the Kaplan-Meier survival curves.  
  
The lack of concordance in the results between smear (ZN) and culture (BACTEC) conversion 
illustrates the complexity of this disease and the subtly different end points measured by the two 
techniques. At month 2, 31% of patients were smear negative but still culture positive. Roth et al 
found an association between VDR genotypes and culture conversion times (as measured by 
MODS) [285] whereas in our large study of patients with strict inclusion criteria and intensive 
follow-up, associations were found with smear conversion times. Culture is more sensitive, but as 
a very low number of bacteria can give rise to a positive culture, it may be a less robust tool for 
measuring an endpoint of sputum conversion time.  
 
Further investigations into the effects of Vitamin D metabolism in response to the medication 
used in DOTS, would also be of benefit to better understand the role of Vitamin D and its 
receptor on response to tuberculosis treatment [41, 64]. There have been some reports on the 
benefits of vitamin D supplementation during tuberculosis treatment but they have been 
methodologically flawed [201]. A double blind trial placebo-controlled study was recently 
reported which showed that a single oral dose of 2.5mg vitamin D significantly enhanced the 
ability of participants’ whole blood to restrict BCG-lux in vitro 6 weeks later [202].   
 
Currently, in most tuberculosis programmes, the first measure of effective therapy is sputum 
conversion at 2 months. The discovery of a genetic or immunological marker indicating how 
efficiently a patient responds to treatment could have a major impact on clinical trials and shorten 
the time period necessary for drug testing. In the coming era of personalized medicine, genetic 
markers have the potential to be developed into simple, affordable tests applicable even in high-
burden countries. Estimates of disease transmission in the community studied here are extremely 
high, and the percentage of tuberculosis due to transmission could be in excess of 70% [362]. 
The extended time to microbial resolution of tuberculosis may be a contributory factor in the 
continuation of the tuberculosis epidemic. 
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Chapter 7 
 
 
 
Concluding remarks 
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In the South African Coloured (SAC) population, susceptibility to tuberculosis was investigated 
using a case-control study design. With the number of samples available, there was sufficient 
power to determine whether there was an association with tuberculosis susceptibility in a variety 
of candidate genes (Table 7.1). Polymorphisms in these candidate genes were assessed for an 
association with susceptibility to active tuberculosis and not susceptibility to Mycobacterium 
tuberculosis (M. tuberculosis) infection (otherwise healthy individuals that are latently infected). 
 
Table 7.1: Summary of all the polymorphisms investigated via a case-control method using the 
SAC population. 
Gene SNP 
Results in 
table: 
significant 
p values  Comment 
RANTES -403(rs2107538) 3.1   
RANTES +1092(rs1065341) 3.1   
CCR5 59029(rs1799987) 3.1   
CCR5 ∆32(rs333) 3.1   
CCR2 64I(rs1799864) 3.1   
SDF1 3'A(rs1801157) 3.1   
DC-SIGN -939 4.1   
DC-SIGN -871 4.1 8.2x10
-4  
DC-SIGN -336 4.1 0.01  
DC-SIGN -139 4.1   
DC-SIGN 2392 4.1   
DC-SIGN 3220 4.1   
DC-SIGN 3838 4.1   
DC-SIGN 4235 4.1   
DC-SIGN neck length variation 4.3   
L-SIGN neck length variation 4.3   
SP110 rs2114592 5.2   
SP110 rs1365776 5.2   
SP110 rs41545715 5.2   
SP110 rs3948464 5.2   
SP110 rs1135791 5.2   
SP110 rs3948463 5.2   
SP110 rs41541917 5.2   
SP110 rs35495464 5.2   
VDR FokI (rs10735810) 6.3   
VDR ApaI (rs7975232) 6.3  Appears to weakly contribute to smear 
conversion time (Table 6.13) 
VDR TaqI (rs731236) 6.3  Appears to weakly contribute to smear 
conversion time (Table 6.13) 
 
 
In addition, this admixed population was formally assessed for population stratification and the 
Ravensmead/Uitsig SACs were found not to be stratified. However, a possible criticism is that 
the 25 single nucleotide polymorphisms (SNPs) used were not enough to confidently assess the 
stratification within an admixed population. Further analysis of more SNPs or microsatellites 
could be done [258] to strengthen the evidence that the SAC population is not stratified. The 
impact that possible population stratification could have on case-control association studies is 
debated and the extent and implications have not been established [47, 96, 346, 377]. 
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Candidate polymorphisms in RANTES, CCR5, CCR2 and SDF1, which had previously been 
associated with a number of diseases, were not associated with tuberculosis susceptibility. The 
polymorphisms occurred at high enough frequencies to provide sufficient power to detect an OR 
of at least 1.6. The RANTES polymorphism -403 initially showed an association, which was lost 
when additional samples were genotyped. This illustrates one of the challenges with association 
studies.  
 
The DC-SIGN gene was re-sequenced using samples from the SAC population, and the 
genotyping of promoter polymorphisms -336 and -871 found both to be associated with 
tuberculosis susceptibility. The association was strong and was still present after (non-significant) 
stratification adjustment. The DC-SIGN -336A variant has been implicated in increased DC-
SIGN expression which could explain its role in tuberculosis susceptibility. The increased 
expression of DC-SIGN may be the underlying reason for an increased efficiency of host 
phagocytes. As both DC-SIGN -336 and -871 are promoter polymorphisms, further studies 
assessing their functional consequences, for example gene expression studies where luciferase 
reporter vectors are utilised, are now required to eventually develop knowledge-based and 
effective pathway-targeted treatments. These functional studies are being done at the Pasteur 
Institute, Paris, France. Additional DC-SIGN haplotype tagging SNPs (htSNPs) were also 
investigated but not associated with tuberculosis susceptibility.  
 
The SP110 gene was identified as a potential susceptibility gene through mouse studies, as was 
SLC11A1 (NRAMP1). Re-sequencing sections of the SP110 gene identified fourteen novel 
polymorphisms and in the case-control study eight polymorphisms in the SP110 gene were 
genotyped. No SP110 genotypes or haplotypes were associated with tuberculosis susceptibility. 
Although, SLC11A1 was identified through mouse studies and subsequently proved to be a 
susceptibility gene for tuberculosis in humans, the same does not appear to be true for the SP110 
gene. The mouse model has its uses but it is not designed to identify human candidate genes, as 
the mouse does not always reflect the human disease model sufficiently to allow findings to be 
translated to the human patient.  
 
Both the SP110 and DC-SIGN genes were re-sequenced to determine the frequencies of the 
polymorphisms, identify novel SNPs and determine linkage disequilibrium (LD) and infer 
haplotypes present in the SAC population. When testing for an association with tuberculosis, 
haplotype tags (htSNPs) and tagSNPs were desired, as one polymorphism could provide 
information on a whole haplotype. In particular, in an admixed population it is useful to sequence 
and identify LD and haplotypes within that population. Re-sequencing SP110 gene sections to 
determine the haplotype and LD showed low LOD values and no tagSNPs could be determined. 
The re-sequencing of the DC-SIGN gene did enable us to determine htSNPs.  
 
There are indications that 60 independent samples would provide optimal performance of 
tagSNPs, when considering a common SNP (>5% frequency) [220]. In a resource-poor setting 
the sequencing of 60 samples might not be feasible, in particular when the gene is fairly large. 
The use of htSNPs and tagSNPs does reduce the cost of genotyping as all SNPs spanning the 
gene do not need to be genotyped. Information on tagSNPs and htSNPs is available from the 
HapMap database (http://www.hapmap.org/). The SAC population is not represented in this 
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database, but the information has been found to be translatable to other populations. Using 
online resources will provide a wealth of information from reference populations, but they 
seldom reflect admixed populations, a term that can refer to many distinct populations. As the 
SAC population is admixed with contributions from Asian, Caucasian and African populations, 
all the tagSNPs spanning the gene of interest from all the reference populations should be used, 
as this will provide the most reliable information. This includes polymorphisms that are unique to 
one of the reference populations together with the other tagSNPs identified, and common to all 
three reference populations (M. Möller PhD thesis 2007). However, this could result in a large 
number of polymorphisms that would need to be genotyped. Thus the initial expenditure of re-
sequencing genes in samples from the SAC population might be beneficial in providing valuable 
information on LD, tagSNPs and novel SNPs in this population. Re-sequencing or using online 
resources both have their advantages and disadvantages and do not have to be mutually 
exclusive. Combining the information from both sources provides the most information. 
 
Care must be taken when assessing published positive associations with disease. There are many 
underpowered, poorly-defined studies published and they should be used with caution. Specific 
guidelines for the publication of association studies have been released to ensure that there is no 
bias towards positive associations, and studies are published on the basis of correct design, not a 
positive result [281].  
 
There are a plethora of positive association studies that have not been replicated and there are 
numerous reasons why some studies cannot be replicated [58]. As seen in Chapter 3, there was 
initially a positive association with the RANTES -403 polymorphism but after analysis of more 
samples there was no association. The positive association could be spurious and also indicates 
why replication in an independent study and with an alternative population is important. The 
initial study should be scrutinised to assess whether it has enough power to justify its claims. A 
simple check is to assess if the cases and controls are reasonably closely matched for age, 
ethnicity, gender and, if feasible, similar exposure in environment. Care must be taken that 
reporting of subgroups is not done in an attempt to put a positive spin on negative results.  
 
Polymorphisms in the SP110 gene were associated with tuberculosis susceptibility in West 
African populations but not in SAC, Russian and Ghanaian populations. This could indicate a 
spurious result in the original West African populations, or the polymorphisms could be 
indirectly associated with disease through LD. The investigations in Ghana and Russia used 
thousands of samples in their case-control association studies [335, 348]. Only if the 
polymorphism occurs at a low frequency are these numbers required. A large number of samples 
is not always necessary if there is sufficient power in the statistical analysis [43], but it does 
provide convincing evidence for negative results. However, when a polymorphism with a low 
frequency is associated with susceptibility for a common disease, the practical implications are 
limited, as the population attributable fraction of the susceptibility genotype will be low. In other 
words, the findings will have theoretical value but have little practical public health value [279].  
 
Finally, VDR gene polymorphisms FokI, ApaI and TaqI were investigated in a case-control study 
and found not to be associated with susceptibility to tuberculosis. The 249 cases were from a 
longitudinal study, known as the Surrogate Marker (SM) cohort, of first time pulmonary 
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tuberculosis patients, which were followed during and after their treatment. With the regular 
sputum sample testing which had been done, it was possible to reliably determine when sputum 
conversion, from a positive to negative result, took place. Sputum results were available for both 
smear and culture. Apart from Kaplan-Meier survival curves and univariate analysis, an optimal 
Cox regression (multivariate) analysis was done. The optimal Cox regression model is a useful 
analytical method as it takes all variables into consideration and no statistical correction for 
multiple testing is required. The final optimal model lists all factors that may contribute to the 
outcome being investigated, i.e. time to sputum conversion. The optimal model identified that 
the VDR polymorphisms, ApaI and TaqI contributed to smear conversion time. The extent of 
tuberculosis at diagnosis, according to the chest radiograph, was the only variable that 
contributed to both smear and culture conversion time. This model provides a wealth of 
information that takes factors from the environment, host and pathogen into a holistic 
consideration, and not merely as individual factors. This provides a more nuanced investigation 
of gene effects than the conventional case-control study.  
 
The SM cohort will be useful for further studies investigating time to sputum conversion in 
tuberculosis patients and the contributions of various genetic loci to treatment outcome. This 
type of investigation has only been done with the VDR gene in SAC and Peruvian populations. 
Knowledge of which gene polymorphisms contribute to sputum conversion would provide 
valuable information for antibiotic development and trials, and possibly provide a surrogate 
marker to identify poor responders to treatment. Selection of candidate genes for association 
with time to sputum conversion would be different from those assessing associations with 
susceptibility to tuberculosis disease, as sputum conversion will involve genes important in 
recovery from tuberculosis disease while on treatment and not necessarily those involved in 
progression to disease. 
 
The ability of the M. tuberculosis strains to elicit a heterogenous response from the human host 
and the role that genetic variants play needs further investigation. The interaction between M. 
tuberculosis strains and VDR genotype was briefly assessed in the SM cohort, with respect to 
influence on time to sputum conversion, but there were no significant findings. In genetic 
association studies it would require the cases to be phenotyped and catergorised by the strain type 
of the patient and the clinical form of disease. There are clearly interacting roles for the host, 
pathogen and the environment and we require a better understanding of the intricate interplay 
taking place.  
 
Tuberculosis susceptibility has been investigated in a number of genes worldwide and a number 
of positive associations (some unpublished) have been found. The combined effects, either 
additive or epistatic, of these polymorphisms needs to be determined [229]. As the response to 
M. tuberculosis infection is complex, it is possible that individual susceptibility genes may occur in 
complementary pathways, or gene function may be compensated for by another redundant gene. 
In addition, epigenetic effects might also be playing a key role in susceptibility to tuberculosis 
disease and these have not been explored yet [144]. Comprehensive studies considering the 
genomics, transcriptomics, proteomics and metabolomics would provide a complete view of the 
hosts’ response to M. tuberculosis infection. 
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These results, and other association studies, could have implications for vaccine and drug 
development [114, 392]. The design of drug and vaccine trials might need to take the effect of 
these polymorphisms into consideration, either by stratification of study populations or 
correction in statistical analysis of the efficacy of the drug or vaccine. Failure to consider inter-
population genetic differences could have implications on the efficiency and the outcome of trials 
when tested in different populations. This important point has already been raised in HIV 
vaccine trials [114, 392] but would apply equally to tuberculosis. This may already be 
demonstrated by the variable efficacy of BCG vaccination in different populations [9]. Host 
genetic variability might not only affect the efficacy of a trial between sites but in addition disease 
progression and the outcome of treatment. Knowledge of the genetic background of the 
susceptibility to a disease is required to implement effective treatment. Positive genetic 
associations in the population that we studied would need to be replicated in other population 
groups, including those from other areas in South Africa, before we could contemplate using this 
knowledge to improve tuberculosis treatment and public health. 
 
Tuberculosis is a major burden to the world, especially developing countries. With no major 
developments in vaccines and drug therapy for over 40 years, something drastic needs to happen. 
There are new drugs in the clinical trial pipeline but there seem to be no ‘golden bullets’ within 
sight. There is still a lot we do not understand and we require better knowledge on what 
contributes to tuberculosis disease, which will hopefully help develop better vaccines or 
therapeutics. Therapeutics that reduces the treatment period of 6 months and the development 
of rapid, low cost diagnostics are required. A vaccine that would protect both children and adults 
and particularly one that could target the genetically susceptible groups would help to reverse the 
epidemic. 
 
 
   ■ 
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Appendix 1 
 
Methods and Materials 
 
 
These Methods were used in the following publications: 
 
Babb C, Keet EH, van Helden PD, Hoal EG (2007)  
SP110 polymorphisms are not associated with pulmonary tuberculosis in a South African 
population.  
Hum. Genet. 121:521-2 
 
Babb C, van der Merwe L., Beyers N, Pheiffer C, Walzl G, Duncan K, van Helden P, Hoal EG.  
Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis 
patients.  
Tuberculosis 2007;87:295-302. 
 
Barreiro LB, Neyrolles O, Babb CL, Tailleux L, Quach H, McElreavey K, Helden PD, Hoal EG, 
Gicquel B, Quintana-Murci L (2006)  
Promoter Variation in the DC-SIGN Encoding Gene CD209 Is Associated with Tuberculosis. 
PLoS Medicine 3:e20 
 
Barreiro LB, Neyrolles O, Babb CL, van Helden PD, Gicquel B, Hoal EG, Quintana-Murci L 
(2007)  
Length Variation of DC-SIGN and L-SIGN Neck-Region has no Impact on Tuberculosis 
Susceptibility.  
Human Immunology 68:106-12
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A1.1 Patients and Controls 
 
Samples have been collected over the last 10 years from the Ravensmead and Uitsig communities 
and some adjacent suburbs in the proximity of Tygerberg Hospital, Parow, Western Cape. 
Individuals that were enrolled for the studies are from the population discussed in Chapter 2, 
namely the South African Coloured. 
 
All projects received ethical approval from the ethics committee of the Faculty of Health 
Sciences, University of Stellenbosch, South Africa. The case-control study received project 
registration number: 95/072, the Surrogate Marker has project registration number 99/039 with 
amendments and the Sequella/ Aeras study has registration number 95/072 with amendments. 
 
Tuberculosis patients are diagnosed and bacteriologically confirmed through the local health 
system and placed in the direct observed therapy, short course (DOTS) treatment as prescribed 
by the South African National Tuberculosis Programme, based on World Health Organization 
(WHO) guidelines discussed in Chapter 1.1.4. For the human susceptibility to tuberculosis 
studies described, only HIV negative patients were included.  
 
Controls were enrolled from a variety of sources such as clinics, households and places of work 
in the same area as the tuberculosis cases. They were all from high TB incidence suburbs, similar 
socio-economic status and the SAC population group. They reported having no clinical 
symptoms of tuberculosis and have no record or recollection ever having had tuberculosis. In 
addition their medical records (if any) were checked for a history of tuberculosis. No PPD results 
were known, but as discussed in Chapter 1, they are very likely to be positive because of the high 
tuberculosis exposure in this community [371, 372, 383]. Familial information was collected for 
over 225 families, to allow for family-based studies, such as transmission disequilibrium test 
(TDT) studies. I checked and constructed all pedigrees, for future TDT studies, in Cyrillic 
version 3.0.3. However no familial studies were done for this thesis.  
 
Venous blood samples of between 2 and 10 ml were collected from subjects in one to two 
EDTA lavender vacutainers (BD Vacutainer Systems, Plymouth, UK, provided by Scientific 
Group Cat no. BD367655). The date of sampling, date of birth, medical history, consent forms 
and, in some cases questionnaires, were all collected at the same time. Records were kept in the 
“EileenTB” database which is stored on the server “Zeus” in the Division of Molecular Biology 
and Human Genetics, Faculty of Health Sciences, Tygerberg Campus, University of Stellenbosch. 
Confidentiality is strictly adhered to with numerical Patient IDs being assigned on the first visit. 
All clinical and epidemiological information is linked to the Patient ID and only clinicians, the 
primary investigator and database manager were permitted access to patient names.  
 
A1.2 Genomic DNA Isolation  
 
On the day of phlebotomy samples were kept upright at room temperature. Once the plasma had 
settled one millilitre was pipetted from each of the vacutainers into a 2ml tube. This was then 
centrifuged at 14 000 rpm for 1 minute, so that any remaining red blood cells pelleted. Two ml of 
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plasma was then pipetted into two one millilitre eppendorfs to be stored at minus eighty degrees. 
The collection tube containing the pellet was discarded. The two aliquots of remaining whole 
blood were then pooled in a 50ml sterilon collection tube and stored at minus 20°C until 
genomic DNA was extracted using the Nucleon BACC3 Kit for blood (Amersham Biosciences, 
UK Catalogue number: BACC RPN-8512). Extractions were done according to manufacturers 
instructions, which are briefly described below. 
 
Outline of Nucleon DNA extraction case-control Samples 
1. Dilute Reagent A 1 to 4 in distilled water: (12 samples = 94.5ml Reagent A + 283.5ml 
water). 
Cell lysis 
2. Collect the defrosted 50ml collection tubes, containing the pooled blood, from cold 
room.  Two millilitres of plasma has been removed and should contain 5-10 ml of 
whole blood.  Fill with diluted Reagent A to 30 ml. 
3. Vortex each tube for +- 30 seconds 
4. Centrifuge at 1300g for 15 minutes (Switch the waterbath on and dilute some bleach). 
5. Pour off the supernatant into the diluted bleach. Be careful not decant the pellet. 
6. Add 2ml of diluted Reagent A to the remaining pellet in the 50ml collection tube (double 
lysis).  Shake by hand to release the pellet from the bottom of the tube. 
7. Centrifuge the 50ml tubes at 1300g for 15 minutes. Collect 15 ml sterilon tubes, two for 
each sample. Add 500µl of sodium perchlorate to one set of empty 15ml tubes. 
8. Pour off the supernatant in the 50ml tubes into the diluted bleach, again being careful not 
to loss the pellet. 
9. Add 2ml Reagent B to the 50ml tube. 
10. Place the samples in the water bath (37°C) until the pellets are dissolved in reagent B. 
Check and swirl by hand every few minutes. 
Deproteinisation 
11. Transfer the diluted pellet to the 15ml sterilon tube, containing the 500µl of sodium 
perchlorate solution, by pouring.  Mix by inverting ± 20 by hand. 
DNA extraction 
12. Add 2ml of chloroform to the 15ml tube containing the sample.  Mix by inverting ± 20 
by hand. 
13. Add 300 µl of resin that is supplied with the kit.  Add slowly and close to surface so it 
does not splatter. 
14. Centrifuge the sample at 1300g for 8 minutes 
DNA precipitation 
15. Remove the top layer, ~2.5ml (NOT RESIN), to an empty 15ml sterilon tube. 
16. Add 5ml of ice cold ethanol. The DNA will precipitate and become visible. 
17. Remove the strands out of the ethanol by pipetting, to a 1.5 ml eppendorf tube. +- 70 
µl of ethanol can be pipetted with the DNA.  Invert the 15ml tube as more DNA 
lumps may appear, collect any precipitate. 
DNA washing 
18. Centrifuge the 1.5ml tube at top speed (4000g) for 5 minutes to pellet the DNA. 
19. Pour off the ethanol supernatant. 
20. Add ~ 1.5ml of 70% ethanol. 
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21. Centrifuge for 5 minutes at top speed. 
22. Pour the ethanol off completely. Carefully as not to loose the pellet of DNA. 
23. Reconstitute the DNA pellet with TE. The volume of TE required depends on the size 
of the pellet, usually between 200 and 1000 µl when starting with 5-10ml of whole 
blood.  Flick the 1.5ml tube to release the pellet. The pellet must dissolve fully before 
reading the concentration on the Nanodrop (NanoDrop Technologies Inc., USA). 
Advisable to leave on a rotary wheel, at least, overnight. 
 
A1.3 Polymerase Chain Reaction  
 
All techniques in this thesis used PCR as the starting point of all genotyping. The different 
elements of PCR will be discussed in this section. Unless stated otherwise all PCRs were done on 
an Eppendorf Mastercycler Gradient PCR Machine (Eppendorf, Hamburg, Germany). 
A1.3.1 Primer Design 
 
Correct primer design is important to achieve accurate results. Using online databases is essential 
but should be used with caution as mislabelling and incorrect alignments can sometimes occur. 
Online databases store globally produced data and make them publicly available. The most 
commonly used are: NCBI (http://www.ncbi.nlm.nih.gov/), Ensembl 
(http://www.ensembl.org) and EMBL (http://www.ebi.ac.uk/embl/). A comparison of the 
desired target nucleotide sequence between these different databases is desirable because, even 
though they have overlap in data input, they also have unique submissions of data from various 
sources around the world. When designing a primer, and consideration for pseudogenes, 
incorrect alignment and homologues must be taken.  
 
If possible the target DNA sequence should be sequenced. Not only will sequencing ensure that 
the correct sequence is being used, but will also allow for the detection of novel polymorphisms 
that may not be present in populations that currently dominate genome projects, such as the 
CEPH group, white American or African American. Once the correct target nucleotide sequence 
template has been identified, primer design can take place.  
 
There are a number of computer programs that can assist with primer design. We used DNAman 
Version 4.1 (http://www.lynnon.com/), but another that is commonly used is Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Information on the primer 
includes the GC content, melting temperature (Tm), molecular weight and more. Primer design 
must follow these basic guidelines: avoidance of substantial tandem repeats of one or more 
nucleotides, avoid sequences prone to secondary structures which could form hairpin loops and 
dimerization, and the Tm should be between 50 and 60 °C. 
 
The program Oligocalculator (http://trishul.sci.gu.edu.au/tools/OligoCalculator.html) was used 
as an independent check for the Tm and the GC content. Testing for the presence of hairpins 
and dimers was done by using Scitools Oligoanalyzer 3.0 
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(http://scitools.idtdna.com/Analyzer/oligocalc.asp). This program tests for auto- and hetero-
dimers, and hairpin loops. Any dimers that were more than 4 bp and overlapped the 3’ end were 
rejected, as were primers where a hairpin bound at the 3’end and had a Tm above 39.9 °C. The 
program AutoDimer was used as an additional check [359]. 
 
To check that the primers will anneal only to the desired target, a BLAST needs to be conducted. 
This is done through the NCBI website (http://www.ncbi.nlm.nih.gov/blast/) and choosing the 
"search for short nearly exact matches" or "nucleotide-nucleotide BLAST" option to ensure 
specificity. Selection of  "chromosome" as the database, "Homo sapiens" as the organism, and 
checking the "Mask for lookup table only" box, which then gives a real idea of the hits on the 
genome without all the confusion of different genes, mRNA etc. It must be noted that the 
BLAST results are ranked by "expect value", and this calculation means that a hit of 16 
continuous bases in a 20bp primer will rank higher than a 19bp hit with one gap in it. Therefore 
all hits must be manually checked to find the ones of biological importance.  
 
A virtual PCR on the website (http://grup.cribi.unipd.it/cgi-bin/mateo/vpcr2.cgi) was done to 
check if amplification would occur with the chosen primer pair. However this is just a check and 
cannot replace actual experimentation and optimisation of the PCR, as it is not always accurate.  
 
A1.3.2 PCR amplification 
 
Super-Therm Gold DNA polymerase (JMR holdings, USA, Catalogue Number JMR 850 
supplied by Southern Cross SA) was the Taq used throughout all the experiments. 
Deoxynucleotide triphosphates (dNTPs) were all supplied from Bioline (catalogue number BIO-
39025) and a master mix with 25mM of each dNTP, with a working concentration of 2.5mM was 
used throughout. Primers were manufactured by Integrated DNA Technologies Inc (IDT, USA; 
supplied by Whitehead Scientific, SA). The stock was diluted with distilled water to a 
concentration of 100µM and a working concentration of 10µM. Genomic DNA was used at a 
concentration between 10 and 50ng/µl. 
 
PCR programs were done with the general program: 1 cycle at 94°C for 15 minutes followed by 
35 cycles at 94°C for 30 seconds, annealing temperature °C for 30 seconds and 72°C for 45 
seconds, then 1 cycle at 72 °C for 10 minutes and finally a 15°C hold step. 
 
Agarose gels were either Tris-borate-ethylenediaminetetra acetic acid (TBE) or Sodium Boric 
(SB) acid [42] buffer gels. SB buffer allows gels to be run at higher voltage without causing a high 
temperature increase, which decreases the run time of a gel. 
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A1.4 Sequencing 
 
Instead of the Sanger/ chain terminator sequencing method, labelled terminators were used, 
commonly called 'dye terminator sequencing'. The major advantage of this approach is that the 
complete sequencing set can be performed in a single reaction. This is accomplished by labelling 
each of the dideoxynucleotide chain-terminators with a separate fluorescent dye, each with a 
different wavelength. Software allows for automated calling of the bases.  
 
A1.4.1 PCR Clean-Up 
 
To get good quality sequencing, cleaning/purification of PCR products is required to remove 
primers, buffers and dNTPs. Initially, all purification for genomic DNA sequencing was done 
using the Wizard ® SV Gel and PCR Clean-Up system (Promega, Catalogue number: A9282), 
briefly described below.  
 
Outline of Wizard ® SV Gel and PCR Clean-Up system 
This is a DNA purification done by centrifugation protocol, as described by the 
manufacturer:  
Processing PCR reactions 
1. Added equal volumes of the membrane binding solution to the PCR reaction. 
Binding of DNA 
2. The SV minicolumn was inserted into the collection tube. 
3. The prepared PCR sample was transferred to the minicolumn assembly and incubated at 
room temperature for 1 minute. 
4. Then was centrifuged at 16 000g for 1 minute. The through-flow was discarded and the 
minicolumn reinserted into the collection tube. 
Washing 
5. 700µl of Membrane Wash Solution (ethanol already added, as required by manufacturer) 
was added to the minicolumn. Then was centrifuged at 16 000x g for 1 minute. Through 
flow was discarded and the minicolumn reinserted into the collection tube. 
6. The above step was repeated with 500µl of membrane wash solution,  and centrifuged at 
16 000g for 5 minutes. 
Elution 
7. Carefully transferred the minicolumn to a clean 1.5ml microcentrifuge tube.  
8. 50µl of nuclease free water was added to the minicolumn and incubated for 1 minute at 
room temperature, then was centrifuged at 16 000g for 1 minute.  
9. Discarded the minicolumn and stored the cleaned PCR product at 4°C or -20°C until 
needed. 
 
The above method worked but we found that the ExoSAP-IT (USB Corporation, Catalogue 
Number: US78201) clean-up method produced a definite improvement in sequencing results. 
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The ExoSAP-IT protocol, briefly described below, was easier and simpler to follow and despite 
being more expensive, the benefits of having clean, clear sequencing outweighed the costs.  
 
Outline of ExoSAP-IT Clean-Up 
1. ExoSAP-IT was to be stored on ice through the whole set-up. 
2. 8µl of post-PCR reaction product was mixed with 4µl of ExoSAP-IT. Giving a total of 
14µl. This gave excess volume for bi-directional sequencing (one sequencing reaction 
required 6 µl). Compared to the manufacturers’ advice we added a slight excess of 
ExoSAP-IT to guarantee Clean-Up.  
3. The mix was incubated at 37°C for 15 minutes to degrade the remaining PCR primers 
and nucleotides. 
4. A further incubation step at 80°C for 15 minutes was done to inactivate the ExoSAP-IT 
enzymes. 
5. The cleaned PCR product was then stored at 4°C or -20°C until needed. 
 
A1.4.2 Sequencing reactions 
 
Sequencing was done by using the ABI PRISM BigDye Terminator v3.1 Ready Reaction Cycle 
Sequencing Kit (100 Reactions) (Applied Biosystems, CA, USA, Part Number: 4337455), from 
here on referred to as the sequencing kit. It contains all the required reagents in a premixed, ready 
to use format, including the fluorescently labelled dideoxynucleotides ([F]ddNTPs), which are 
added sequentially to the primer through the sequencing reaction. Sequencing templates should 
generally be shorter than 800bp, but there are other kits on the market which will sequence over 
1000bp successfully.  
 
Per sample, the reaction required 0.5µl of DMSO, 1.5µl of sequencing kit (these were premixed 
in a 1:3 ratio), 5µl of primer at a concentration of 1.1µM, and 5µl of cleaned template PCR 
product. The additive DMSO is required to open secondary structures that may form. For 
bidirectional sequencing, 10µl of PCR product is required and 5µl of each primer, per sample. 
Sequencing reactions were done in a 96-well plate format. Each plate contained a positive control 
which is provided with the kit. The positive control requires twice the volume of the sequencing 
premixed reagents (3µl), 1µl of DMSO and 1.5µl of pGEM template with 5µl of T13 primer. The 
sequencing reaction for the samples was scaled down from manufacturers’ recommendations to 
save consumables. 
 
After setting up the sequencing reaction, the plate was run on a 3700xl thermocycler (Applied 
Biosystems) with the following cycles: 95°C for 5 minutes, followed by 35 cycles of 95°C for 45 
seconds followed by 58°C for 4 minutes and then a hold step of 4°C.  
 
A further cleaning step to remove the [F]ddNTPS and primers was required using the Centri-
SEP 96 protocol, briefly described below, was also in plate format. The samples were then ready 
to be run on the ABI-Prism 3130xl DNA analyzer platform. 
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Outline of Centri-SEP 96 Protocol 
Clean-up of the sequencing reaction was done according to the Centri-Sep 96 protocol 
(Princeton Separations, USA Catalogue number CS-965). This is a simple and easy 
method to follow.  
1. The Centri-Sep 96 plate must be at room temperature before use. Removed the adhesive 
from the bottom and then from the top of the Centri-Sep 96 plate. 
2. The Centri-Sep 96 plate was stacked on top of a 96-well wash plate and centrifuged at 
1500xg for 2 minutes. (The use of an external timer was advised.) Discarded the liquid 
from the wash plate. The gel matrix in the wells appeared opaque now. 
3. The samples (20µl or less) were transferred to the Centri-Sep 96 plate, taking care to place 
the samples in the centre of the gel beds. 
4. The Centri-Sep 96 plate was stacked on top of a 96 well collection plate (96-well optical 
reaction plate, Applied Biosystems, Part number: 430673) and centrifuged at 1500g for 2 
minutes, again using an external timer. The samples were ready to be analysed.   
 
In the Data Collection software Version 3.0 (Applied Biosystems), the layout of the plate was 
entered, and linked to the plate loaded on the platform of the sequencer. The assignment of 
sample names was done so that the sample name and the primer used were easily identified. Prior 
to loading the plate on the analyzer, it was ensured that the running buffer (stock solution of 
running buffer with EDTA was a 10x concentrate (Applied Biosystems: Part number 402824 
25ml)) was fresh and replaced if necessary.  
 
The sequencing reaction was run on a 36 cm 16 capillary array (3130 Cap Array 36cm, Applied 
Biosystems, part number: 4315931) with Performance Optimum Polymer (POP) 7 (Applied 
Biosystems, part number 4352759) in the Division of Molecular Biology and Human Genetics 
using the Sequencing analysis software Version 5.2 (Applied Biosystems) with the Instrument 
protocol ‘Seq_Z_36_POP7’ and Analysis Protocol ‘3130POP7_BDTv3-KB-Denovo_v5.2’. 
Sample results were then analysed on the Sequencing Analysis software. As part of quality 
control, all plates contained pGEM with primer T13 as a positive control and all results were 
analysed first by the sequencer operator and subsequently and independently by the researcher.  
 
The SP110 gene was sequenced to identify novel polymorphisms and to search for the presence 
and frequency of known polymorphisms in our population. We sequenced SP110 exons 4 to 8, 
11, 14, 15, alternative 15, 17 and 18, including surrounding intronic regions. Per sample, 
amplification was done using 0.13µl of Taq, with 2.5µl of 10x PCR buffer, 2µl of dNTPs, 13µl of 
distilled water and 0.35µl of each primer (forward and reverse), giving a total volume of 19µl 
before 1µl of DNA template was added. The final 20µl reaction mix was amplified using the 
primers listed in Table A1.1. The samples were then cleaned with ExoSAP-IT before undergoing 
the sequencing reaction, the Centri-Sep 96 purification and finally being run on the ABI Prism 
3130xl Genetic Analyzer, as described previously. 
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Table A1.1: Amplification and Sequencing Primers for the SP110 gene with the fragment lengths 
and annealing temperatures. 
Primer Name Orientation Sequence 5’ → 3’ 
Fragment 
Length 
Annealing 
temp.  (°C) 
SP110Exon4,5 Sense TCT GAG TCT CCA GGG TAC TGA TG 796 62 
  Antisense GGT TGG CAG ACG CAT GTT     
SP110Exon6 Sense AGC TTC TCA AAT TGT ATC ACT TGT CC 737 62 
  Antisense CTA TCC AAG TCT ACC TTT TCC AGA CT      
SP110Exon7 Sense GCA GAG CTT TAT ATG TCT TTG CTG  821 62 
  Antisense GTC ACA TAG TGG TGC TCT TGC CA     
SP110Exon8 Sense CCT TTC AAA CCT CAA GCC CT  781 64.5 
  Antisense TGG CTT CCC ATT GCA TTT A     
SP110Exon11 Sense TGA GCA AGA CAG ACA CAA ATC C 765 62 
  Antisense CAA TCC TGC AAA TGT GTC CA     
SP110Exon14 Sense TGG AAA GGT AGA AGG CCA CA 797 62 
  Antisense CCA TTC CTT TCT CCT TCC ATT T     
SP110Exon15 Sense CCA CAG GGT CAG CAT TCG TG 397 59 
  Antisense CTG TCC AGG GAA TAG CAT ACT AG     
SP110Exon15 Sense CAG TGT GAT GTC TGG GTA CAG 460 61 
 Alternative Antisense GGT CTT GCT ATG TTG CCT AGG     
SP110Exon17,18 Sense CTT GGA CAC TCT GGG AGG TG 789 66.7 
  Antisense ACC AGG TAG TCC CTC TCC AGA     
 
A1.5 Genotyping of Polymorphisms 
 
There were a variety of genotyping methods that were used to assess the various genes. The 
methods used include; Restriction enzyme digestion (for genotyping CCR5, CCR2, SDF1 and 
VDR), Amplification refractory mutation system (ARMS; for genotyping RANTES 
polymorphisms), Template-directed Dye-terminator Incorporation with Fluorescence 
Polarization (TDI-FP; for genotyping of DC-SIGN) and SNaPshot (for genotyping SP110). 
Taqman, a hybridisation method which requires no post-PCR processing or label-separation 
steps was also used in the analysis of the DC-SIGN gene but was not conducted as part of this 
thesis, so will not be discussed. The ARMS method is an oligonucleotide ligation technique;    
TDI-FP and SNaPshot are both primer extension techniques, which is also known as mini-
sequencing. All are frequently used for genotyping of single nucleotide changes in the genome 
[334]. In addition two insertion-deletion (indel) polymorphisms (CCR5∆32 and SP110indel) were 
also genotyped by band separation on agarose gels. The repeat length variation in the neck region 
of DC-SIGN and L-SIGN were also genotyped in the same manner at the Pasteur Institute, 
France. 
 
The principle of primer extension for the analysis of PCR products, is that a primer is designed 
so that the 3’end hybridises one base prior to the 5’end of the polymorphism. This does have its 
limitations as the design of a primer is confined to the sequence surrounding the polymorphism, 
which does not always allow for annealing of a primer.  
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A1.5.1 SNaPshot ® Multiplex System 
 
SNaPshot ® multiplex system (Applied Biosystems) is a primer extension technique that can 
interrogate up to ten polymorphisms between one and ten templates in a single reaction [40, 265, 
355]. SNaPshot was done on the ABI-Prism® 3130xl DNA analyzer platform for the genotyping 
of polymorphisms in the SP110 gene (Chapter 5).  
A1.5.1.1 Primer design for SNaPshot (primer extension method) 
 
The design of SNaPshot primers requires them to be designed so that they are immediately 
adjacent to the polymorphism of interest. The correct primer design can save expense, time and 
improve quality of data. Particularly when a multiplex SNaPshot reaction is used, correct design 
is vital as there is always the risk of unforeseen cross reactions, binding of primers and 
hybridisation with the incorrect sequence. To reduce the chance of this happening there are a 
number of steps that were taken when designing SNaPshot primers for the analysis of the SP110 
gene. 
 
The SNaPshot primers were initially designed as standard primers (section 2.3.1), and checks for 
hairpins, dimers and BLAST analyses were done. Not only must the primers pass these checks 
individually but also when combined, particularly avoiding dimerisation with each other and 
binding to the incorrect fragment. Dimers where the bases were complementary at the extreme 3’ 
end of two primers were avoided as they could reduce amplification efficiency and this could 
result in spurious or incorrect results. If a primer failed any checks, the complementary strand 
was used as a template for redesign. Primers that were intended to run in a multiplex were 
designed to have equal or similar annealing temperatures. 
 
Following completion of primer design for the polymorphisms of interest, compatibility of the 
primers for a SNaPshot multiplex was assessed by conducting a Local BLAST in Bioedit version 
7.0.5.3 [120]. This required the construction of a nucleotide database file with FASTA reports for 
all the fragments amplified. (Open the program ‘Bioedit’, ‘Accessory application’ in the toolbar, 
then selection of ‘BLAST’ and subsequently ‘Create a local nucleotide database file’). A Local 
BLAST is then conducted on this database (Open the program ‘Bioedit’, ‘Accessory application’ 
in the toolbar, then selection of ‘BLAST’ and subsequently ‘Local BLAST’), with a query done on 
the SNaPshot primers designed for the multiplex. Each primer should only match the fragment 
where the polymorphism of interest is situated.  
 
Analysis of the polymorphisms by SNaPshot was done by two assessments; the electrophoretic 
mobility (run length) of the primers, and detection of the dye present. To ensure that the primers 
have varying lengths and therefore different electrophoretic mobility, 5’ non-homologous tails of 
neutral sequence (dC) or (dGACT) were added to the 3’ end in order to act as mobility modifiers 
(Table A1.2). This is recommended by the manufacturers of the SNaPshot assays (Applied 
Biosystems) and has been verified in various studies [40, 265].  
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Table A1.2: Extension primers used in the genotyping by SNaPshot of seven polymorphisms in 
the SP110 gene.  
SP110 SNP Orientation 
SNaPshot Primer 
Sequence 5’ → 3’ [expected allele call] 
Primer 
conc. in 
the master 
mix for 
SNaPshot 
(µM) 
rs3948463 Sense AGTTGCACCTTCTGCAGGAT[g/a] 0.2 
rs3948464 Sense ATGTGCCCGAAAGTCCAGAT[c/t] 0.5 
rs1135791 Sense CCCCCCGGAATATACGTTGTGAGGAA[c/t] 0.5 
rs1365776 Antisense CCCCCCCCCCCCTTGTACTCTCATCTTACCTC[c/t] 0.5 
rs2114592 Antisense CTGACTGACTGACTGACTGACTTCTATTGCTTTGACGTCTATGT[g/a] 0.5 
rs35495464 Sense ACTGACTGACTGACTGACTGACAACTTCTCTGCTGCGG[c/t] 0.3 
rs41541917 Antisense CTGACTGACTGACTGACTTCTGTTCTCCAGCTTCCTGA[g/a]  0.2 
 
 
To achieve adequate separation of the products during electrophoresis, the primers are required 
to be separated by 4 to 6 bp. Polymorphisms with complimentary pairs could be the same length 
(Figure A1.1A), but in hindsight it would have been more beneficial, for analysis purposes, to 
have them at slightly different lengths (Figure A1.1B).  
 
 
 
This suggested spacing would have avoided the incorrect automated annotation when there was 
spectral pull up (Figure A1.2), a phenomenon which occurs when there is overloading and the 
[F]ddNTP extended primer calling ‘pulls’ up all other fluorescent colours as well.  
 
G/T   
6bp                                     6bp 
G/A  C/T   G/A  C/T   
G/A             C/T          G/A             C/T                    G/T 
 
3bp                3bp              3bp                    6bp 
Figure A1.1: Spacing of the SNaPshot primers.  
A: As advised and used in this thesis for SP110 gene polymorphisms. 
B: Separation that in hindsight would have eased analysis. 
A) 
 
 
 
 
 
B) 
Stellenbosch University  http://scholar.sun.ac.za
 108 
 
When all SNPs have the same alleles present, a complimentary pair can be created by designing 
the primer on the antisense strand, as the reverse complementary base will then be called, i.e. the 
dyes will be different. Is important to note when a primer has been designed on the antisense 
strand as then the results will be the reverse complementary of the expected polymorphism. The 
advice of Applied Biosystems is that primers over 30 oligonucleotides in length should be high 
performance liquid chromatography (HPLC) purified, however all primers were HPLC purified 
in this study. 
 
Despite primer design being done correctly, there was no guarantee that they would work 
successfully in a SNaPshot multiplex, so optimisation was carried out. This required testing 
individual primers in a singleplex and then in a multiplex. Samples with a known genotype run in 
a singleplex, allowed us to determine the electrophoretic mobility for each primer, before 
combining them in a multiplex. Heterozygotes were preferably run as this allowed for the 
identification of the run length for each allele and therefore we were able to determine the bins.  
 
The optimisation of the SNaPshot multiplex was done on samples that had been sequenced. The 
fragments that had been amplified for sequencing in singleplexes (seven separate PCR reactions) 
were pooled for the optimisation of the SNaPshot multiplex. Initially the concentration of each 
primer was 0.5µM, but this was adjusted according to the intensity of the fluorescence detected 
during the optimisation runs. Ideally all fluorescent peaks should be of a similar height and 
decreasing or increasing primer concentrations in the multiplex this can be corrected (Table 
A1.2). 
 
A1.5.1.2 Preparation of the PCR template for SNaPshot 
 
Before the SNaPshot reaction can be run, an amplification PCR is required to amplify the 
fragments of the SP110 gene containing the polymorphisms of interest. The seven 
polymorphisms that had been optimised in the SNaPshot reaction were found in seven different 
fragments. To reduce the number of amplification reactions from seven, which was time 
consuming and required 7µl of DNA, a multiplex amplification PCR was optimised. When 
Figure A1.2: An example of spectral pull up. This occurs when an A allele (green) is called, but 
because of spectral pull up the G allele (blue) was also called, which was manually removed. If 
the G bin had not fallen within the A allele bin, this would not have occurred. 
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possible the sequencing primers were used, however these PCR products had similar lengths and 
varying annealing temperatures (Table A1.1). This made it difficult to optimise one multiplex 
reaction as the bands would overlap when run on an agarose gel. Initially there were seven single 
amplifications, but with redesign of primer SP110 Exon 4 and 5 this was reduced to four, where 
one multiplex PCR contained four primer sets (Table A1.3). 
 
Table A1.3: Primers used in amplification of samples for SNaPshot of the SP110 gene. 
Primer Name Orientation Sequence 5’ → 3’ 
Fragment 
Length 
SP110Exon4,5B* Sense GGT ACA AAC CCA AAC TCA ACT TTT AT 1440 
  Antisense ACT AGT GTG AGT GTT ACG CAG GTT AC   
SP110Exon7* Sense GCA GAG CTT TAT ATG TCT TTG CTG  821 
  Antisense GTC ACA TAG TGG TGC TCT TGC CA   
SP110Exon8 Sense CCT TTC AAA CCT CAA GCC CT  781 
  Antisense TGG CTT CCC ATT GCA TTT A   
SP110Exon11* Sense TGA GCA AGA CAG ACA CAA ATC C 765 
  Antisense CAA TCC TGC AAA TGT GTC CA   
SP110Exon14 Sense TGG AAA GGT AGA AGG CCA CA 797 
  Antisense CCA TTC CTT TCT CCT TCC ATT T   
SP110Exon15* Sense CCA CAG GGT CAG CAT TCG TG 397 
  Antisense CTG TCC AGG GAA TAG CAT ACT AG   
SP110Exon17,18 Sense CTT GGA CAC TCT GGG AGG TG 789 
  Antisense ACC AGG TAG TCC CTC TCC AGA   
* in the multiplex PCR   
 
 
Amplification of SP110 Exon 8, 14 and 17 were done in singleplex reactions using 0.13µl of Taq 
with 2.5µl of 10x PCR buffer, 2µl of dNTPs, 13µl of distilled water and 0.35µl of each primer 
(forward and reverse), giving a total volume of 19µl per sample before 1µl of DNA template was 
added. The final 20µl reaction mix was amplified according to the following program: 1 cycle at 
94°C for 15 minutes followed by 35 cycles at 94°C for 30 seconds, annealing temperature in 
Table A1.1 (°C) for 30 seconds and 72°C for 45 seconds, then 1 cycle at 72 °C for 10 minutes 
and finally a 15°C hold step. 
 
The multiplex PCR consisted of the four primer sets; SP110Exon11, SP110Exon7, 
SP110Exon4,5B and SP110Exon15 (Table A1.3). During optimization we adjusted the primer 
concentrations to get similar quantities of product for each fragment. The final volumes per 
primer were 0.35µl for SP110Exon11 and SP110Exon7, 0.70µl for SP110Exon4,5B and 0.18µl 
for SP110Exon15 (final concentrations were therefore 0.175µM, 0.35µM and 0.09µM 
respectively). The amplification was done as above but with an annealing temperature of 62°C.  
 
Prior to SNaPshot analysis, quality control was done by running samples on a 1% agarose gel at 
150V for 40 minutes to ensure amplification of all fragments. The expected fragment sizes are in 
Table A1.2. Once amplified, the four separate PCR products of the same sample were mixed in 
equal volumes into one sample to use in the SNaPshot reaction. A plate format was used and as 
quality control, each plate contained a negative control and a sample that had previously been 
sequenced. 
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Purification was required to remove primers, dNTPs, enzymes and buffer. Purification for 
SNaPshot was done with a Shrimp Alkaline Phosphatase (SAP) (Promega Cooperation, USA) 
and ExoI (USB, USA) treatment (not ExoSAP-IT). The use of this method reduces the 
background level of ‘noise’. In the SP110 project it was found that 1.5 times the usual SAP and 
ExoI ratio worked more effectively. 1µl of PCR product was used and 0.5µl (stock 1U/ µl) of 
SAP and 0.02µl (stock 5U/µl) of ExoI was added. The SAP-ExoI mixture was thoroughly mixed 
with the PCR template and incubated at 37°C for 1 hour. To inactivate the enzymes an additional 
incubation step at 75°C for 30 minutes was done. Subsequently the samples were kept on ice.  
 
A1.5.1.3 SNaPshot reaction 
 
The SNaPshot reaction incorporates the [F]ddNTPs which are present in the SNaPshot 
Multiplex Ready Reaction Mix (Applied Biosystems, Part Number: 4323154).  
 
The following master mix was prepared (per sample): 5µl of SNaPshot Multiplex Ready reaction 
mix, 1µl of the pooled SNaPshot primers (Table A1.2) and 1µl of deionized water. A volume of 
7µl of the master mix was aliquoted into plates and 3µl of purified PCR products was added, 
giving a total volume of 10µl.  
 
A1.5.1.4 Thermal cycling and SNaPshot Post-extension treatment 
 
The plates were placed in a GeneAmp 9700 thermal cycler (Applied Biosystems) and the 
following cycles were repeated 27 times: 96°C for 10 seconds, 58°C for 5 seconds, 60°C for 30 
seconds, followed by a hold at 4°C. Instead of 58°C a temperature of 50°C is usually used, but 
with this primer combination a higher temperature worked better.  
 
The post-extension treatment was done by adding 1 Unit of SAP (Promega, Catalogue number: 
M8201) to the SNaPshot post-extension product. This removed [F]ddNTPs that would 
otherwise co-migrate with the fragments of interest and could cause interference. Once mixed 
thoroughly with the SAP it was incubated at 37°C for 1 hour. Deactivation of the enzyme 
required a further incubation at 75°C for 30 minutes. Samples were then stored at 4°C.  
 
A1.5.1.5 Preparation of Sample for Electrophoresis on the ABI PRISM 3130 xl DNA analyzer 
 
The ABI Prism 3130xl Genetic Analyzer was set up with a 36cm capillary array and POP-4 
polymer (Applied Biosystems, Part number: 4352755) with dye set E5 for analysis by SNaPshot. 
 
Sample preparation requires genetic analysis grade Hi-Di formamide (Applied Biosystems part 
number: 4311320), SNaPshot PCR product and GeneScan-120LIZ size standard (Applied 
Biosystems, Part number 4324287). 10µl of Hi-Di formamide is added to each well of a new 96-
well optical reaction plate. 1µl of SNaPshot post-extension product is added to each well, along 
with 0.4µl of GeneScan-120LIZ size standard. The septa sealed plate was then vortexed and spun 
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down. Denaturation of the samples was done by placing them at 95°C for 5 minutes in a 9700 
thermal cycler (Applied Biosystems). As soon as the 5 minutes was completed the samples were 
placed on ice, to hinder re-annealing of the product. The samples were then ready to load on the 
ABI Prism 3130xl Genetic Analyzer. The protocol used was the preset run module 
“SNP_E5_36_POP4_run”. In this preset run SNaPshot products were injected electronically for 
22 seconds at 2kV and electrophoresed at 15kV and 5µA at 60°C. 
 
A1.5.1.6 Analysis of SNaPshot results in GeneMapper 
 
Analysis of SNaPshot results was done on the GeneMapper software version 3.7 (Applied 
Biosystems). A ‘bin’ was created for each allele and is defined as the fragment size or bp range 
and dye colour that define an allele. A bin set (one set per polymorphism) was set up for each 
primer and included a separate bin for each allele (Figure A1.3). During optimisation, bin sets 
were determined for all polymorphisms to allow for automated annotation of the fluorescent 
peaks (Figure A1.4). This is why SNaPshot primers are required to be 4 or 6 bps apart, so that 
bins which have the same dye colour (ie incorporation of the same base) do not overlap. All 
primers were designed to be 6bp apart to lessen the chance of this occurring.  
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Figure A1.3: 
Example of an electropherogram 
sample run for SNaPshot analysis of 
SNP rs2114592 (G/A) in the SP110 
gene. 
A) All dye colours with bins for 
alleles in rs2114592 
Dyes colours separated: 
B) dye blue (G) with bin  
C) dye green (A) with bin 
D) dye red (T). The peak seen is 
for another SNP, which will 
have a different bin for it to be 
called. 
E) dye yellow (C) (appears black 
on software for easier reading). 
The peak seen is for another 
SNP. 
F) dye orange- the size standard 
GeneScan-120 Liz 
 
Fluorescent peaks that fall out of the 
bin for this SNP, such as in E), are for 
different primers (i.e. polymorphisms) 
and are only shown here for 
demonstration purposes. 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
D 
 
 
 
 
 
 
 
 
 
E 
 
 
 
 
 
 
 
 
 
F 
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Figure A1.4: Bin sets for the analysis of 8 polymorphisms in the SP110 gene by 
SNaPshot in the GeneMapper Software version 3.7 (Applied Biosystems). 
 
 
The size of the primer detected will not always be as expected (Table A1.4). This is because of 
differences in the electrophoretic mobility of the primers, mainly determined by length, sequence 
and the dye incorporated [265]. As long as the same colours (ie base calling) do not coincide, this 
does not inhibit analysis.  
 
 
 
A negative control was run at all times, both in the optimization with singleplex and later and all 
plates had at least one negative control sample with no template. Apart from being able to detect 
contamination, the negative control would reveal whether primers are annealing to each other. 
The automated genotype calling was checked by the technician and subsequently by the 
researcher and discrepancies were further investigated. 
 
Table A1.4: SP110 SNaPshot primer expected and observed run lengths as 
determined by GeneMapper. 
SP110 SNP 
Expected run 
length 
Observed run 
length, allele 1 
Observed run 
length, allele 2 
rs3948463 20 23.5-27.9 23.5-25.3 
rs3948464 20 24.5-26.5 26.5-28.2 
rs1135791 26 29-32.3 29-31.1 
rs1365776 32 34.4-36 35.5-37.5 
*rs2114592 44 46-49.5 46-48 
rs35495464 38 40-44.5 40-41.5 
rs41541917 38 40.5-43.5 40.5-42 
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As mentioned previously, there is the possible problem of spectral pull up (Figure A1.2). If a bin, 
for a different fluorescent colour, was overlapping another fluorescent bin and spectral pull up 
occurred this could cause incorrect annotation. However the software flagged samples with 
spectral pull up and manual annotation of the bin was done.  
 
A1.5.2 Restriction enzyme digestion 
 
Restriction enzyme digestion, also known as allele specific restriction enzyme array (ASREA), 
makes use of an enzyme that cuts at a specific location of a PCR amplified fragment. The 
presence/absence of a SNP will often determine if the recognition sequence of the enzyme 
exists. It is advisable to have an internal control cut site (where the enzyme always cuts) to ensure 
that enough enzyme was added and the conditions were correct for a reaction to take place. 
Appendix 1 lists the enzymes and their cut sites that were used for the analysis of the 
polymorphisms CCR5-59029, CCR2-64I, SDFI 3’A, VDR FokI, VDR ApaI and VDR TaqI.  
 
A1.5.2.1 Amplification of the CCR5, CCR2, and SDFI fragments for restriction enzyme digestion 
 
The method of analysis for CCR5-59029, CCR2-64I and SDFI 3’A was as reported by 
Kristiansen et al [160], with some modifications. CCR2-64I required antisense primer (5’ GAG 
CCC ACA ATG GGA GAG TA 3’). Amplification of CCR2-64I was done using 0.13µl of Taq 
with 2.5µl of 10x PCR buffer, 2µl of dNTPs, 18.7µl of distilled water and 0.35µl of each primer 
(forward and reverse) (Table A1.5), giving a total volume of 24µl per sample before 1µl of DNA 
template was added. The final 25µl reaction mix required an annealing step of 60°C. 10µl of PCR 
product was aliquoted out for digestion with 1µl of the appropriate enzyme. 
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Table A1.5: Primers used in the PCR amplification of CCR5, SDF1, CCR2 and VDR fragments 
for restriction enzyme digestion. 
Polymorphism Orientation Sequence 5’ → 3’ 
Annealing 
temperature 
(°C) 
CCR5-59029 Sense TGG GGT GGG ATA GGG GAT AC  Multiplex 66 
  Antisense TGT ATT GAA GGC GAA AAG AAT CAG   
SDF1 3' Sense CAG TCA ACC TGG GCA AAG CC  Multiplex 66 
  Antisense AGC TTT GGT CCT GAG AGT CC   
CCR5∆32*  Sense CTT CAT CAT CCT CCT GAC AAT CG 60.3 
  Antisense GAC CAG CCC CAA GTT GAC TAT C   
CCR2-64I Sense TTG TGG GCA ACA TGA TGG   Multiplex 66 
  Antisense GAG CCC ACA ATG GGA GAG TA    
VDR-FokI Sense AGC TGG CCC TGG CAC TGA CTC TGC TCT   67.5 
  Antisense ATG GAA ACA CCT TGC TTC TTC TCC CTC    
VDR-ApaI Sense same as TaqI  67 
  Antisense same as TaqI   
VDR-TaqI Sense GGG ACG ATG AGG GAT GGA CAG AGC   67 
  Antisense GGA AAG GGG TTA GGT TGG ACA GGA   
*(used in indel genotyping, Section A1.5.4)  
 
 
The multiplex PCR for CCR5-59029, CCR5∆32 and SDF1 3’A, was done using 0.13µl of Taq 
with 2.5µl of 10x PCR buffer, 2µl of dNTPs, 16.7µl of distilled water and 0.35µl of each forward 
and each reverse primer (Table A1.5), giving a total volume of 14µl per sample, before 1µl of 
DNA template was added. The final 24µl reaction mix was amplified with an annealing 
temperature of 66°C. 10µl aliquots were taken for digestion with 1µl of the appropriate enzyme, 
except CCR5∆32 (Section A1.5.4) insertion/deletion detection.  
 
A1.5.2.2 Amplification of the VDR fragments for restriction enzyme digestion 
 
Primers used are listed in Table A1.6 [391]. Samples were amplified using an annealing 
temperature of 67°C. The FokI fragment was amplified by using 0.13µl Taq with 2.5µl of 10x 
PCR buffer, 2µl of dNTPs, 13.5µl of distilled water and 0.35µl of each primer, giving a total 
volume of 19µl per sample, before 1µl of DNA template was added. Conversely the TaqI 
fragment (including ApaI fragment), per sample, used 0.16µl of Taq with 3.2µl of 10x PCR 
buffer, 2.5µl of dNTPs, 17.3µl of distilled water and 0.44µl of each primer, giving a total volume 
of 24µl before 1µl of DNA template was added. 
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Table A1.6: Restriction enzyme digestion and the expected fragment lengths that would be visible 
on a gel. 
   Fragment lengths in base pairs 
Polymorphisms 
investigated 
Restriction 
enzyme 
Digestion 
temp. (°C) wild type heterozygote homozygote 
CCR5-59029 Bsp1286I 37 453 453,408 408 
SDF1'3A MspI 37 201, 101 201,101,302 302 
CCR2-64I BsaI 60 129 (21),108,121 (21),108 
VDR-FokI FokI 55 270 270, 208, 62 208,62 
VDR-ApaI ApaI 37 716 716, 485, 231 485, 231 
VDR-TaqI TaqI 67 512, 204 512, 311, 204, 201 311, 204, 201 
 
A1.5.2.3 Enzyme digestion 
 
Enzymatic digestion was described previously [37, 160, 285, 391, 399] with the following 
conditions; The Bsp1286I (Amersham Biosciences, USA) (CCR5-59029) and the MspI (Promega, 
USA) (SDF1 3’A) digests were incubated at 37°C for at least 1 hour. CCR2-64I PCR products 
were digested by BsaI (New England Biolabs, USA) at 60ºC for at least 3 hours. Analysis of 
CCR5∆32 does not require restriction enzyme digestion and the fragment does not contain a cut 
site for any of the restriction enzymes used, as a mismatch was added into the reverse primer to 
prevent the amplification of a non-mutation specific BsaI endonuclease cut site [160]. Therefore 
the CCR5∆32 results could be read in conjunction with another digested sample (Section A1.5.4). 
All VDR fragments were digested overnight at 65°C, 37°C and 55°C with TaqI, ApaI and BseGI / 
FokI restriction enzymes (Fermentas, Canada), respectively. The restriction enzymes, their 
recognition cut sites and incubation temperatures are listed in Table A1.7. 
 
Table A1.7: Alphabetical list of the restriction enzymes, their recognition cut sites and incubation 
temperatures used for the analysis of SNPs in the genes VDR, CCR2, CCR5 and SDF1. 
Restriction 
enzymes  
Polymorphism 
Analysed Recognition site 
Incubation 
temperature 
 ApaI  VDR ApaI 5’ – G    GGCC ↓ C - 3’ 37°C 
    3’ – C ↑ CCGG    G – 5’   
BsaI CCR2-64I 5’ – GATNN  ↓  NNATC – 3’ 60 ºC 
    3’ -  CTANN  ↑ NNTAG – 5’   
Bsp1286I CCR5-59029 A/G 5’ – G   (A/G/T)GC(A/C/T) ↓  C – 3’ 30ºC 
    3’ – C ↑ (T/A/C)CG(T/G/A)   G – 5’   
FokI VDR FokI 5’ – GGATG   NN ↓  – 3’ 55°C 
    3’ – CCTAC ↑ NN    – 5’   
MspI SDF1-3’A 5’ – C  ↓  CG      G - -3’ 37 ºC 
    3’ – G      GC  ↑  C – 5’   
TaqI VDR TaqI 5’ – T ↓ CG    A – 3’ 67°C 
    3’ – A    GC ↑ T – 5’   
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The enzymatically digested PCR aliquots were separated on a 2 or 3% Agarose gel (Hispanagar, 
Spain), using SB buffer [42] containing 5µg ethidium bromide / 100ml. Gels were run at 180V 
for an hour and viewed under UV light (Figure A1.5). Resulting fragment sizes are listed in Table 
A1.6. For the VDR polymorphisms a lower case (‘f’, ‘a’ or ‘t’) was used to indicate the presence 
of an endonuclease site. 
 
Figure A1.5: Gel electrophorectic analysis after restriction enzyme digestion of the VDR gene: 
genotyping of the SNPs FokI, ApaI and TaqI (left to right). 
 
A1.5.3 Amplification Refractory Mutation System (ARMS) 
 
ARMS [235] is an oligonucleotide ligation technique that has a primer designed for both of the 
alleles present at a polymorphic site. The technique generally requires two reactions (one for each 
allele specific primer) but has been modified to be done in a single reaction [89]. 
 
Genotyping of the RANTES polymorphisms -403, -109, -28 and +1092 was done by means of a 
two-tube ARMS and was done by Hanno Nel and Erika Truter of our Division Molecular 
Biology and Human Genetics. Amplification of the regions surrounding the polymorphism of 
interest was done by external primers and an allele specific primer (Table A1.8). A mismatch was 
introduced in the allele specific primer to destabilise non-specific allele binding where the non-
specific primer partially primes to the DNA. The SNPs are named according to the numerical 
system used by Liu et al [176] that considered +1 as the first nucleotide of the RANTES mRNA.  
FF        ff           Ff Aa         aa          AA Tt           TT        tt 
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Table A1.8: Primers used for amplification refractory mutation system (ARMS) analysis of the 
RANTES polymorphisms. 
Polymorphism  Orientation Sequence 5’ → 3’ 
Annealing temp. (°C) 
RANTES-403 Sense GGT CGC CTT AGC AAG TAA ATG G 60 
  Antisense GTC CAC GTG CTG TCT TGA TC   
  Allele Specific CAT GGA TGA GGG AAG GCG [G/A]   
RANTES-109 Sense GGT CGC TTA GCA AGT AAA TGG 58 
  Antisense GTC CAC GTG CAG TCT TGA TC   
  Allele Specific CGG AGG CTA TTT CAG TTT TGT [C/T]   
RANTES-28 Sense ACT CTA GAT GAG AGA GCA GT 50.4 
  Antisense GAC AGT ATT CAT GCT ACA GTT G   
  Allele Specific CCT AGG GAT GC CAT [G/C]   
RANTES+1092 Sense AGA GCT TCT GAG GCG CTG 58 
  Antisense CGG GAG GAA ATC AAG AGT C   
  Allele Specific GGA AGC TTA AGA GTG CTG [C/T]   
[ ] indicate the two possible oligonucleotides that were added to the ends of the allele specific primers. 
Bases are underlined where a mismatch was introduced to destabilise non-specific allele primer binding. 
 
PCR amplification was done with the following protocol using an Eppendorf Mastercycler 
Gradient PCR Machine (Eppendorf, Hamburg, Germany) and a Hybaid Touchdown 
Thermocycler system. The final reaction contained 1x Buffer A, 300µM dNTPs each, 3-4mM 
MgCl2, 25-5pmol primers and 1-2U of Taq. Specific concentrations of MgCl2 and primers for 
each ARMS-PCR analysis are shown in Table A1.9.  
 
Table A1.9: Magnesium Chloride and primer concentrations for the set up of ARMS analysis of 
the RANTES gene. 
RANTES 
Polymorphism 
MgCl2 
(mM) 
Allele specific 
primer (pmol) 
Shared primers 
(pmol) 
Control primers 
(pmol) 
-403A/G 4 7-8 4.5 1.6 
-109T/C 2.5 10-12 10 4 
-28C/G 4 2.8-3 5.5 0.7 
+1092A/G 3 9-11 6.3 2.3 
 
The following program was used: 1 cycle at 95°C for 5 minutes followed by 35 cycles at 94°C for 
30 seconds, annealing temperature in Table A1.7 °C for 30 seconds and 72°C for 60 seconds, 
then 1 cycle at 72 °C for 10 minutes and finally a 4°C hold step. Per sample this was 0.3µl of Taq 
with 3µl of MgCl2, 0.6µl of dNTPs, 38µl of distilled water, 0.5µl of the allele specific and reverse 
primer and 0.2µl of the forward primer.  
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A1.5.4 Insertion/deletion detection 
 
If there is an insertion/deletion (indel) present in an amplified PCR product of a heterozygote 
there will be two fragments of different lengths. Depending on the size of the indel and the 
amplified fragment, the gels used for analysis should be at a sufficient concentration to allow for 
adequate separation. 
 
Through sequencing, a four base pair indel was identified in intron 10 of the SP110 gene. 
Amplification was done using primers SP110indelF 5’-TGA GCA AGA CAG ACA CAA ATC 
C-3’ and SP110R 5’- CTT CTC ATG TTC CCA GCC C-3’. The PCR reaction, per sample, was 
0.07µl of Taq with 1.25µl of 10x PCR buffer, 1µl of dNTPs, 6.7µl of distilled water and 0.18µl of 
each primer, giving a total volume of 9.5µl before 0.5µl of DNA template was added and 
amplified with an annealing temperature of 58°C. 5µl of PCR product was run on a 3% gel at 
120V for 120 minutes. The fragment lengths that could be seen were 216 and/or 212bp in length 
(Figure A1.6). 
 
 
 
Amplification of the indel CCR5∆32 was done using the primers in Table A1.5, where a 
multiplex PCR was performed to analyse other polymorphisms by restriction enzyme digestion 
(Section A1.5.2). Analysis of CCR5∆32 did not require restriction enzyme digestion [160]. The 
presence of the 32bp deletion, and the length of the fragment meant that the CCR5∆32 could be 
detected on a gel in conjunction with another digested sample (Section A1.5.2). 
 
A1.5.5 Template-directed Dye-terminator Incorporation with Fluorescence Polarization detection 
(TDI-FP) using Victor (Perkin Elmer) (primer extension method) 
 
The AcycloPrime™-FP SNP Detection Kit (Perkin Elmer, USA) utilizes Template-directed Dye-
terminator Incorporation with Fluorescence Polarization (TDI-FP) [97, 164] technology with the 
use of the Victor instrument (Perkin Elmer, USA). This procedure involves primer extension, 
similarly to the SNaPshot technique, and primer design should follow the same principles 
(Section A1.5.1). However, unlike SNaPshot, this procedure was used to analyze one SNP per 
reaction. The kits contain [F]ddNTPs which are labeled with either the fluorescent dyes TAMRA 
Figure A1.6: Insertion deletion in the SP110 gene, intron 10. Fragment run on a 3% 
agarose gel. 
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or R110. The detection kit required was determined by the polymorphism present and the 
orientation of the extension primer. The various combinations of polymorphisms and the dye 
labelling the base are listed in Table A1.10.  
 
Table A1.10: AcycloPrime ™ -FP SNP detection kit combinations of polymorphisms that can be 
detected with fluorescently labeled ddNTPs. 
 R110/TAMRA 
 G/A 
 G/C 
 G/T 
 C/A 
  A/T 
 C/T 
 
For analysis using TDI-FP, it was necessary to do an amplification PCR and then a second 
extension PCR using the extension/Victor primer that incorporates the [F]ddNTP at the site of 
interest. Polymorphisms were selected after the sequencing (Section 2.4) of 28 randomly chosen 
samples and determination of tagging SNPs (Section 2.6.3).  
 
The amplification PCR used 0.1µl of Taq, 0.15µl of MgCl2 at a concentration of 25mM, 2.15µl of 
distilled water, 0.6µl of dNTPs at a concentration of 1.25mM and finally 0.25µl of each 
amplification primer (Table A1.11) at concentrations of 3µM. This gave a total volume of 4µl per 
sample to which 1µl of DNA template was added. Template DNA concentration needed to be 
10ng/µl as this was vital to ensure similar PCR yields for the extension step, and was important 
for the fluorescent polarization intensity. We ensured correct concentrations by diluting all 
samples after conducting spectrometry readings. One possible way to correct for irregular 
concentrations of DNA is to first do whole genome amplification on the samples prior to testing. 
This ensures that there is sufficient sample for all the tests and that the DNA concentration is 
constant in all samples.  
 
The PCR program used for amplification was: 94°C for 10 minutes followed by 40 cycles of 94°C 
for 15 sec, annealing temperature from Table A1.11 °C for 30 seconds, 72°C for one minute, 
followed by a step at 72°C for 10 minutes and a hold at 15°C.  
 
Random samples were chosen and run on a 2% agarose gel to check for amplification. Then a 
PCR Clean-Up was done using enzymes supplied in the AcycloPrime™-FP SNP detection kit, 
where 0.2µl of PCR Clean-up enzyme and 1.8µl of buffer was added to 2µl of PCR product. 
Subsequently the primer extension with the [F]ddNTPS could be performed, as in Table A1.12.  
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Table A1.12: Victor PCR mixture that incorporates the [F]ddNTP. 
Ingredient µl (per sample) 
AcyloPol 0.05 
10x Buffer 2.0 
AcycloTerminator mix (R110/TAMRA) 1.0 
SNP Primer V (10µM) 0.5 
dH2O 9.45 
Total 13 
PCR product per aliquot 7 
 
Since fluorescent polarization was used for detection, specific plates are required and black 
microplates (MJ research) were used. Each plate had eight control samples to ensure that the dyes 
were read correctly. The controls included 2 wildtype homozygotes, 2 heterozygotes, 2 homozygotes 
for the polymorphism and 2 blanks. Nine 96-well micro-plates of DNA stocks were set up for the 
case-control analysis of DC-SIGN and L-SIGN genes (Chapter 4). The first column in the plate was 
left empty to allow for the control samples. 
 
A1.5.5.1 Analysis of results using Victor and fluorescent polarization 
 
The SNP ‘macro Victor 96-well’, an Excel-based workbook for data analysis and allele calling 
(available for download at http://lifesciences.perkinelmer.com/products/snp.asp) automatically 
analyzed the polarization of labelled samples and, with the use of the known control samples and the 
blanks, the allele-calling could be done. The TAMRA polarization and R110 polarization for each 
sample was plotted on an Excel graph. The dye which was incorporated at the site of the 
polymorphism determined where a sample fell in the plot, e.g. the bottom left cluster contains the 
blanks and the top right cluster contains the heterozygotes (Figure A1.7 A). 
 
The primer extension PCR done with the commercially available detection kit is a very stable 
reaction and samples could be subjected to additional thermocycles if the clustering of samples was 
not appropriate for scoring (Figure A1.7 A and B). In addition the centrifugation of the plate also 
affected the reading of a sample (Figure A1.7 C and D). This was useful for repeated analysis of 
samples that fell outside an allocated quadrant.  
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Figure A1.7: SNP detection by TDI-FP using VICTOR.  
A) 25 thermocycles  
B) an additional 5 cycles to plate in A), giving a 
total of 30 cycles 
C) mild centrifugation 
D) additional centrifugation on the same 
plate as C) 
The red bar is the division of positive (above) and negative (below) for TAMRA incorporation. 
If a sample falls within the box, it is considered as a ‘no call’ result. The yellow bar applies to 
R110 incorporation. 
 
A1.6 Analysis 
Databases 
 
Apart from the “EileenTB” database used for management of the case-control data, the “Surrogate 
Marker (SM) Database version 3” was used in this thesis. These had the relevant information on 
subjects and different collection procedures and ethic approvals. The SM Database was used for the 
VDR study (Chapter 6). All databases were managed by the software package Microsoft-ACCESS. 
As dual entry had not been used, considerable time was spent checking and cleaning the data as well 
as managing and maintaining the databases.  Publicly available online databases of nucleotide 
sequences and polymorphism used include NCBI (http://www.ncbi.nlm.nih.gov/) and Ensembl 
(http://www.ensembl.org/index.html). Microsoft-Excel worksheets were used during active analysis. 
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A1.6.1 Hardy-Weinberg Equilibrium 
 
The Hardy Weinberg Equilibrium (HWE) states that the segregation of two alleles in a large, 
randomly mating population will be such that there will be constant proportions of the three possible 
genotypes. The Hardy Weinberg Theorem predicts genotype frequencies AA, Aa, and aa are p2, 2pq, 
and q2, respectively, and uses a binomial equation: p2 +2pq + p2 = 1, where p and q are the 
proportions of the alleles present. It is primarily used as a data quality check. When an allele falls out 
of HWE it could be for a number of reasons such as poor genotyping (primarily occurring when 
heterozygotes are genotyped as homozygotes) inbreeding, population stratification, or selection, 
however it could be a sign of disease association particularly if only the case population is out of 
HWE. A locus that falls out of HWE should not be immediately discarded, but carefully investigated 
to determine the cause [396]. 
 
The binomial equation will calculate the expected frequencies of the genotypes from the known 
frequencies of the alleles. The χ2 statistic calculated using the equation                               
χ2=Σ(observed-expected)2/expected, should be less then 3.84 (one degree of freedom), not to be 
significantly out of HWE. This is also known as the Pearson’s χ2 analysis which tests for deviations 
from HW between the observed and expected frequencies of the polymorphism. HWE was checked 
in this population for all genotypes tested.  
 
A1.6.2 Testing for an Association  
 
To test for an association with tuberculosis, genotype frequencies were compared between cases and 
controls. The frequency of the genotypes, alleles, minor allele containing genotypes versus the 
remaining, haplotypes and diplotypes were also compared between cases and controls.  
 
GraphPad Prism version 4.03 and version 5 were used for statistical analysis in the case-control 
studies. Associations were tested by construction of a 2xn contingency table. For genotypes this was 
a 2x3 table containing the number of individuals with each genotype in the groups of cases and 
controls. Chi-square (χ2) tests were subsequently carried out with a confidence interval of 95%. In 
addition, a dominant/recessive model was constructed where the genotypes with the most frequent 
allele were compared to the homozygote of the rare allele, and then the genotypes with the rare allele 
were compared to the homozygote of the most frequent allele. Associations for the 
dominant/recessive model were analysed using a 2x2 contingency table and a Fishers exact test 
where the odds ratios and relative risks with 95% confidence intervals were calculated as well as the 
p value. This is not always recommended, as it requires an assumption of HWE in cases and controls 
combined [18]. For the analysis of the alleles, 2x2 contingency tables with Fishers exact test were 
done to test for an association with tuberculosis.  
 
When analyzing the VDR gene in relation to sputum conversion time, a number of additional 
statistical analyses were done, including Kaplan-Meier survival curves using PRISM and Cox 
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regression analysis using the program R: A language and environment for statistical computing, Base 
R [266] as well as packages survival [345], genetics [381], and haplo.stats [312]. This was discussed in 
Chapter 6. 
 
Statistical genetics has the difficult issue of multiple testing. It is important to consider in association 
studies but there is no ‘best fit’ approach to handling this thorny issue. Within our analyses, we made 
corrections for multiple testing as much as possible. There is always the risk of over-correction, in 
particular when multiple polymorphisms are investigated in one gene [238]. The Bonferroni 
correction is widely used. This is a conservative correction where the number of independent tests 
done (usually individual SNPs analysed) is used to ‘correct’ the p value. However, polymorphisms in 
a single gene are seldom independent, and associations might suffer a multiple testing penalty [18]. 
 
To correct for population stratification is another issue. As discussed in Chapter 2 the population 
used in this study is admixed and the concern of population stratification is not unwarranted but, 
considering the history of the population, is unlikely. With the analysis of 25 unlinked SNPs the level 
of stratification (µ) could be represented by the mean χ2 statistic among the SNPs investigated and 
could be used to correct for stratification [272].    
 
A1.6.3 Linkage Disequilibrium Analysis and Haplotypes 
  
Linkage disequilibrium (LD) refers to the situation where two apparently independent loci occur 
more or less frequently than would be expected. Loci that are in complete LD are considered to be 
linked and are co-inherited. The programs HaploView version 3.32 [23], PHASE version 2.1 [329] 
and GOLD version 1.0 [3] were used to analyse LD and infer haplotypes for the various genes 
investigated (weblinks for the various programs are listed in Table A1.13). The most frequently used 
LD coefficients are D’ and r2. D’ is biased upward inversely with sample size [386] and is known to 
fluctuate when assessing small numbers or rare alleles. Loci are considered to be in ‘complete’ LD 
when D’=1 and are completely reshuffled when D’=0. D’ is useful in assessing the probability of 
historical recombination in a given population whereas the square of the correlation coefficient 
between the loci, r2, is more useful in the context of association studies [225, 259, 386].  
 
 
 
Through using PHASE and HaploView the determination of haplotypes was possible. As cases and 
controls were used, with no familial data, haplotypes could only be inferred, i.e. the data was 
unphased. HaploView uses an expectation-maximization algorithm for the assignment of alleles to a 
Table A1.13: Weblinks for downloading of haplotype analysis programs. 
PHASE http://www.stat.washington.edu/stephens/ 
Haploview http://www.broad.mit.edu/mpg/haploview 
Unphased http://www.hgmp.mrc.ac.uk/~fdudbrid/software/unphased/ 
GOLD http://www.well.ox.ac.uk/asthma/GOLD 
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haplotype with a high probability. The only limitation with this algorithm is that it assumes HWE in 
cases and controls. The reconstruction of haplotypes was therefore also done using PHASE which 
implements a Bayesian statistical method [328, 329]. HaploView [23] was used to determine 
haplotype tagging SNPs. Tagging SNPs partially or totally report the state of other polymorphisms in 
the same haplotype which are considered tagged SNPs [121]. An association analysis between the 
haplotypes in the cases versus controls was carried out. In addition ‘Cocaphase’ within the program 
Unphased version 2.404 [81] was used to test for association of multilocus haplotypes for unphased 
genotype data.  
 
Power Calculations were done using EpiInfo 2000 version 1.1 (http://www.cdc.gov/epiinfo) 
subprogram Statcalc. Sample size and power calculations for unmatched cases and controls, at a 
confidence interval of 95% and a power of 80% were performed and these, depending on the 
frequency of the polymorphism, indicated the odds ratio of the association found. 
 
A1.7 Submission of SNPs into NCBI database 
 
All SNPs, novel and known, were submitted to the NCBI SNP database (dbSNP) [305]. The handle 
that is used by our group is EILEEN. To check that the SNP was not already in the database, or to 
find the NCBI dbSNP rs number, the online program BLAT (http://genome.ucsc.edu/cgi-
bin/hgBlat?command=start) was used. It requires a short sequence surrounding the polymorphism 
to be entered and will identify, if present, the dbSNP rs number.  
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A1.8 Materials 
 
Agarose Gels 
1% w/v to 2% w/v were made up with 1x TBE \ SB running buffer 
 
0.5M ethylenediaminetetraacetic acid/ ethylene-diamino-tetra-acetate (EDTA) 
93.06g EDTA.2H2O 
Approximately 10g NaOH pellets 
Add 400ml distilled water, adjust the pH to 8.0 using the 10M NaOH pellets.  
Make up to 500ml 
Autoclave and store at room temperature 
 
Ethidium Bromide stock solution 
Ethidium bromide was dissolved in TE buffer to a final concentration of 10mg/ml 
 
Orange G Gel loading dye 
0.1% Orange G 
20% Ficoll 
10mM EDTA pH 7 
Filter through a 0.22µm filter 
 
20 x Sodium Boric (SB) buffer 
19.1 g of disodium tetraborate decahydrate in 500 ml of distilled water.  
 
1x TBE 
200ml of 5x TBE made up to 1000ml with distilled water 
 
TE buffer 
1.21g Tris-HCl  
0.372g EDTA 
Add approximately 800ml distilled water and mix. Once dissolved adjust the pH to 8.0 with 
concentrated HCl and make up to a final volume of 1000ml.  
Autoclave 
 
5x  Tris-Borate-EDTA buffer (TBE) 
54g Tris-HCl (1M pH 8.0 or 7.6) 
27.5g Boric acid 
20ml 0.5M EDTA (pH8.0) 
Make up to 1000ml with distilled water 
 
1 M Tris-HCl 
121.1g in 800ml dH2O pH to 8.0 or 7.6 make up to 1000ml using 10M Hydrogen Chloride (HCl) 
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Appendix 2 
 
 
 
Supplementary Documentation for the 
Surrogate Marker database version 4 provided 
by K. Lawrence, Desmond Tutu TB centre, 
Tygerberg Campus, Stellenbosch University. 
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Initial file descriptions for the SM database: 
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Updates to the above file: 
 
 
 
 
•   Initial protocol violators 
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Keys for the Surrogate Marker Database 
KEY education    
Nil 0    
<Std3 1   
Std 4-7 2   
Std8-10 3   
Diploma 4   
   
 
 
1 = yes     
0 = no     
     
Gender     
m =male     
f= female     
       
Sensitivity      
1=R   Outcome episode table 
0=S   1 C cured 
   2 TC treatment complete 
Key Income    3 F failed 
Nil 0  4 Defaulter 
2 consecutive months no 
medication taken 
<R250 pm 1  no ProtViol left study 
R251-500 pm 2  no Trans transferred out of study area 
R501-1000 pm 3     
R 1001-1500 pm 4  Censored Date    
R1501-2000 5  1 Cured, all information available 
>2001 pm 6  0 censored   
      
Key extent Alv Disease   Last positive   
1 <RUL  -1 never had a positive result 
2  = RUL  0 day 0   
3 >RUL     
4 >1 LUNG     
      
Genotypic Groups Family (RFLP) 
1 31,29,27,25,20 
2 1,2,3,4,6,7,9,10,11,13,14,15,19,24,26,28,32,110,120,130,140,150 
3 5,8,16,17,18,21,22,23 
4 Unclassified 
0 Pseudofamily 0 
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Website Information 
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Websites used and additional sites of interest 
 
Program Link and description 
AutoDimer 
http://www.cstl.nist.gov/div831/strbase//AutoDimerHomepage/AutoDim
erProgramHomepage.htm  
 
Rapidly screens previously selected PCR primers for primer-dimer and 
hairpin interactions in short DNA oligomers (< 30 nucleotides).   
Biocarta http://www.biocarta.com/genes/index.asp  
 Illustrates how genes interact in dynamic graphical models. 
Bioedit http://www.mbio.ncsu.edu/BioEdit/bioedit.html  
 Allows for sequence alignment. 
BLAST  http://www.ncbi.nlm.nih.gov/BLAST/  
 Finds regions of local similarity between sequences. 
ClustalW http://align.genome.jp/  
 Allows for the aligment of multiple sequences. 
DNAMan http://www.lynnon.com/  
 For molecular biology applications for high efficiency sequence analysis.  
EMBL http://www.ebi.ac.uk/embl/  
 Europe's primary nucleotide sequence resource. 
Ensembl http://www.ensembl.org/index.html  
 
A joint project between EMBL - European Bioinformatics Institute and the 
Wellcome Trust Sanger Institute to develop a software system which 
produces and maintains automatic annotation on selected eukaryotic 
genomes. 
GAIA http://bbu.cf.ac.uk/html/research/biostats.htm  
 Tests for statistical interactions between loci. 
GOLD http://www.sph.umich.edu/csg/abecasis/GOLD/  
 A graphical summary of linkage disequilibrium in human genetic data. 
Haploview http://www.broad.mit.edu/mpg/haploview  
 Simplifies and expedites the process of haplotype analysis.  
HapMap http://www.hapmap.org/  
 
The International HapMap Project is a multi-country effort to identify and 
catalog genetic similarities and differences in human beings. 
http://harvester.fzk.de/harvester/  Harvester 
Harvester is a bioinformatic tool that crosslinks a large number of databases 
including : BLAST, ensEMBL, Entrez, gopubmed, HomoloGene, MapView, 
Mitocheck, OMIM, STRING, Unigene, UniprotKB.  
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Program Link and description 
Human Blat Search http://genome.ucsc.edu/cgi-bin/hgBlat  
 
With the entry of about 30 base pairs of sequence results surrounding an 
identified SNP, databases are screened to identify if the SNP is already 
known in any online databases. 
NCBI http://www.ncbi.nlm.nih.gov/  
 National Centre for Biotechnology Information. Public database porthole. 
Oligocalculator http://trishul.sci.gu.edu.au/tools/OligoCalculator.html  
 Checks the melting temperature and the GC content of primers. 
primer3 http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi  
 Identifies primers in a DNA sequence. 
Pubmed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed  
 Journal and citation search engine. 
Scitools Oligoanalyzer  http://scitools.idtdna.com/Analyzer/oligocalc.asp  
 Tests for the presence of hairpins and dimers in primers. 
Sequencher http://www.genecodes.com/  
 Used for alignment of multiple sequences (very useful) 
Software for Genetic 
analysis http://dmoz.org/Science/Biology/Genetics/Software/  
 http://linkage.rockefeller.edu/soft/list.html  
 Lists software available for genetic analysis 
String http://string.embl.de/  
 A database of known and predicted protein-protein interactions. 
Virtual PCR http://grup.cribi.unipd.it/cgi-bin/mateo/vpcr2.cgi  
 Conducts a virtual PCR using information from the NCBI database 
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Appendix 4 
Published articles 
 
From Chapter 2 
Lombard Z, Brune AE, Hoal EG, Babb C, van Helden PD, Epplen JT, Bornman L. HLA class II 
disease associations in southern Africa. Tissue Antigens 2006;67:97-110. 
 
From Chapter 4 and partly Chapter 2 
Barreiro LB, Neyrolles O, Babb CL, Tailleux L, Quach H, McElreavey K, Helden PD, Hoal EG, 
Gicquel B, Quintana-Murci L. Promoter Variation in the DC-SIGN Encoding Gene CD209 Is 
Associated with Tuberculosis. PLoS Medicine 2006; 3: e20. 
 
From Chapter 4 
Barreiro LB, Neyrolles O, Babb CL, van Helden PD, Gicquel B, Hoal EG, Quintana-Murci L. 
Length Variation of DC-SIGN and L-SIGN Neck-Region has no Impact on Tuberculosis 
Susceptibility. Human Immunology 2007; 68: 106-12. 
 
From Chapter 5 
Babb C, Keet EH, van Helden PD, Hoal EG. SP110 polymorphisms are not associated with 
pulmonary tuberculosis in a South African population. Human Genetics 2007; 121: 521-22. 
 
From Chapter 6 
Babb C, van der Merwe L., Beyers N, Pheiffer C, Walzl G, Duncan K, van Helden P, Hoal EG. 
Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis 
patients. Tuberculosis 2007; 87: 295-302. 
 
van Helden PD, Moller M, Babb C, Warren R, Walzl G, Uys P, Hoal E. TB epidemiology and 
human genetics. Novartis Found Symposium 2006; 279: 17-31. 
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